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Abstract 
Background: 
Primary Sjögren’s syndrome (PSS) is an autoimmune disease which primarily targets 
secretory glands causing sicca/dryness symptoms. Patients with PSS also experience a 
range of other symptoms including fatigue, pain, sleep disturbances, low mood and 
anxiety. These symptoms impact on activities of daily living, participation and quality 
of life. PSS has been an under researched disease, and as a consequence many needs 
of patients remain unmet within clinical settings. 
Aim: 
To design a non-pharmacological intervention strategy for people with PSS focussing 
on patient-relevant targets in order to improve daily function and participation.  
Methods: 
In this project, I use a mixed methods approach. I conducted a systematic review of 
published interventions of non-pharmacological interventions for PSS. Then concept 
mapping, a participatory mixed methods approach, was used to identify factors which 
interfere with performance of daily activity for people with PSS. These results were 
discussed with a steering group and used as a basis to develop an intervention 
strategy. I then conducted focus groups with patients and their spouses to discuss the 
main factors deemed to interfere with activities, ascertain strategies patients use to 
manage these problems, and to determine the acceptability of potential future 
interventions to address these factors. Finally a model for the delivery of non-
pharmacological interventions to address these factors was developed with patients.  
Results: 
The systematic review found there was insufficient published evidence to either 
support or refute non-pharmacological interventions for PSS. The concept mapping 
study revealed that in addition to dryness; fatigue, pain and sleep disturbances were 
priority targets for future interventions. The qualitative focus groups demonstrated 
that patients currently deploy a range of strategies to self-manage fatigue, sleep and 
      v 
pain. However, these strategies are not always successful and patients require 
individualised therapies which target their own priorities and required level of support.  
Conclusion: 
The work within this thesis provides a comprehensive understanding of factors which 
influence daily function and participation in PSS patients. This work presents a 
stakeholder-informed model for delivering future non-pharmacological interventions 
to address stakeholder informed priorities. As such, a model has been developed 
which will ultimately support patients to manage symptoms of fatigue, sleep 
disturbances and pain, which are perceived by patients, their families and health 
professionals to impact on performance of daily activities and participation.  
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Chapter 1. Introduction 
1.1 Introduction to the thesis 
I have a clinical background in rheumatology occupational therapy and chronic fatigue 
syndrome (CFS). Whilst attending a research symposium in fatigue at Newcastle 
University in 2011, I heard Professor Ng give a presentation on fatigue in primary 
Sjögren’s syndrome (PSS). PSS is a disease which is usually diagnosed and managed in 
rheumatology departments. However, despite the eight years I spent working in 
rheumatology departments, I could only recall seeing one patient with this condition. 
The years I spent working with CFS patients highlighted to me the debilitating impact 
chronic fatigue has on people’s ability to carry out their daily activities and maintain 
their life roles. If people with CFS struggled to function and if PSS patients experienced 
a similar type of fatigue; then I hypothesised that they might also experience 
functional difficulties. This led to the collection and analysis of pilot data, which I 
conducted prior to starting my PhD and is discussed later in this chapter (see Section 
1.5.2). 
In this thesis, I use mixed methods research to identify factors which interfere with 
people with PSS from being able to conduct their daily activities. The methods I use 
include a systematic review of the literature, group concept mapping (Trochim, 1989), 
clinician involvement and qualitative focus groups. 
1.2 Researcher perspective 
I am an occupational therapist and I subscribe to the primary goal of occupational 
therapists stated in the quote in the front pages: 
The primary goal of occupational therapy is to enable people to participate in 
the activities of everyday life. Occupational therapists achieve this outcome by 
working with people and communities to enhance their ability to engage in the 
occupations they want to, need to, or are expected to do, or by modifying the 
occupation or the environment to better support their occupational 
engagement. (World Federation of Occupational Therapists, 2012) 
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This philosophical standpoint will inevitably have affected the way I have conducted 
the research described in this thesis. In my clinical role, my primary goal is to see my 
patients being able to participate in activities of everyday life, regardless of their 
physical, cognitive or mental health impairments. Whilst conducting the research 
described in this thesis, I had the same ultimate goal in mind for people with PSS.  
Before beginning my PhD study, I was a senior occupational therapist working with 
people with long term conditions. I have worked clinically for sixteen years in 
rheumatology and chronic fatigue syndrome (CFS) services. Whilst I was familiar with 
working with patients who experienced chronic fatigue and pain within the context of 
their rheumatic disease or CFS, I assumed that PSS patients experience dry eyes and 
mouth without any other accompanying symptoms. However, after hearing Professor 
Fai Ng (my primary supervisor) present his work in 2011, I realised that this disease 
had may other features, which appeared to be potentially quite disabling, including 
chronic fatigue. Consequently, I started to question why these patients seemed to 
rarely be referred to occupational therapy services (Hackett et al., 2012a; Hackett et 
al., 2012b) and started my research journey by investigating the difficulties that these 
patients can experience on a daily basis.  
1.3 Background 
PSS is a systemic autoimmune disease characterised by dryness (sicca) symptoms. It 
falls under the umbrella of connective tissue diseases and is usually diagnosed and 
treated by rheumatologists. In PSS, the body attacks its own secretory glands. 
Lymphocytes infiltrate these exocrine glands causing inflammation and damage over 
time. Consequently, people with the disease experience dryness, particularly in the 
eyes and mouth. These clinical features are visible during medical examination. 
However, there are further extra-glandular manifestations commonly experienced by 
people with PSS, which are less visible. These include pain (Segal et al., 2013; Segal et 
al., 2014; Koh et al., 2016), fatigue (Bardsen et al., 2016; Howard Tripp et al., 2016; 
Karageorgas et al., 2016) and low mood (Westhoff et al., 2012). There can also be 
systemic involvement in PSS and this may affect any organ resulting in manifestations 
such as vasculitis, neuropathy as well as skin, lung and kidney involvement (Seror et al., 
2015).  
      3 
1.3.1 History of Sjögren’s syndrome 
Sjögren’s syndrome is named after Henrik Sjögren, a Swedish ophthalmologist who 
first described the condition (Sjögren, 1933). However, others including Henri 
Gougerot, a French dermatologist and  Jan Mikulicz-Radecki, an Austrian/Polish 
surgeon had previously described cases which are likely to be Sjögren’s syndrome in 
1926 and 1892 respectively (Bowman, 2016). 
1.3.2 Prevalence 
A recent meta-analysis has identified a PSS prevalence rate of 65 per 100,000 
inhabitants and a female to male ratio incidence of 9.15 to 1 (Qin et al., 2015). It is 
thought to be one of the more common autoimmune rheumatic diseases (Holdgate 
and St Clair, 2016).  
1.3.3 Secondary Sjögren’s syndrome 
Secondary Sjögren’s syndrome can occur in conjunction with other autoimmune 
rheumatic diseases such as systemic lupus erythematosus, scleroderma or rheumatoid 
arthritis. Secondary Sjögren’s syndrome shares some of the clinical features of PSS that 
I describe next. However, in this thesis I focus on Sjögren’s syndrome, which occurs in 
isolation to these other diseases. I therefore continue to refer to it as ‘primary’ 
Sjögren’s syndrome. 
1.3.4 Age of onset 
There are two main age peaks when PSS tends to develop. These are during the 20’s to 
30’s and in the 50’s following menopause (Fox, 2005). Qin et al.’s (2015) recent meta-
analysis found the average age of onset to be 52. 
1.3.5 Diagnosis 
Currently, the most widely accepted criteria for PSS are the American-European 
Consensus Group (AECG) criteria (Vitali et al., 1996) (see Table 1-1). More recently, an 
American College of Rheumatology (ACR) – European League Against Rheumatism 
(EULAR) criteria has been proposed (Shiboski et al., 2012; Shiboski et al., 2017). It is 
likely that the two criteria describe largely an overlapping population.
      
 
Table 1-1 The American-European Consensus Group PSS classification criteria, from Vitali et al. (2002) 
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5
 
 Katie L Hackett - May 2017   6 
1.3.6 Burden of PSS 
There are significant direct and indirect health-related costs associated with the 
disease. Direct health care costs have been estimated at £1831 to £2546 per PSS 
patient per year in the UK, which is approximately 80% of the cost associated with 
rheumatoid arthritis (RA) in the era preceding widespread use of biological therapy for 
(RA) (2004-2005)  (Callaghan et al., 2007).  Indirect costs in the UK are between 69%-
83% of those associated with a patient with RA, and equate to £7677 to £13502 per 
PSS patient per year (Bowman et al., 2010). This is supported by data gathered in the 
Netherlands, Germany and the USA, which demonstrates that PSS patients are 
significantly less likely to be in gainful employment, and are more likely to work 
reduced hours, be in receipt of benefits, and access health care services more 
frequently (Meijer et al., 2009; Segal et al., 2009; Westhoff et al., 2012).  
1.3.7 Treatment recommendations for PSS in the United Kingdom 
Current treatments for PSS are limited. Pharmacological treatments tend to focus on 
topical treatments for dryness or oral muscarinic agonists which increase tear 
production and salivary flow (Moreland, 2004; Ramos-Casals et al., 2010). However 
new national treatment guidelines for PSS should be published for the first time in the 
very near future (Price, 2016a; Price et al., 2016). These guidelines make use of 
available published evidence and expert opinion. Within these guidelines are 
recommendations for specific topical and systemic treatments. There is also one non-
pharmacological recommendation, which recommends graded exercise for PSS fatigue. 
However, as these recommendations are not yet published, it will be some time before 
the impact of the recommendations can be measured, in terms of widespread 
implementation in clinical practice. 
1.3.8 Research into PSS 
Compared to most other rheumatological autoimmune diseases such as rheumatoid 
arthritis or systemic lupus erythematosus (SLE), there has been little research and 
intervention attention into PSS (Fox, 2005). For instance, I conducted a literature 
search in October 2016 using PubMed Central. When I used the search term ‘primary 
Sjogren’s syndrome’, 4486 articles were revealed. In contrast, when I used the search 
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term ‘rheumatoid arthritis’, 129645 articles were revealed and my search for ‘systemic 
lupus erythematosus’ retrieved 63439 articles. This simple search illustrates the limited 
research into this condition; especially when the prevalence rates, the health 
economic impact of the disease and the fact that there is currently no effective 
treatment are taken into account.   
In recent years, the limited clinical trials of drug treatments, did not demonstrate 
benefit over placebo. The majority of these trials have focussed on the sicca features, 
despite a range of symptoms experienced by PSS patients. Whilst there is some 
evidence from controlled trials of the benefits of pharmacological agents such as 
pilocarpine and cevimeline (both oral muscarinic agonists), as well as topical 
cylosporine for moderate and severe dry eyes; anti-tumour-necrosis factor drugs have 
not been shown to be efficacious at improving joint pain, fatigue and dryness (Ramos-
Casals et al., 2010). The results of recent rituximab and belimumab trials (both b-cell 
targeted therapies) have also failed to meet their primary outcomes (30% reduction in 
2 or more 10cm visual analogue scale (VAS) scores for global disease, fatigue, pain and 
dryness at 28 weeks following the start of treatment) (Devauchelle-Pensec et al., 2014; 
Mariette et al., 2015). Furthermore, a large trial of hydroxychloroquine also failed to 
demonstrate improvements in dryness, pain and fatigue at 24 weeks (Gottenberg et 
al., 2014).  
Although there has been limited research into pharmacological interventions and 
limited pharmacological treatment options (Birt et al., 2017), there have been even 
fewer studies investigating non-pharmacological interventions. However, a systematic 
review of the literature into non-drug interventions has not previously been 
conducted. Therefore, it was important to conduct such a review to determine 
whether there are currently any known efficacious non-drug interventions, which may 
improve quality of life in PSS patients (see Chapter 2).  
1.3.9 The United Kingdom Primary Sjögren’s Syndrome Registry 
The United Kingdom Primary Sjögren’s Syndrome Registry (UKPSSR) was set up in 
Newcastle upon Tyne in 2011 with Medical Research Council (MRC) funding in order to 
facilitate high quality research into PSS (Ng et al., 2011). Patients are recruited to the 
UKPSSR from centres across the UK and all participants fulfil the AECG classification 
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criteria. All participants have indicated whether they would like to take part in further 
studies into PSS. The UKPSSR is hosted in Newcastle upon Tyne. Newcastle is therefore 
the ideal place to conduct this PhD research, as there is a well-defined clinical cohort 
of patients who have consented to being contacted for further research, including the 
studies reported within this thesis. 
1.3.10 Symptoms of PSS 
There is a range of symptoms experienced by people with PSS. These symptoms have a 
huge impact on quality of life (Lendrem et al., 2014; Cornec et al., 2017), and can affect 
patients’ ability to participate fully in life and to independently carry out a range of 
functional activities of daily living (Hackett et al., 2012a; Hackett et al., 2012b). In this 
section, I provide a brief summary of these symptoms and in the following section, I 
give an indication on the impact of these symptoms on daily function and 
participation. 
1.3.11 Dryness 
1.3.11.1 Oral dryness 
Impaired function of the exocrine glands results in oral dryness or xerostomia (Ng and 
Bowman, 2010). Xerostomia may result in oral infections including candidiasis, oral 
lesions, enlargement of the salivary glands and dental caries (Yan et al., 2011; Castro et 
al., 2013; Likar-Manookin et al., 2013; Gonzalez et al., 2014; Napenas and Rouleau, 
2014). 
1.3.11.2 Ocular dryness 
PSS patients regularly experience a moderate to severe aqueous-deficient form of dry 
eye due to a destructive autoimmune response in the lacrimal glands (Coursey and de 
Paiva, 2014). Ocular dryness, also known as keratoconjunctivitis sicca, can result in 
varying levels of symptoms, such as burning, photophobia, foreign body sensation, 
grittiness, and redness, and corneal ulceration (Benelli, 2011). 
1.3.11.3 Other forms of dryness 
Vaginal dryness and dyspareunia occur more frequently in women with PSS compared 
to controls (Cirpan et al., 2007). Dryness of the airways may also contribute towards 
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the development of chronic cough in some PSS patients (Fairfax et al., 1981; Flament 
et al., 2016).  
1.3.12 Vasculitis 
Skin vasculitis is one of the most common extraglandular features of PSS with palpable 
purpura and leukocytoslastic vasculitis on pathological examination (Scofield 2011). 
Cutaneous vasculitis is usually a self-limiting condition which is more likely to affect 
small vessels, although it can also affect medium-sized vessels and cause erythematous 
papules (Ng et al., 2016). Furthermore, Raynaud’s phenomenon is common in PSS 
patients (Horvath et al., 2014).  
1.3.13 Internal organ involvement 
PSS is a systemic disease, which can affect other organs including the kidneys, liver and 
lungs (Mavragani and Moutsopoulos 2010a). Although severe renal involvement is 
uncommon, interstitial nephritis can occur due to lymphocytic infiltration and this may 
result in renal tubular acidosis (Ng et al., 2016). Pancreatitis is also more common in 
PSS (Ebert, 2012; Terzin et al., 2012), with serious pancreatic complications occurring 
in 1% of patients (Price, 2016b). 
1.3.14 Gastrointestinal disease and symptoms 
Patients with PSS may experience a range of gastrointestinal symptoms. This may be 
due to a reduction in mucous in the gastrointestinal tract. PSS patients are more likely 
to experience gut motility problems (Bengtsson et al., 2011) and may experience 
gastrointestinal disease including dysphagia, pancreatitis, pernicious anaemia and 
autoimmune hepatitis; as well as symptoms of irritable bowel syndrome including 
diarrhoea, abdominal pain, bloating and nausea (Ebert, 2012; Kim-Lee et al., 2015). 
Coeliac disease is also present in up to 4.5% of PSS patients (Price, 2016b), which is 
higher than the 0.5% incidence in the general population (Feighery, 1999). 
1.3.15 Lymphoma 
A further complication of PSS includes an increased risk of the development of 
lymphoma (Rua-Figueroa et al., 2016), particularly mucosal-associated lymphoid tissue 
(MALT) lymphomas (Lazarus et al., 2006). PSS patients have a 15-20 fold increased risk 
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of developing lymphoma compared to the general population (Theander et al., 2006), 
and the relative risk of lymphoma development in PSS is among the highest of all 
autoimmune diseases (Dong et al., 2013). Therefore, careful monitoring of those at risk 
of developing lymphoma is essential. Recent research by colleagues at Newcastle 
University has identified potential biomarkers, (Al-Ali et al., 2014; Tarn et al., 2014) 
which in the near future could identify these susceptible individuals in a clinical setting. 
This raises the question – should all PSS patients follow the same treatment pathway? 
Perhaps an alternative pathway could be available to the majority of patients who are 
at much lower risk of developing lymphoma. 
1.3.16 Neurological features 
1.3.16.1 Peripheral neuropathy 
The nervous system is affected in approximately 20% of people with PSS (Chai and 
Logigian, 2010; Tobon et al., 2012) and 5-15% of patients have peripheral neuropathy 
(Birnbaum, 2010; Brito-Zeron et al., 2013), while central nervous system 
manifestations are less common. There are generally 3 neuropathy subtypes; large 
fibre, small fibre and ganglionopathy. Sensory ganglionopathy for example, may 
present as paraesthesia, unsteady gait and/or difficulties with fine motor movements 
due to decreased proprioception. Small fibre neuropathy may cause burning 
sensations, particularly in the feet and be more noticeable at night (Fauchais et al., 
2011; Berkowitz and Samuels, 2014). 
1.3.16.2 Autonomic dysfunction 
Autonomic dysfunction is common in PSS patients with a preponderance of certain 
symptoms such as orthostatic intolerance and vasomotor impairment (Cai et al., 2008; 
Newton et al., 2012; Ng et al., 2012). Autonomic symptoms occur in over half of PSS 
patients and correlate with fatigue and depression (Newton et al., 2012). 
1.3.16.3 Cognitive impairment 
Symptoms of cognitive impairment are significantly more apparent in a PSS population 
compared with controls and have been associated with cerebral frontal lobe white 
matter lesions (Segal et al., 2010). The cognitive dysfunction and mild dementia seen 
in PSS patients is comparable with cognitive impairment seen in patients with multiple 
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sclerosis (Akasbi et al., 2012; Blanc et al., 2013). Furthermore, memory dysfunction in 
PSS has been associated with anti-NR2 antibodies in serum (Lauvsnes et al., 2013). 
1.3.17 PSS and mental health symptoms 
PSS patients are significantly more likely to report symptoms of depression, with one 
study reporting an incidence of 47% in PSS patients compared with a 6% incidence in 
controls (Segal et al., 2009). This incidence is higher than the rates of depression 
reported in other chronic diseases (9-23%) (Moussavi et al., 2007). Depression is 
associated with reduced health related quality of life in PSS (Segal et al., 2009; 
Lendrem et al., 2014). In a recent study, depression in PSS was associated with raised 
anti-NR2 antibodies in cerebrospinal fluid and serum and this was the first study to 
demonstrate any potential relationship with depression in PSS and potential 
biomarkers (Lauvsnes et al., 2013). 
An increased level of psychological distress is reported in the PSS patients compared 
with healthy controls and certain personality features are more likely to be found in 
this patient group including perfectionism, negativity and preoccupation with detail 
(Price, 2016b). A recent Taiwanese population based retrospective cohort study found 
the adjusted hazard ratio of an anxiety disorder occurring in PSS patients was 1.86 
(Shen et al., 2015).    
1.3.18 Fatigue 
Fatigue is a dominant symptom for approximately 70% of PSS patients and is seen in 
75% of patients with PSS (Ng and Bowman, 2010). Defined as ‘an overwhelming sense 
of tiredness, lack of energy and a feeling of exhaustion’ (Shen et al., 2006), it is a good 
predictor of poor health (Segal et al., 2009) and is associated with functional 
impairment (Hackett et al., 2012a; Fox and Fox, 2016). Previous studies have shown 
that physical fatigue measured with the somatic component of the Profile of Fatigue 
scale (Bowman et al., 2004) is more prevalent and severe in PSS patients than mental 
fatigue as measured with the mental component of the same scale (Bowman et al., 
2004; Segal et al., 2008; Theander et al., 2010). Not surprisingly, PSS patients report 
excessive daytime sleepiness (Walker et al., 2003; Theander et al., 2010). 
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1.3.19 Sleep disturbances 
Sleep is often disturbed in patients with PSS (Gudbjornsson et al., 1993) and my recent 
systematic review found that a range of sleep disturbances are commonly reported in 
PSS patients including; subjective sleep disturbances, daytime sleepiness, night 
awakenings and obstructive sleep apnoea (Hackett et al., 2016a). Sleep is further 
influenced by musculoskeletal pain and anxiety (Theander et al., 2010) and sleep 
disturbance affects fatigue levels and can affect daytime functioning (Goodchild et al., 
2010). 
1.3.20 Pain 
Over half of PSS patients report chronic pain and 37-40% of patients in one study 
reported neuropathic pain, which was equally distributed amongst sero-positive 
patients (those with antibodies to Ro (SSA) or La (SSB)) and sero-negative patients 
(those with no SSA or SSB antibodies) (Segal et al., 2013). Severe pain is reported more 
commonly in sero-negative patients (Segal et al 2013). Pain in PSS is associated with 
functional difficulties (Hackett et al., 2012a) and psychological distress (Segal et al., 
2014). Joint pain is a common feature of PSS affecting up to 54% of patients, and in 
some cases associated with clinically-apparent synovitis (Pease et al., 1993). 
1.3.21 Arthritis 
Arthritis and/or arthralgia has been reported as being present in 54% of PSS patients 
(Pease et al., 1993). Hand x-rays obtained from PSS patients revealed evidence of joint 
erosions in 33% of proximal interphalangeal joints, 27% of metacarpal phalangeal 
joints and 12% of wrist joints in PSS patients (Pease et al., 1993).  
1.3.22 Quality of life 
Although mortality in PSS is similar to the general population, the disease has a 
profound impact on patients’ quality of life (QOL) (Strombeck et al., 2000; Meijer et al., 
2009; Ibn Yacoub et al., 2012; Lendrem et al., 2014). QOL is a broad concept, which 
attempts to describe general well-being of both individuals and societies (Carr et al 
1996) and incorporates function and mental and physical wellbeing. Studies have 
examined QOL in PSS using the Medical Outcomes Study Short Form-36 (SF-36) (Meijer 
et al., 2009; Segal et al., 2009; Cho et al., 2013; Cornec et al., 2017) and the European 
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quality of life – five dimension (EQ-5D) (Lendrem et al., 2014). It seems that there are 
many co-dependant variables contributing towards QOL in PSS and large sample sizes 
and multivariate methods allow the variability in QOL in PSS to be broken down into 
component parts (Lendrem et al., 2014). Only four studies have done this, and two 
with sample sizes >200. These include Lendrem et al.’s study (2014), which found pain 
and depression to be the greatest predictors of QOL measured by EQ-5D. Segal et al. 
(2009) however, found somatic fatigue was the dominant predictor of physical 
function and general health while depression was the main predictor of emotional 
well-being using the SF-36. Interestingly and perhaps rather alarmingly, data from the 
UKPSSR (Ng et al., 2011) suggests that PSS patients are on average willing to sacrifice 
3.7 months of their lives every year to be free from PSS (Lendrem et al., 2014).  
A recent study investigating predictors of poor QOL in PSS has confirmed that patient 
reported symptoms of pain, fatigue and dryness are greater predictors of reduced 
quality of life than systemic disease activity (Cornec et al., 2017).  
1.4 Measuring PSS disease activity and symptoms 
1.4.1 Measuring symptoms and disease severity 
A range of measures can be used to quantify various symptoms and disease severity in 
PSS. Disease severity scores, which show the systemic manifestations of the disease, 
are designed to be completed by a clinician. Symptom scores are usually patient-
reported outcomes. The core set of measures which are collected in patients who have 
been recruited to the UKPSSR (Ng et al., 2011) can be viewed in Table 1-2. 
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Clinician's assessment Patient-reported outcome 
 AECG consensus criteria 
 Demographics 
 Treatment (pharmacological and 
non- 
 pharmacological) 
 Comorbidity 
 Disease activity 
     ESSDAI 
     SCAI 
     SSDAI 
 Disease damage 
     SSDI 
 Optional 
     Cardiovascular risk  
                 assessment 
 Symptom assessment 
     PROFAD 
                 SSI 
     ESSPRI 
     Epworth Sleepiness    
                 Scale 
     Orthostatic Symptoms  
                 Scale 
 Quality of life 
     EQ-5D 
     SF-36 
 Anxiety and depressive 
symptoms 
     HADS 
 Optional 
 Autonomic symptoms and 
cardiovascular risk 
     COMPASS 
              Lifestyle (smoking,  
                 physical activity) 
COMPASS: Composite Autonomic Symptom Scale; EQ-5D: European quality of life five dimensions; ESSDAI: European 
League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index; ESSPRI: EULAR Patient Reported 
Index; HADS: Hospital Anxiety and Depression Scale; PROFAD: Profile of Fatigue and Discomfort; SCAI: Sjögren’s 
systemic Clinical Activity Index; SF-36: Short Form 36; SSDI: Sjögren’s Syndrome Damage Index; SSI: Sicca Symptoms 
Inventory. 
Table 1-2 Core set of measures collected in patients recruited from the UKPSSR, 
adapted from Ng et al. (2011) 
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1.4.2 Composite scores 
There are several different symptom and disease activity scores, which can be used in 
PSS. Consequently, an international group developed two consensus based activity 
indexes (Seror et al., 2014). These indexes provide composite scores for PSS symptoms 
and disease activity:  
1) Disease activity can be measured by the European League Against 
Rheumatism (EULAR) Sjögren’s syndrome disease activity index – the 
ESSDAI (Seror et al., 2010). The measure includes twelve organ specific 
domains, which are scored by a physician. The ESSDAI is sensitive to 
change and disease activity states can be scored as being low (ESSDAI 
<5), moderate (≥5ESSDAI≤13) and high (ESSDAI≥14) (Seror et al., 2016).   
2) The EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) (Seror 
et al., 2011) can be used as a composite symptom score and is 
completed by patients. It comprises of three 0-10 Likert rating scales for 
dryness, fatigue and pain. The composite score is the mean of the three 
domains. A disadvantage of the ESSPRI is that it is not as sensitive to 
change as the ESSDAI (Seror et al., 2014). The patient satisfactory 
symptom state has been defined as ESSPRI<5 and the minimally 
important improvement as at least one point or 15% (Seror et al., 2016). 
Quality of life is measured using composite scores. As can be seen in Table 1-2, this can 
be evaluated in PSS using the EQ-5D (Brooks et al., 2003) and the Short Form 36 (SF-
36) (Ware and Sherbourne, 1992). 
1.4.3 Objective dryness scores 
Other objective measurements of disease activity include objective glandular function 
tests (Ng et al., 2016). Schirmers I test measures tear production. A piece of filter 
paper is placed in the lower eyelid for 5 minutes. A measurement of ≤5 mm moisture 
indicates a positive test, whereas >10 mm of moisture shows normal tear production 
(Ng et al., 2016). Other objective ocular assessments can include vital staining - where 
the eye is stained to assess damage; tear break-up time and tear film osmorality (Ruaz, 
2016).  
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Salivary gland function can be measured by testing salivary flow. Saliva is collected in a 
cup over five minutes and this can either be unstimulated, or stimulated with paraffin 
wax or citric acid (Vissink et al., 2016). Ultrasound of the parotid gland and labial gland 
biopsy are alternative ways of examining the salivary glands (Vissink et al., 2016). 
1.4.4 Measuring symptom severity; patient reported measures 
The main patient reported outcome measures which capture subjective symptoms 
scores from patients can also be seen in Table 1-2. In addition to these measures, the 
Ocular Surface Disease Index (Miller et al., 2010) is a subjective measure of ocular 
symptoms, and 10cm visual analogue scales can be used to measure perceived global 
disease, pain, fatigue and dryness (Devauchelle-Pensec et al., 2014). 
1.5 Impact of PSS symptoms upon functional ability and participation 
In this section, I first describe the World Health Organisation’s (WHO) International 
Classification of Functioning, Disability and Health (ICF) model (WHO, 2001). I then 
summarise some pilot work, which forms the background to the studies contained 
within this thesis. This background work demonstrates the high levels of functional 
ability in PSS patients. I then describe how occupational therapists view function and 
participation, within the context of the ICF model and the Canadian Model of 
Occupational Performance (CMOP) (Townsend, 2002). Finally, I describe how the 
symptoms of PSS can affect specific areas of occupational performance. 
1.5.1 The International Classification of Functioning, Disability and Health: 
Function and participation 
The WHO describes the concept of functioning in the ICF model (see Figure 1:1). The 
ICF model is based on the biopsychosocial model of disability (Engel, 1977; Engel, 
1980). In this model, a reduced ability to participate or function is due to a range of 
biological, psychological and social factors. The physiological functions of a person’s 
body systems, their psychology and their involvement in life situations, can all 
influence the actions or tasks a person makes. Furthermore, all this needs to be 
considered within the context of environmental and personal factors (WHO, 2001). 
Consequently, disability can be regarded as a reduction in functional capacity in one or 
more domains of the ICF (Cieza et al., 2014). 
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WHO describes participation as involvement in a life situation (WHO, 2001). 
Participation is therefore about sharing or taking part, especially in activity and it is 
influential on health and well-being (Law, 2002). An example of participation is taking 
part in a sporting activity.  
Functional ability may be different to participation, as a person may not be physically 
or cognitively able to complete an activity independently due to impairment. However, 
their impairment does not necessarily prevent them from participating, as appropriate 
support could enable participation e.g. a piece of equipment, or support from another 
person.   
 
Figure 1:1 Conceptual framework of the International Classification of Functioning, 
Health and Disability (WHO 2002) 
1.5.2 Functional difficulties in PSS 
Recent studies in Newcastle have shown that liver-transplant recipients and patients 
with primary biliary cirrhosis or chronic fatigue syndrome (CFS) have significant 
impairment of their functional capacity which is independently associated with fatigue, 
orthostatic symptoms and daytime somnolence (Costigan et al., 2010; Elliott et al., 
2011; Newton et al., 2011). In PSS there are similar symptoms, however, the overall 
impact of these symptoms upon functional ability had not previously been reported. 
Therefore, prior to beginning my PhD work, I performed a study to systematically 
assess the physical function of patients with PSS using a validated instrument, the 
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Improved Health Assessment Questionnaire© (Improved HAQ) (Hackett et al., 2012a). 
The aim of the study was to assess the physical function of PSS patients and determine 
the relationship between the functional impairment experienced by PSS patients and 
disease activity, patient reported symptoms and quality of life. The following is taken 
from the published abstract. 
Sixty nine PSS patients who fulfilled the AECG Classification Criteria completed 
the Improved HAQ. They also completed the following measures: European 
League Against Rheumatism (EULAR)  Sjögren’s Syndrome Patient Reported 
Index (ESSPRI), EULAR Sicca Scale (measures overall severity of dryness), Profile 
of Fatigue, Epworth Sleepiness Scale (measures daytime sleepiness), Hospital 
Anxiety and Depression Scale (measures anxiety and depression), Orthostatic 
grading Scale (measures orthostatic intolerance) and EuroQOL-5 domain 
(measures health related quality of life). In addition, the EULAR Sjögren’s 
Syndrome Disease Activity Index (ESSDAI) and levels of systemic inflammation 
were assessed using C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR). Data were compared to 69 healthy volunteers matched for age and 
sex. 
The study demonstrated that PSS patients experience greater functional 
impairment than controls (Improved HAQ total scores (mean±SD): PSS=24±25 
vs. controls=9±19; p=0.0002) across all domains of activity. In PSS, functional 
impairment was significantly associated with physical fatigue (p<0.0001; 
R2=0.3), pain (p<0.0001; R2=0.3), depression (p<0.0001; R2=0.3), total 
symptom burden (p<0.0001; R2=0.3), systemic disease activity (p=0.002; 
R2=0.15), quality of life (p<0.0001; R2=0.3), dryness (p=0.002; R2=0.12), 
daytime somnolence (p=0.02, R2=0.08) anxiety score (p=0.03, R2=0.07), and 
CRP (p=0.04, R2=0.06). Only CRP was independently associated with functional 
impairment (β=0.38; p=0.025). (Hackett et al., 2012a). 
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Figure 1:2 Individual Improved HAQ domain scores for PSS patients and controls 
(from Hackett et al., 2012a) 
PSS patients experience significant functional disability compared to age-matched 
healthy controls. Impaired function was associated with reduced quality of life and 
symptoms such as pain, fatigue and depression as well as disease activity, illustrating 
the importance of optimal management of all aspects of the disease (Hackett et al., 
2012a). 
1.5.3 Occupational therapy 
Occupational therapists consider that participation in meaningful activities can have a 
positive influence on a person’s health and wellbeing (Stamm et al., 2006). A 
description of occupational therapy is given below: 
Occupational therapy takes a whole-person approach to both mental and 
physical health and wellbeing, enabling individuals to achieve their full 
potential. Occupational therapy provides practical support to enable people to 
facilitate recovery and overcome any barriers that prevent them from doing the 
activities (occupations) that matter to them. This helps to increase people's 
independence and satisfaction in all aspects of life. (COT, 2016) 
Occupational therapists therefore aim to enable people with health conditions to 
participate in, and carry out, functional activities of their choosing. In the context of 
the ICF model, they do this by addressing environmental and personal factors as well 
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as addressing body functions and structure. These activities or occupations can be 
grouped into self-care, productivity and leisure categories (ENOTHE, 2004).  
In the following section, I describe the theoretical impact of PSS on self-care, 
productivity and leisure. This formed part of a publication, as well as the background 
work for my PhD research proposal (Hackett et al., 2012b).  
1.5.4 The impact of PSS on self-care, productivity and leisure  
Symptoms and associated factors of PSS can influence the performance of those with 
the disease in their self-care, productivity and leisure activities. It was recently 
reported that PSS patients perceive that fatigue is the symptom which impacts most 
on their functional ability (Fox and Fox, 2016). However, a range of symptoms can also 
influence function and participation.  
In this section, I provide an indication of how symptoms discussed earlier in this 
chapter (Section 1.3.10), may influence function and participation. I have used the 
domains of self-care, productivity and leisure, (which are described in the Canadian 
Model of Occupational Performance (CMOP) (Townsend, 2002) and the Canadian 
Occupational Performance Measure (COPM) (Law et al., 2005a)), as a framework to 
structure the discussion.  
1.5.4.1 PSS and self-care 
The impact of having PSS can affect function and participation in a range of self-care 
activities.  
I have already reported difficulties with aspects of personal care in this chapter 
(Section 1.5). Others have also reported difficulties with the self-care tasks of washing, 
dressing and toileting in this patient group (Sutcliffe et al., 1998).  
People with PSS can also have difficulty with eating due to severe xerostomia (dry 
mouth) leading to diminished taste, reduced appetite and difficulty in chewing and 
swallowing food (Palmer and Singh, 2008).  
The consequences of dyspareunia and vaginal dryness in women with PSS can affect 
sexual function, pleasure and impact on personal relationships (Tristano, 2009; 
Maddali Bongi et al., 2013). A further consequence of PSS symptoms within the 
context of personal relationships is oral dryness and the associated problems of a dry 
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mouth, including infections, lesions and halitosis as these can affect kissing (Tristano, 
2009) and confidence at being within close proximity of others. Low mood, pain and 
fatigue are further symptoms, which can influence sexual functioning and personal 
relationships (Hackett et al., 2012b). 
Emotional expression, is also considered by the COPM as belonging within the self-care 
domain. This can affect people with PSS due to inflammation and damage to their 
lacrimal glands and hence an inability to make tears while crying (Hackett et al., 2012b; 
van Leeuwen et al., 2016).  
Sleep is another factor, that lies within the self-care domain of the COPM. The sleep 
disturbance reported in people with PSS, including difficulties with falling asleep and 
more frequent and prolonged night wakening (Gudbjornsson et al., 1993) can have an 
impact on daytime physical and mental fatigue (Goodchild et al., 2008). This in turn 
can affect many aspects of function and participation, including self-care activities. 
In addition to the mobility difficulties previously described (in Section 1.5), another 
research group has shown that functional mobility can be affected due to a decrease in 
physical capacity which may be related to a person’s experience of fatigue (Strombeck 
et al., 2007). It also makes sense that the presence of muscle and joint pain in PSS 
patients, may also affect their mobility (Hackett et al., 2012b). Therefore, individuals 
with PSS may experience difficulties with walking, manoeuvring in bed, managing stairs 
or transferring effectively (Hackett et al., 2012a; Hackett et al., 2012b). 
Managing and organising tasks at home, work and within the community including 
budgeting, planning and driving may be affected by cognitive difficulties and mental 
fatigue (Goodchild et al., 2010; Segal et al., 2010; Hackett et al., 2012b; Segal et al., 
2012; Blanc et al., 2013). Fatigue, daytime sleepiness and pain could also have an 
impact on driving, and reduced clarity of vision due to dry eyes (Goto et al., 2002) 
could further affect community management tasks such as driving, which demands a 
high degree of visual acuity. 
1.5.4.2 PSS and productivity  
Westhoff et al (2012) found that people with PSS who had higher levels of fatigue and 
depression were more likely to have increased levels of work disability. People with 
PSS are more likely to move to a less demanding schedule or job and less likely to 
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remain in employment (Meijer et al., 2009; Bowman et al., 2010). Oral dryness could 
be especially problematic in jobs relying heavily on oral communication such as 
teaching, call centre work or sales. Ocular dryness may particularly affect people 
whose jobs rely on visual clarity or prolonged use of visual display equipment, which in 
turn can exacerbate the symptom of dry eyes (Hackett et al., 2012b). Furthermore, air 
conditioning systems and dry heat in the work place (which a person with PSS may 
have very little control over) can irritate the eyes (Ruaz, 2016).  
Fatigue, pain, discomfort and impaired cognition can affect a person’s ability and 
tolerance in carrying out domestic tasks such as food shopping, cooking, housework, 
cleaning and caring for children (Hackett et al., 2012b). Bowman et al (2010) have 
demonstrated that people with PSS have reduced capacity in carrying out household 
work.  
Participation in education such as school, college or university may be affected by PSS. 
While it is rare for children to have this condition, it does affect some (Saad-Magalhaes 
et al., 2011). It is more likely that adults may struggle to achieve their education goals 
due to physical and mental fatigue, pain, discomfort, difficulties with visual clarity and 
cognition. Furthermore, ocular dryness can result in difficulties with reading or using 
computer screens for periods of time and oral dryness may mean that giving verbal 
presentations can be problematic. 
1.5.4.3 PSS and leisure activities 
Capacity to undertake quiet recreational tasks such as reading or crafts might be 
reduced, due to reduced concentration and cognition. Ocular dryness can make 
reading, using a computer and watching films or television more uncomfortable and 
tiring (Hackett et al., 2012b). 
Active recreation, including participation in sports is likely to be affected due to 
decreased physical capacity and reduced aerobic capacity (Strombeck et al., 2007). 
Fatigue and pain may also be limiting factors in taking part in active recreation. 
Sutcliffe et al. (Sutcliffe et al., 1998) have shown that a proportion of people suffering 
from PSS are restricted in their social activities such as visiting friends. People with the 
condition often report that they do not have enough energy to go out socially because 
of fatigue. Due to their dry mouth and difficulties in swallowing, many individuals with 
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PSS also avoid dining out because of their concern about the kind of food that they can 
eat as well as causing potential embarrassment from taking excessive time in 
consuming the food (Hackett et al., 2012a). 
A further consequence of how oral dryness may result in further social isolation is 
evident from the following statement:  
I rarely smile or talk in public since my inability to produce saliva has caused 
embarrassing tooth decay. (Sjögren's Syndrome Foundation, 2016) 
The consequences of oral dryness mean that this person has now changed how they 
relate to others in social situations.  
1.5.5 Developing interventions for PSS 
I have demonstrated from the literature that there are a range of symptoms in PSS, 
which seem to influence participation and the ability to perform daily activities. It 
therefore seems appropriate to develop some form of intervention to support and 
enable PSS patients to do the activities in life they want to or need to do. Such an 
intervention is likely to be complex, as it will comprise of ‘various interconnecting 
parts’ which are likely to have more variation than a drug (Campbell et al., 2000). 
1.5.5.1 Developing complex interventions: The MRC Framework 
The Medical Research Council (MRC) framework for complex intervention 
development (Craig et al., 2008) recommends an iterative stepped, structured, mixed-
methods approach to designing and developing a complex intervention. This pathway 
can be compared to that which is followed in the development of a new drug 
(Campbell et al., 2000) (see Figure 1:3).  
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Figure taken from (Campbell et al., 2000) and (Thornicroft et al., 2002). 
 
Figure 1:3 Sequential phases of developing randomised controlled trials of complex 
interventions (Campbell et al. 2000) 
However, although the MRC framework for complex intervention development has 
been developed, there is an acknowledgement that the development of a complex 
intervention does not always follow a linear process. Therefore the development of a 
complex intervention may start in the development phase, then move into the 
feasibility and piloting stage, be followed by a formal evaluation of effectiveness and 
finally move into the implementation phase (Craig et al., 2006) (see Figure 1:4).This 
process may involve several backward steps along the way. For example if the 
developed intervention is not deemed as being feasible during the feasibility and 
piloting phase. 
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Figure taken from (Craig et al., 2006) 
 
Figure 1:4 The MRC Framework: Key elements of the development and evaluation 
process (Craig 2006) 
In the development stage, when little is known about the bio-psychosocial 
determinates of illness and illness-associated functional capacity, a combination of 
qualitative techniques to explore and describe patient experience and review of the 
existing evidence is recommended. Such findings will then form the theoretical and 
empirical basis for intervention development, and disease model construction. The key 
tasks of this stage are to identify intervention targets, the mechanisms whereby the 
proposed intervention will lead to functional change, and a specification of how this 
change will be measured.  
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1.6 Aim and objectives 
The aim of this PhD study is to develop a model for intervention in PSS (Hackett et al., 
2014). 
The objectives are:   
1. To determine the effectiveness of any current non-pharmacological 
interventions for PSS. 
2. To collect data from different stakeholder groups to identify priority 
intervention target areas in PSS. 
3. To use existing clinical evidence to establish the optimum intervention targets 
and mechanism of effect of intervention for selected intervention targets. 
4. To establish which of these priority areas could realistically be delivered within 
a UK NHS setting. 
1.7 Summary structure of the thesis 
The studies contained within this thesis fall within the development stage of the MRC 
complex intervention framework (Craig et al., 2006). In Chapter 2, I present a summary 
of existing evidence of non-pharmacological interventions for PSS. In Chapter 3, I 
present a mixed methods concept mapping study in which candidate intervention 
targets are identified and prioritised by patient, family and health care professional 
stakeholders. I explore the results of this study further in Chapter 4 with input from 
clinicians. In Chapters 5, 6 and 7, I explore the priority targets and delivery of possible 
future interventions with patient and family member stakeholders in qualitative focus 
group discussions. I present the overall conclusions in Chapter 8, together with 
recommendations for future research. 
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Chapter 2. A systematic review of non-pharmacological 
interventions for primary Sjögren’s syndrome 
In Chapter 1, I demonstrated the impact the symptoms of PSS can have on those with 
the disease, in particular, how these symptoms may affect patients’ ability to 
participate fully in daily life by engaging in activities of their choosing or by taking on 
life roles. The conclusion of Chapter 1 was that, although non-pharmacological 
interventions may improve participation and increase function ability, we do not know 
which interventions, if any, work. Furthermore, the effectiveness of non-
pharmacological interventions for this patient group are not yet known. In this chapter, 
I report the methods and results of a systematic review where I have searched for all 
the available published evidence of non-pharmacological interventions for PSS and 
assessed their effects. 
2.1 Background and rationale for this systematic review 
Non-pharmacological interventions for PSS may vary according to the particular 
symptom, which they are targeting. They may be complex, target several symptoms at 
once and be conducted by more than one member of a multidisciplinary team 
(Guillemin et al., 2011). Such interventions may include fatigue and mood 
management (Westhoff et al., 2012) and patient education by healthcare professionals 
(Cockshott et al., 2005). Other interventions may be conducted by a clinician with 
specialist skills; such as occupational therapy to establish a balance in daily activities 
and improve function (Hackett et al., 2012b); insertion of lacrimal punctal plugs for dry 
eye symptoms (Valim et al., 2015) or the use of acupuncture for the symptomatic relief 
of dry mouth (O'Sullivan and Higginson, 2010). 
Treatments in clinics for people with PSS tend to focus on pharmacological 
interventions. However, a recent systematic review has shown that evidence to 
support efficacy of pharmacological therapies in PSS is poor (Ramos-Casals et al., 
2010). Given the range of bio-psychosocial symptoms that these patients experience, it 
is possible that there are effective non-pharmacological treatments which could 
improve symptoms. The reduced impact of symptoms consequently may lead to an 
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improvement in quality of life, improved work capacity and a reduction in economic 
costs to society.  
2.1.1 Aims 
The aims of this review were to identify published randomised controlled trials (RCTs) 
of any non-pharmacological interventions for adults with PSS and to assess the effects 
of these interventions on any outcome on these patients.  
2.2 Methodology 
2.2.1 Justification of methodology 
A general review of the literature on any topic can highlight key papers in the area of 
interest. However literature reviews which are not systematic are inherently subject to 
greater levels of bias compared with a systematic approach following explicit methods 
(Mulrow, 1994). A systematic literature review provides an effective approach to 
integrate existing information, provide data for decision making, to establish whether 
findings are consistent between studies and determine whether they can be 
generalised across populations and settings. Furthermore using explicit methods 
(particularly when registered a priori) limits bias and should improve reliability and 
accuracy of conclusions, compared with non-systematic approaches (Mulrow, 1994). A 
systematic approach was therefore taken to conduct this sub-project and the protocol 
was registered a priori in the PROSPERO database (Hackett et al., 2013). 
2.2.2 The systematic review process 
2.3 Method 
I identified relevant experimental studies and based my methods on those 
recommended in the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins and Green, 2008). 
2.3.1 Types of studies 
All RCTs were included in this review. Non-randomised studies were excluded as 
potential biases are likely to be greater in these studies compared with RCTs (Reeves et 
al., 2008). Selection bias can be a particular problem in non-randomised studies. 
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Biased selection of participants can occur in both RCTs and non-randomised studies. 
However, biased allocation to an intervention group can be a particular problem in 
non-randomised studies, when participants selected for an intervention have differing 
characteristics from those who are allocated to a control group or alternative 
intervention. A clinician often has this choice, but it can also be influenced by patient 
preference or a patients’ disease severity. This bias can result in unmatched groups 
such as the intervention group containing a greater proportion of participants with 
severe illness compared with the alternative group (Bradford Hill, 1977; Deeks et al., 
2003; Reeves et al., 2008). Therefore, only RCTs were included in this review.  
2.3.2 Types of participants 
I included adult participants (over the age of 18) with a diagnosis of PSS. Children 
rarely develop PSS and, as I was looking to develop interventions for adults with PSS, it 
was logical to only include adults in the systematic review. Although it would be useful 
to only include studies which have used the American European Consensus Criteria 
(AECG) for PSS (Vitali et al., 2002), I included all PSS patients diagnosed by a clinician. I 
did not stipulate the use of these criteria as I anticipated that there would be very few 
studies left to be included the review. However the criteria for diagnosis is discussed in 
the results. 
2.3.3 Types of interventions 
I considered all non-pharmacological interventions which aimed to improve a 
symptom or symptoms of PSS were for inclusion. Pharmacological interventions are 
classified as medicinal products in accordance with EU Directive 2001/83/EEC (Council 
Directive, 2001) and these were excluded from the review. I regarded homeopathic 
remedies, herbal medicines and trials of vitamins as pharmacological interventions for 
the purpose of this review and these were excluded, as the claimed mechanism of 
action is a chemistry change within the body. I also excluded surgical procedures. The 
comparison could be a placebo, alternative intervention which may be 
pharmacological or non-pharmacological, or usual care. 
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2.3.4 Types of outcome measures 
The outcomes I considered within this review fell within the main domains addressed 
by the World Health Organisation (WHO) International Classification of Functioning 
Disability and Health (ICF)(WHO, 2001) (see Figure 1:1). 
2.3.4.1 Primary Outcomes 
Primary outcomes included assessments of activities of daily living, for example, the 
short-form (SF)-36 physical functioning scale (Ware and Sherbourne, 1992) and the 
improved HAQ (Fries et al., 2009); and participation outcomes pertaining to work, 
return to work and social engagement, measured by, for example, The Work and Social 
Adjustment Scale (Mundt et al., 2002). 
2.3.4.2 Secondary Outcomes 
Impairment of body functions and structures included outcomes of mood, dryness, 
disease activity, daytime sleepiness, fatigue and cognitive function. Environmental 
factors included outcomes of costs, carer strain and willingness of employer to adapt 
the work environment. Personal factors included self-efficacy level of education and 
quality of life. Adverse events were also considered. 
2.3.5 Search methods for identification of studies 
There are a large number of possible non-pharmacological interventions and each may 
have many synonyms. I therefore performed a search for any randomised controlled 
trial or controlled clinical trial for PSS initially. I combined the Medical Sub Headings 
(MeSH) terms and keywords for PSS with the Cochrane Highly Sensitive Search 
Strategy for identifying randomised controlled trials (Lefebvre, 2008). The Medline 
search terms can be viewed in Table 2-1. 
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Search Terms 
sjogrens syndrome/ 
sjogrens syndrome.mp. 
1 or 2 
randomized controlled trial.pt. 
controlled clinical trial.pt. 
randomized.ab. 
placebo.ab. 
randomly.ab. 
trial.ab. 
groups.ab. 
4 or 5 or 6 or 7 or 8 or 9 or 10 
exp animals/ not humans.sh. 
11 not 12 
3 and 13 
Table 2-1 Medline search terms 
 
I carried out electronic searches on the following electronic databases from inception 
to June 2016: Cochrane Central Register of Controlled Trials (CENTRAL); Cochrane 
Database of Systematic Reviews (CDSR); Medline via OVID; Embase via OVID; 
PsychINFO via OVID; Cinahl via EBSCO; Current Controlled Trials Register (USA); World 
Health Organisation International Clinical Trials Registry Platform (WHO ICTRP); The 
National Research Register Archive (NRR) (UK); The UK Clinical Trials Gateway (UK). 
I imported the titles and abstracts into Endnote Version X7 reference managing 
software, combined them into one file, removed duplicate titles and reviewed the 
titles and abstracts of all remaining studies.  
2.3.6 Selection of studies 
I reviewed titles and abstracts of all remaining studies and highlighted all studies which 
initially seemed to fit the inclusion criteria. A second reviewer (Victoria Strassheim) 
also carried out this screening process independently to ensure that no relevant 
studies were missed (Edwards et al., 2002). I obtained full text articles for all 
highlighted studies.  
Next, I screened all full text articles against the inclusion criteria. This process was also 
carried out independently by a second reviewer (Katherine Deane). The purpose of 
having two reviewers was again, to minimise bias. Some experts suggest that it can be 
advantageous having a second reviewer who is not an expert in the subject area of the 
systematic review (Higgins and Deeks, 2008) as this can help reduce bias. We resolved 
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any disagreements over decisions through discussion. I then searched the reference 
list of studies fitting the inclusion criteria for any further potential studies for inclusion 
and retrieved the full text articles of any titles seeming to fit the criteria. These were 
reviewed both by myself and the second reviewer (KD). 
2.3.7 Assessment of risk of bias 
I reviewed the studies for methodological quality using the Cochrane Risk of Bias Tool 
(Higgins and Altman, 2008). This process was repeated independently by a second 
reviewer (KD) and again, any discrepancies were easily resolved through discussion. Six 
items were used to assess risk of bias using only published material. I contacted the 
authors to seek clarification, but no replies were received so a number of items 
remained unclear. 
The following types of bias were assessed and follow the materials which accompany 
the Cochrane Risk of Bias Tool (Higgins and Altman, 2008): 
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i.  Random sequence generation: The methods used to determine which group a 
participant would be randomised to, were assessed. Random sequence generation 
usually results in prognostic factors being balanced evenly between groups. 
Methods which were not considered to be random, such as alternation (where 
consecutive participants are randomised to alternate groups) were considered to 
be at high risk of bias, as the future assignment of a participant might be 
anticipated which could result in selective enrolment in light of the predicted group 
allocation. 
ii.  Allocation concealment (selection bias): The method used to conceal the 
allocation sequence was assessed. A study was deemed to be of high risk of bias if 
the investigators enrolling participants and the participants could foresee which 
group a participant might be allocated to. Methods such as central allocation (e.g. 
telephone or web-based randomisation) can be used to conceal allocation and 
minimise selection bias. 
iii.  Blinding of participants and personnel (performance bias): A study was deemed 
to be at high risk of performance bias if participants or study personnel had 
knowledge of which group the participant was allocated during the study. 
iv.  Blinding of outcome assessment (detection bias): If the outcome assessors had 
knowledge of participants’ group allocation, the study was deemed to be at high 
risk of detection bias. 
v.  Incomplete outcome data (attrition bias): If incomplete outcome data were not 
addressed adequately, the study was deemed to be at high risk of attrition bias. 
vi.  Selective reporting (reporting bias): A study was deemed to be at low risk of 
reporting bias if the authors had published an a priori protocol and the pre-
specified primary and secondary outcomes were reported as indicated in the 
protocol. If there was no protocol available, the study was scored as unclear risk of 
reporting bias as it is impossible to tell whether the outcomes reported were those 
which were originally planned prior to the start of the study. 
vii.  In addition to scoring each of the above items, for risk of bias, an overall risk of 
bias score was awarded to each included study. I scored each study (with 
agreement from the second reviewer KD) as being at: 
 Low risk of bias if ≥4 of the individual items were deemed to be at low risk of 
bias. 
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 Moderate risk of bias if 1-3 individual items were deemed to be at low risk of 
bias and a maximum of 2 individual items were deemed to be at high risk of 
bias. 
 High risk of bias if no individual items were deemed to be at low risk of bias 
and/or >2 individual items deemed to be at high risk of bias. 
2.4 Results 
2.4.1 Search Results 
The literature search, including the ten databases resulted in the identification of 1806 
records. 174 duplicate papers were removed. A hand search of the references from the 
included papers revealed a further 2 studies. 
2.4.2 The Selection of Papers for Inclusion 
Following a review of the potential relevance of all 1814 citations, 149 titles were 
duplicates. Following a review of titles and abstracts of the remaining 1657 titles, the 
full texts of 20 studies seemed to match the inclusion criteria and were retrieved. After 
reading the full texts of these 20 studies, 12 studies were deemed not to fit the 
inclusion criteria. The remaining 8 studies were included in the review. The references 
of these included papers were checked and a further 2 full text papers were retrieved. 
However, after reviewing the full texts, these papers were deemed by both reviewers 
(KH and KD) not to fit the inclusion criteria. This left a total of 8 papers which for 
inclusion in the systematic review. Due to the heterogeneity of the included studies, 
no papers were included in a meta-analysis. Figure 2:1 is a PRISMA flow diagram 
(Moher et al., 2009) demonstrating the steps taken during the selection of papers for 
inclusion in this review. Table 2-2 reveals the numbers of records identified within 
each database.  
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Figure 2:1 PRISMA Flow diagram of study selection 
  
 Katie L Hackett - May 2017   36 
Database Number of Records 
AMED 8 
CENTRAL 62 
CDSR  3 
CINAHL 177 
Current Controlled Trials Register 62 
Embase 52 
Medline 1136 
National Research Register Archive 70 
PsychINFO 177 
UK Clinical Trials Gateway 2 
WHO ICTRP 65 
Table 2-2 Results of the systematic review search of ten databases 
2.4.3 Excluded studies 
The 14 publications which were subsequently excluded did not meet the review 
inclusion criteria: 8 were not RCTs  (Freeman, 1975; Blom et al., 1993; Frost et al., 
1997; Blom and Lundeberg, 2000; Strombeck et al., 2000; Bai et al., 2007; Strombeck 
and Jacobsson, 2007b; Strombeck et al., 2007), 4 did not report the PSS data 
separately for PSS participants (Steller et al., 1988; Talal et al., 1992; Frost et al., 2002; 
Strietzel et al., 2011)  and 2 studies were conference abstracts only (Migita et al., 1982; 
Ngo et al., 2015) (see Table 2-3).  
  
 Katie L Hackett - May 2017   37 
Study Reason for Exclusion 
Bai (2007) Not an RCT 
Blom (1993) Not an RCT 
Blom (2000) Not an RCT 
Freeman (1975) Not an RCT 
Frost (1997) Not an RCT 
Frost (2002) PSS data not reported 
separately for PSS patients 
Migita (1982) Abstract only, outcomes not 
reported 
Ngo (2015) Abstract only 
Steller (1988) PSS data not reported 
separately for PSS patients 
Streitzel (2011) PSS data not reported 
separately for PSS patients 
Strombeck (2000) Not an RCT 
Strombeck (2007a) Not an RCT 
Strombeck (2007c) Not an RCT 
Talal (1992) PSS data not reported 
separately for PSS patients 
Table 2-3 Excluded studies with reasons for exclusion 
There were 2 registered relevant clinical trials identified which have yet to publish 
data. These trials are either in process or have not yet published their findings in full 
(see Table 2-4). 
  
 Katie L Hackett - May 2017   38 
Ongoing clinical trials 
Effects of exercise training in PSS, myositis and Takayasu’s arteritis: University of Sao 
Paulo, Brazil (Miyamoto, 2015) 
Effect of debridement-scaling on the relief of dry eye signs and symptoms in 
Sjogren’s syndrome: University of Waterloo, Ontaria, Canada (University of 
Waterloo, 2014) 
Management of fatigue in sicca syndromes: University of Utrecht, Netherlands (van 
Leeuwen, 2012) 
Table 2-4 Ongoing clinical trials 
2.4.4 Included studies 
The final selection, based on consensus resulted in 8 trials being included in the review 
(Poulsen, 1991; List et al., 1998; Frost et al., 2006; Mansour et al., 2007; Qiu et al., 
2013; Cafaro et al., 2015; Li et al., 2015; Lin et al., 2015). See Table 2-5 for a description 
of the included studies.  
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Study 
Description of 
Intervention 
Comparator Participants Quality Results 
Cafaro 
2015 
Laser acupuncture to 
increase salivary flow 
Placebo laser 
acupuncture (no 
radiation was emitted) 
n=26 
Female=26 
Average age=70 
Low risk of bias Improvement in salivary flow 
Frost 
2006 
Intra oral lubricating 
device 
Treatment as usual n=29 
Female=27 
Average age=62 
Moderate risk of 
bias 
Whole saliva and ‘PUTTICA’ 
speech test improved. 
No difference in dryness 
outcome 
Li 2015 Silicone hydrogel contact 
lenses 
Autologous serum eye 
drops 
n=37 
Female=36 
Average age=48 
Moderate risk of 
bias 
Improvement in corneal 
staining 
Lin 2015 Acupuncture for dry eyes  Carboxymethyl-
cellulose sodium eye 
drops 
n=18 
Female=6 in intervention 
group and 0 in control 
group 
Moderate risk of 
bias 
No difference between groups 
3
9
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List 1998 Acupuncture to increase 
salivary flow 
Treatment as usual 
(waiting list) 
N=21 
Female=20 
Average age=65 
Moderate risk of 
bias 
Saliva production not stated. 
Mouth and eye burning not 
stated. No difference between 
groups 
Mansour 
2007 
Punctum plugs for dry eyes Treatment as usual n=20 
Female=17 
Average age=55 
High risk of bias No data extractable from the 
full text paper. Results 
unknown. 
Poulson 
1991 
Psychodynamic therapy Treatment as usual 
(waiting list) 
N=18 
Female=16 
Average age=54 
High risk of bias No difference between groups 
Qui 2013 Punctum plugs for dry eyes Eye drops n=42 
Female=36 
Average age=35 
Low risk of bias No difference between groups. 
Each group improved. 
Table 2-5 Description of the included Studies
4
0
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2.4.5 Risk of bias in included studies 
See Figure 2:2 for a risk of bias summary, which demonstrates the reviewer’s 
judgements about each risk of bias item for each included study. Each risk of bias item 
within the figure is discussed in turn. 
 
Figure 2:2 Risk of bias summary: reviewers’ judgements about each risk of bias item 
for each included study 
Sequence generation was judged to be at low risk of bias for three studies (Mansour et 
al., 2007; Qiu et al., 2013; Cafaro et al., 2015). Two used computer generated 
randomisation schemes (Mansour et al., 2007; Qiu et al., 2013) and two other studies 
a permuted random block approach (Cafaro et al., 2015; Lin et al., 2015). However Lin 
et al. (2015) did not fully explain their randomisation methods in the text. The method 
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of sequence generation was not discussed within the text of the remaining four 
included studies (Poulsen, 1991; List et al., 1998; Frost et al., 2006; Li et al., 2015) and 
was therefore deemed to be of unclear risk of bias. Concealment of allocation was 
judged to be at low risk in only two studies (Qiu et al., 2013; Cafaro et al., 2015). In one 
study (Cafaro et al., 2015) the sealed envelopes were opened at the first laser 
acupuncture session and in the other (Qiu et al., 2013), random allocations were 
placed in sealed opaque envelopes marked with study identification numbers by the 
same clinical staff. The remaining six studies did not include a discussion of allocation 
concealment and were judged to be of unknown risk of bias. 
Blinding was not conducted in any of the studies except one (Cafaro et al., 2015). In 
this study the participants did not know if they received the active laser acupuncture. 
The same equipment was used for both groups, with the same noise but the control 
group did not receive the radiation. In all remaining studies, the participants were not 
blinded as to the arm of the study they were in and this lack of blinding was judged to 
make these studies to be at high risk of bias. However blinding the participants to the 
interventions would be difficult with many of the included non-pharmacological 
interventions. Detection bias was deemed to be low in one study (Qiu et al., 2013) 
where the staff performing the assessments and analyses were blinded to the 
treatment allocation. Three studies were judged to be at high risk of detection bias as 
the outcome assessors were not blinded (Poulsen, 1991; Mansour et al., 2007; Lin et 
al., 2015) and the remaining four studies did not mention whether outcome assessors 
were blinded to treatment allocation, so the risk of bias was unclear. 
Five out of the eight included studies were at high risk of bias from incomplete 
outcome data. Follow up measurements were not taken for all of the participants who 
took part in one study and their baseline data were not presented in the analysis 
(Poulsen, 1991). In a study on punctum plugs, six participants had spontaneous plug 
loss and a further participant suffered from a reaction to the plug and the data from 
these seven participants were excluded from the analysis (Mansour et al., 2007). Two 
participants were lost to follow up in two separate studies and their data were 
excluded from the analyses (List et al., 1998; Qiu et al., 2013). In the study by Li et al. 
(2015), baseline data were reported for all participants who were recruited to the 
study. However, the data of three participants who withdrew from the study were not 
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imputed and included in the analysis. The authors did include data in the final analysis 
from three further participants who did not attend their final follow-up visit. In one 
study (Frost et al., 2006) the data presentation was unclear and it was not possible to 
determine if the analysis was intention to treat. Another study only included the 
demographic data for those who completed the study (Lin et al., 2015) and it is not 
possible to tell whether the PSS patients were amongst those who withdrew from the 
study. In the remaining study (Cafaro et al., 2015), all participants completed the study 
and their data were included in the analysis. 
I did not have access to the study protocols and was unable to assess the selective 
reporting risk and have reported this parameter as ‘unclear’ in seven of the studies 
(List et al., 1998; Frost et al., 2006; Mansour et al., 2007; Qiu et al., 2013; Cafaro et al., 
2015; Li et al., 2015; Lin et al., 2015). One study was judged to be at high risk of 
selective reporting (Poulsen, 1991) as an alexithymia (difficulty in identifying and 
describing emotions) measurement was only taken after treatment in the 
experimental group and was compared with baseline measurements from the control 
group in the analysis.  
2.4.6 Participants 
Overall 211 participants with PSS were included in these 8 studies. The number of 
participants with PSS in these studies ranged from 42 (Qiu et al., 2013) to 18 (Poulsen, 
1991; Cafaro et al., 2015). All studies recruited both males and females except one 
which recruited females only (Cafaro et al., 2015). The numbers of males recruited to 
each remaining study were low and ranged from 1 (List et al., 1998; Li et al., 2015) to 4 
(Qiu et al., 2013). The gender distribution of the study population however, is 
representative of the PSS population (Qin et al., 2015).  
A range of diagnostic criteria were used in the included studies. One study (List et al., 
1998) included participants diagnosed with PSS according to the Copenhagen 
(Manthorpe et al., 1986), the San Diego Criteria (Fox and Saito, 1994) and the 
proposed European Community Study Group Criteria (Vitali et al., 1996). Four studies 
(Qiu et al., 2013; Cafaro et al., 2015; Li et al., 2015; Lin et al., 2015) reported that 
participants were diagnosed according to the AECG criteria (Vitali et al., 2002). 
Mansour et al (Mansour et al., 2007) recruited participants diagnosed according to the 
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European Criteria (Vitali et al., 1996). The remaining studies (Poulsen, 1991; Frost et 
al., 2006) did not specify how the participants were diagnosed, although Frost et al 
(Frost et al., 2006) did specify they recruited their participants from a Sjӧgren’s 
syndrome clinic. (See Table 2-6 for a summary of the main findings of the 8 selected 
studies). 
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Studies included in the review: Summary of main findings 
Cafero et al 2015 
Methods Single blind, randomised controlled trial. 
Participants 26 women with a diagnosis of PSS made by a specialist using the 
AECG criteria. Average age 69 years. 
Interventions Laser acupuncture to increase salivary flow rate. This was 
delivered weekly over 5 sessions. Specific acupuncture points 
were stimulated bilaterally with an irradiation time of 120 
seconds per acupoint. The control group received a placebo; the 
same equipment was used, with the same sound, but no 
radiation was emitted. 
Outcomes Oral Schirmer’s test - unstimulated salivary flow rate (mm/5 
minutes). 
Frost et al 2006 
Methods Single blind, randomised cross over study. 
Participants 29 patients from a Sjögren’s syndrome clinic. 27 female. Average 
age 62 years. 
Interventions Oral lubrication device containing a saliva substitute gel versus 
lubrication with their preferred method (sips of water, saliva 
substitute gel, sugar free chewing gum). The oral device was 
fitted for one week. 
Outcomes Oral lubrication diary; questionnaire regarding ability to speak, 
chew and swallow; a clinician reported dry mouth score (1-13 
scale); a whole mouth unstimulated salivary flow (10 minutes); 
bacteriological sample; a parotid stimulated flow (10 minutes); a 
speech test (the phoneme sequence ‘PUTTICA’ was repeated as 
many times as possible over a 2 minute period); periodontal 
measurements (pocket depth, plaque and bleeding). 
Li et al 2015 
Methods Parallel randomised unblinded controlled study. 
Participants 37 participants with PSS and dry eye attending an eye hospital. 
36 female. Average age 48 years. 
Interventions Silicone hydrogel contact lenses worn continuously for 6 weeks. 
These were replaced after 3 weeks with new lenses if there were 
any signs of wear or problems with lens fit. The control arm 
received autologous serum eye drops. They were asked to use 
the drops 8 times a day for 6 weeks. 
Outcomes Visual acuity, corneal fluorescein staining, slit-lamp 
biomicroscopy to examine the anterior segment, tear production 
(Schirmer test), tear break up time. Measurements were 
recorded at baseline, week 3, week 6 and 6 weeks after therapy 
was withdrawn. 
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Lin et al 2015 
Methods Parallel randomised unblinded controlled study. 
Participants 18 patients with PSS diagnosed according to the AECG criteria. All 
female in control group and male-to-female ratio in intervention 
group reported as 0.29. Average age of 47. 
Interventions All participants undertook 2 weeks’ washout where all 
treatments for dry eye were stopped. The intervention group 
then received 12 acupuncture sessions, 3 times a week over 4 
weeks. The control group received carboxymethylcellulose 
sodium eye drops four times a day for 4 weeks in both eyes. 
Outcomes Subjective symptom assessment of visual function, bothersome 
symptoms and environmental triggers. Imaging of tear meniscus 
using optical coherence tomography (height, depth and tear 
meniscus area). Tear break up time. Schirmer test. 
List et al 1998 
Methods Parallel randomised unblinded controlled study. 
Participants 21 patients with primary Sjögren's syndrome diagnosed 
according to the Copenhagen and San Diego criteria, 20 female 
and an average age of 65. 
Interventions Acupuncture twice a week for 10 weeks. Each treatment was 30 
minutes. The needles were placed intramuscularly, mainly in the 
regions of the parotid submandibular and labial glands. The 
needles were stimulated manually and electrically (see paper for 
details). The control arm received treatment as usual which was 
not specified. 
Outcomes Patient reported degree of discomfort from mouth dryness, eye 
dryness and tongue and mouth burning (10 point VAS). Patient 
reported reduction in speech and chewing and a separate 
question on ADL (both 10 point VAS). The overall subjective 
experience of the treatment effect (6 point scale). Unstimulated 
salivary secretion rate (mL/15 minutes) and paraffin stimulated 
saliva secretion rated (mL/5 minutes). 
Mansour et al 2007 
Methods A parallel unblinded randomised controlled study. NB The 
patients' eyes were randomised to the intervention or control 
group. 
Participants 20 patients with dry eyes caused by Sjögren's syndrome, 
diagnosed according to the European criteria. 17 women and an 
average age of 55 years. 
Interventions Uni-ocular punctum occlusion versus no treatment in the other 
eye. 
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Outcomes The Schirmer test, rose Bengal staining, mucus debris in the cul-
de-sac of both eyes, subjective discomfort of patients. 
Poulson 1991 
Methods  A parallel randomised controlled study 
Participants 18 PSS patients. Diagnostic criteria not specified. 16 Female and 
average age of 54 years. 
Interventions Group psychotherapy of 12 meetings of 1.5 hours each, twice a 
month over 6 months. The control group were assigned to a 
waiting list and offered the intervention at the end of the study. 
Outcomes Toronto Alexithymia scale, self-report questionnaire about 
benefit, Yalom's curative factor Q-sort, semi-structured clinical 
assessment interview. 
Qui et al 2013 
Methods Parallel group randomised controlled trial with blinded outcome 
assessors 
Participants 42 participants with dry eyes diagnosed with PSS according to the 
AECG Criteria. 36 female and an average age of 35. 
Interventions A thermo sensitive punctal plug versus artificial tear solution 
containing a carbomer gel and basic fibroblast growth factor. 
Patients in the artificial tears group used the artificial tear 
solution 4 times a day with one drop instilled each time into the 
inferior conjunctival sac of both eyes. Patients in the plug group 
underwent punctal plug insertion in both the superior and 
inferior lacrimal puncta. 
Outcomes Ocular Surface Disease Index; corneal flurorescein staining; tear 
film break up time; Schirmer I test; contrast sensitivity and glare 
disability. 
ADL: Activities of daily living 
Table 2-6 Summary of the main findings of the studies included in the review 
2.4.7 Interventions 
Two of the five studies investigated punctum plugs for dry eyes (Mansour et al., 2007; 
Qiu et al., 2013). One study investigated acupuncture for dry eyes (Lin et al., 2015) and 
another silicon hydrogel contact lenses for dry eyes (Li et al., 2015). One study 
investigated an intraoral lubricating device for dry mouth (Frost et al., 2006), another 
investigated acupuncture for dry mouth (List et al., 1998), another investigated laser 
acupuncture for dry mouth (Cafaro et al., 2015) and the final study investigated 
psychodynamic group therapy (Poulsen, 1991). 
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2.4.8 Outcome measures 
A wide range of outcomes were assessed and this is reflected in the outcome 
measures used. Seven studies measured a range of outcomes relating to dryness (List 
et al., 1998; Frost et al., 2006; Mansour et al., 2007; Qiu et al., 2013; Cafaro et al., 
2015; Li et al., 2015; Lin et al., 2015). These included the following clinician reported 
outcomes of; unstimulated salivary flow over 5 minutes (Cafaro et al., 2015) 10 
minutes (List et al., 1998; Frost et al., 2006; Mansour et al., 2007; Qiu et al., 2013) and 
over 15 minutes (List et al., 1998) and paraffin stimulated salivary flow over 5 minutes 
(List et al., 1998). Further physician reported oral dryness measures included the use of 
a 1-13 clinical dryness scale (Frost et al., 2006) and oral bacteriological sample and 
periodontal measurements (pocket depth, plaque and bleeding) (Frost et al., 2006). 
Clinician reported assessments of ocular dryness included; tear gland function tests 
including Schirmer test (Mansour et al., 2007; Qiu et al., 2013; Li et al., 2015; Lin et al., 
2015), Rose Bengal test and mucus debris in the cul-de-sac (Mansour et al., 2007) and 
tear break up time (Qiu et al., 2013; Li et al., 2015; Lin et al., 2015), ocular contrast 
sensitivity (Qiu et al., 2013), glare disability (Qiu et al., 2013), corneal flurorescein 
staining (Qiu et al., 2013; Li et al., 2015) and tear meniscus depth, height and area (Lin 
et al., 2015).  
Participant reported outcome measures for dryness included discomfort from mouth 
dryness, eye dryness and tongue and mouth burning (10 point visual analogue scale 
(VAS)) (List et al., 1998) and subjective ocular discomfort (Mansour et al., 2007; Li et 
al., 2015; Lin et al., 2015).  
Functional outcomes included a participant reported questionnaire regarding the 
ability to speak, chew and swallow (Frost et al., 2006), a 10 point VAS on both 
perceived global reduction in activities of daily living (ADL), ability to chew and swallow 
(List et al., 1998). Two studies collected data on visual function (Li et al., 2015; Lin et 
al., 2015) but in both of these studies, these were included as part of a total score of 
subjective symptoms and the functional data were not reported separately. A further 
study used a speech test where the phoneme sequence 'PUTTICA' was repeated as 
many times as possible over a 2-minute period (Frost et al., 2006). 
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2.4.9 Adverse events 
No serious adverse events were reported. One of the studies on punctum plugs 
reported spontaneous plug extrusion in 28% of the participants (Mansour et al., 2007). 
One participant withdrew from the silicone hydrogel contact lense group in one study 
(Li et al., 2015) due to not being able to tolerate the lenses. One study reported a 
higher rate of drop out in the acupuncture intervention group than the artificial tear 
group (Lin et al., 2015). This might imply an issue with acceptability in the acupuncture 
group, however acceptability of this intervention was not formally measured.  
2.4.10 Effects of interventions 
2.4.10.1 Primary Outcomes: Activities 
Oral lubrication devices 
Frost et al (Frost et al., 2006) examined speech function but did not present baseline 
data, therefore it is impossible to ascertain whether the difference observed between 
the two groups was due to the intervention as there may have been a difference at 
baseline. 
Psychodynamic group therapy 
Poulsen (Poulsen, 1991) used the Arthritis Impact Measurement Scale (AIMS) before 
and after psychodynamic group therapy. The AIMS is a self-reported questionnaire on 
physical functioning. However the author did not report the actual results, and I am 
therefore unable to comment on the reliability of their claim of positive effect. 
Acupuncture 
List et al (1998) asked patients to report the degree in reduction on their speech and 
chewing on a VAS scale at baseline and after a 10 weeks course of acupuncture. There 
was no significant difference between the control group and the intervention group at 
10 weeks. In addition, participants in the same study were asked to report a global 
estimate of the reduction in daily activities on a scale of 0 to 10 with ‘0’ meaning ‘not 
at all’ and ‘10’ meaning ‘extreme’. However, again there were no significant 
differences between the intervention group and control groups after 10 weeks.  
 Katie L Hackett - May 2017   50 
Participation 
The study by Poulsen (Poulsen, 1991) was the only one which measured participation 
as an outcome and found no improvement in participation. 
2.4.10.2 Secondary Outcomes: Impairments of body functions and 
structures 
Punctal plugs 
Mansour et al (Mansour et al., 2007) asked participants to score eye discomfort on a 1 
to 10 scale in both eyes. These measurements were taken at baseline and at follow up, 
approximately six weeks after a silicone punctum plug was inserted into one of the 
eyes. However as the scale used was not validated, it was unclear how the scoring was 
conducted and the sample size was very small (n=13). Furthermore, the authors did 
not report significant differences between the control eyes and the plugged eyes.  
Qui et al (Qiu et al., 2013) conducted a Schirmer I test to determine dryness of the 
eyes before and after treatment and both groups improved. Although the authors 
claim the plug group improved significantly more that the artificial tear group, they did 
not present the analysis that support this claim. Qui et al (Qiu et al., 2013) also 
examined glare disability and visual acuity (ability to discriminate between two 
objects). Both the artificial tears and punctal plug groups demonstrated improvement 
for these two outcomes, but there was no significant difference between the two 
groups.  
Contact lenses 
Li et al.’s study (2015) found no differences in visual acuity between participants 
wearing silicone hydrogel contact lenses and those in the control group using 
autologous serum at any of the time points during the course of the study.  
Li et al.’s (2015) study also reported significant improvement in subjective eye 
discomfort scores for the group who received the contact lens intervention. These 
scores were significantly better than the group who receiving autologous serum eye 
drops at all time scales following the start of treatment, including 6 weeks following 
the withdrawal of the intervention. There were no significant improvements in tear 
production following the contact lens intervention. Although tear break up time did 
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improve following wear of the contact lenses, these improvements were no greater 
than the improvements seen in the eye drop intervention group.  Corneal staining 
revealed significant reduction in the staining areas at all time points following the 
introduction of the contact lenses. These improvements were significantly better than 
improvements measured in the serum eye drops group and were maintained at 6 
weeks following the withdrawal of the lens treatment. 
Oral lubrication devices 
Frost et al (Frost et al., 2006) presented no baseline data, therefore their results were 
not interpretable. 
Psychodynamic Group therapy 
Poulsen (Poulsen, 1991) reported improvements in alexithymia scores nine months 
after taking part in psychodynamic group therapy, despite not measuring the scores at 
baseline for the intervention group. 
Acupuncture 
List et al (List et al., 1998) asked participants to evaluate mouth dryness, eye dryness 
and burning sensation in the mouth on a VAS scale at baseline and after a 10 week 
course of acupuncture but there were no significant differences between the 
intervention and control groups. 
Lin et al (2015) reported no significant differences in subjective ocular symptoms using 
a validated measure after a course of acupuncture for dry eyes (the Ocular Surface 
Disease Index (Schiffman et al., 2000)). This measure included as score for 
environmental triggers, and these environmental factors were not reported 
separately. The sample size was very small in this study (n=18) meaning that although 
the results were non-significant, the study was probably insufficiently powered to 
detect an effect. 
Laser acupuncture 
Cafaro et al. (2015) reported a significant increase in salivary flow rates following a 
course of laser acupuncture for dry mouth. They found significant differences in 
salivary flow rates between the laser acupuncture intervention group and those 
receiving the placebo immediately following the intervention and at 30, 90 and 180 
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days following the discontinuation of treatment.  However sample size of the study 
was low (n=26) and the mechanism of action unclear. 
2.5 Discussion 
Overall, the quality of most of the included studies was poor. There was high risk of 
bias in most and none had conducted power calculations. Furthermore, the sample 
sizes used were small, meaning the studies were likely to be underpowered to detect 
an effect size that is predicted to be modest. The outcome data from studies included 
within this review could be used to determine power calculations for well-conducted 
multi-centre randomised controlled trials of the interventions. 
The quality of reporting was also poor in many of the studies, including the data 
presentation, which makes data interpretation difficult. For example no differences 
between study baseline and endpoint scores were reported in two of the studies 
(Poulsen, 1991; Frost et al., 2006) and one of these reported improvement in an 
outcome but presented no supporting data (Poulsen, 1991).  
The studies did not conduct the appropriate analysis of change in scores, or the 
analysis of difference between the two groups. Instead, baseline to study endpoint 
scores were reported. The exception was Li et al. (2015) who did conduct the 
appropriate analyses. 
In terms of individual studies, the studies by Lin et al. (2015), Cafaro et al. (2015) and Li 
et al. (2015) were of poor quality and were probably under-powered. Although Lin et 
al. (2015) did not find any differences between the groups in response to the 
acupuncture, this study had such small numbers of participants that the intervention 
may have effects that were not detected by this study. On the other hand, although 
Cafaro et al. (2015) found that their laser acupuncture group had a positive response 
to the intervention, the small numbers of participants in their study means it is 
possible that the result could be due to a type 1 error (in which a positive result is 
detected by chance). Li et al’s (2015) study did make comparisons between groups, but 
did not describe their randomisation methods or make it clear whether the person 
taking the measurements was blinded to the intervention group. Blinding of the 
assessor is unlikely as those in the contact lens group wore the lenses continually. 
Therefore, the results of this study were at risk of bias at many levels. 
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None of the studies measured quality of life, self-efficacy, adverse events or further 
environmental factors such as carer strain and costs. Furthermore, some of the 
included studies used outcome measures, which are not standardised or even 
necessarily appropriate for PSS patients. Recent advances in PSS research have 
resulted in more relevant outcome measures being developed (Cornec et al., 2015; 
Rischmueller et al., 2016; Seror et al., 2016), which might be used in future trials of 
non-pharmacological interventions. 
The comparative groups used in each study varied. Some did not use a placebo group 
at all. Furthermore, since there is not yet a ‘standard’ non-pharmacological treatment 
for PSS, (Price, 2016a) a comparison between two or more groups receiving an active 
treatment does not necessarily tell us anything useful. This is because each 
intervention might be equally effective. 
Overall, my findings were inconclusive. There are suggestions from these studies that 
punctal plugs are effective for outcomes of lacrimal gland function outcomes. This is in 
line with a Cochrane review of punctal plugs in dry eyes (Ervin et al., 2010), which was 
not PSS specific. The oral lubrication devices, psychodynamic therapy and acupuncture 
did not provide evidence of significant benefit. However, given the poor quality of the 
data presented and the small sample size, we cannot be certain that these 
interventions provide no benefit either. 
The studies included some measures of glandular function including saliva production 
and some measures of activities. Of the activity measures, not all related to everyday 
life. An example is the PUTTICA speech test (Frost et al., 2006), which is a surrogate 
outcome with an unclear relationship with ease of speech. Furthermore, not all 
outcome measures were standardised and were not all necessarily appropriate for PSS 
patients. Only one study looked at any aspects of participation (Poulsen, 1991) and 
there seems to be a lack of appropriate outcome measures which are relevant to 
patients in terms of activity and participation. Studies investigating outcomes of body 
function and structures need to determine the relevance of these outcomes to 
patients and investigate the impact of such symptoms on participation, the ability to 
perform daily activities and quality of life. 
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I discovered no published reports of randomised controlled trials of studies looking at 
exercise or cognitive behavioural therapy, which have been examined in chronic 
fatigue syndrome (White et al., 2011). A small study investigating a group aerobic 
exercise intervention (Nordic walking) (Strombeck et al., 2007) was not included as 
participants were not randomised and as previously mentioned, it is difficult to 
determine evidence of efficacy in non-randomised trials (O'Connor et al., 2008).  
Through a search of clinical trials databases I was able to determine that there were 3 
relevant clinical trials (Table 2-4) which have yet to publish their results. This includes a 
randomised controlled trial registered in The Netherlands, investigating cognitive-
behavioural therapy and exercise training to treat fatigue in patients with Sjögren’s 
and non-Sjögren’s sicca syndrome (van Leeuwen, 2012); an exercise intervention 
registered in Brazil (Miyamoto, 2015) and a study of eyelid debridement in Canada 
(University of Waterloo, 2014). Further research is recommended into clinically 
relevant non-pharmacological interventions where there is evidence of efficacy in 
other conditions with similar symptoms; such as cognitive behavioural therapy and 
graded exercise therapy for fatigue management in patients with chronic fatigue 
syndrome.  
A Cochrane systematic reviews of punctal plugs for dry eyes concluded that they 
provided some symptomatic relief in severe dry eyes (Ervin et al., 2010) and it is likely 
that they would be of benefit in PSS as well as other dry patient groups. Further 
investigation into any differences between PSS dry eye treatment and standard dry eye 
treatment is warranted. A further Cochrane review concluded that there was low 
quality evidence that acupuncture was no better than placebo for dry mouth 
symptoms in mixed patient groups and there was insufficient evidence to support the 
use of electro stimulation for oral dryness (Furness et al., 2013). Further studies for 
these interventions are also therefore warranted. 
None of the studies measured quality of life, self-efficacy, adverse events or further 
environmental factors such as carer strain and costs. Furthermore, some of the 
outcome measures used outcome measures which had not been standardised or 
shown to be appropriate for PSS patients.  
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2.6 Conclusions 
Overall, I identified no current evidence to support any non-pharmacological 
interventions to improve PSS. The area of research needs good quality, appropriately 
powered RCTs that are reported according to CONSORT guidelines (Schulz et al., 2010). 
Outcomes should be sensitive to changes that are important and relevant to patients 
including functional and participatory outcomes. 
Interventions are required to support patients with this disease to be able to 
participate more fully in daily life by being able to undertake valued life activities and 
taking on roles of their choosing. With no known evidence based interventions to 
support patients in this regard, the development of such interventions is a priority. 
2.7 Summary 
I conducted this systematic review to determine whether there are any non-
pharmacological interventions which are likely to improve participatory and functional 
outcomes for PSS patients. The results of this review were inconclusive as there was 
not enough evidence to either support or refute non-pharmacological interventions. 
Prior to designing any further interventions to improve function and participation for 
PSS patients, it is essential to determine what prevents people with the disease from 
doing valued life activities which they need or want to do. In the next chapter I 
conduct a study where barriers to activity and participation are identified by 
stakeholders with the lived experience of PSS (patients and family members) and 
clinicians who treat PSS patients. 
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Chapter 3. A group concept mapping study identifying barriers 
to participation and performing daily activities 
The previous chapter demonstrated that there was little evidence for non-
pharmacological interventions and studies included within the systematic review gave 
little attention to functional or participatory outcomes. Interventions should target 
barriers identified by people with an understanding of the disease, either objectively or 
through their lived experience. Of the identified barriers or intervention targets, the 
ones perceived to be of most importance by stakeholders provide an ideal starting 
point. This chapter reports the methods and results of a group concept mapping study, 
where stakeholders with a lived experience of PSS and stakeholders who treat PSS 
patients in clinical settings were asked to identify important barriers to participation 
and performing daily activities for people with PSS.  
3.1 Aim and objectives 
The aim of this study was to determine important key factors or barriers affecting 
participation and ability to perform daily activities for people with PSS and to identify 
factors perceived to be feasible to change.  
The objectives were achieved through the collection of data from different stakeholder 
groups: Patients with PSS, adult household members (AHMs) (i.e. adults who live with 
a person with PSS) and health care professionals (HCPs) who see patients with PSS in 
their clinical settings. The objectives were as follows: 
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i. Identify barriers to participation and being able to perform daily 
activities for people with PSS by completing a brainstorming exercise 
with stakeholders 
ii. Structure the generated ideas into clusters or themes through a sorting 
exercise 
iii. Identify the most important themes and promoters through a rating 
exercise and to identify which areas participants perceive to be feasible 
intervention targets 
iv. Compare similarities and differences in priorities between different 
stakeholder groups 
3.2 Methodology 
3.2.1 Justification of chosen methodology 
I chose group concept mapping (GCM) methodology, to achieve the aims and 
objectives of this study. GCM was developed by Trochim (Trochim, 1989) and is a 
mixed-methods participatory approach which uses a combination of group processes 
(brainstorming, sorting, rating and interpretation) and a sequence of multivariate 
statistical analysis (multidimensional scaling and hierarchical cluster analysis) that 
result in visual representations of all stakeholders opinions in the form of concept 
maps, pattern matches and go-zones. Priority values are added by participants to 
qualitative statements gathered during the brainstorming phase and these can be 
interpreted in pattern matches and go-zones and used in planning or evaluation 
studies (Kane and Trochim, 2007).  
An advantage of GCM over some other methods is that it is an equitable process, 
giving an equal voice to all stakeholder groups and does not direct participants to form 
a consensus. Qualitative interviews and focus groups with stakeholders were 
considered as alternative approaches. These methods can be used to collect detailed 
description about a topic and can give very useful insights (Weiner et al., 2011). 
Unique ideas which have been identified during interviews or focus groups can be 
grouped using thematic analysis (Braun and Clarke, 2014). However, thematic analysis 
has limitations, as it is subjective; it is conducted by a small number of researchers and 
can be subject to bias. Furthermore results from qualitative methods are not easily 
quantifiable (Anderson, 2010). These drawbacks mean that it would be very difficult to 
quantifiably prioritise promoters and compare priorities between stakeholder groups 
using purely qualitative methods.  
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Surveys are a tool which can be used by participants to rank predetermined ideas, e.g. 
with a Likert scale (Likert, 1932). When using this approach, it is important to ensure 
that all concepts are captured within the survey to prevent missing any important 
ideas (Burns et al., 2008). Open-ended survey responses provide an alternative way to 
collect new ideas, at low cost and from large numbers of participants. This type of 
survey also offers greater anonymity than other qualitative approaches and may elicit 
more honest approaches (Erickson and Kaplan, 2000). However, participants who have 
completed the survey do not usually contribute to the thematic analysis in this method 
and the qualitative analysis is again, subject to increased bias. 
Delphi methods offer an alternative solution, as the results are quantifiable. However 
the methods were developed with the purpose of producing consensus of opinion 
between experts (Dalkey and Helmer, 1963). Delphi methods cannot therefore be used 
to identify similarities and differences in opinion between different stakeholder 
groups.  
GCM draws on the advantages of both qualitative and quantitative approaches. It 
allows participants to contribute their ideas until data saturation is achieved. Multi-
dimensional scaling (MDS) and hierarchical cluster analysis reduce risk of bias as every 
participant who completes the sorting exercise takes part in the thematic analysis and 
their opinion counts. The resulting concept maps are therefore co-authored by all 
participants. Key priorities can be identified through the analysis of participants’ rating 
data and comparisons can be made between stakeholder groups. Furthermore, 
comparisons within stakeholder groups can be made, for example between patients, 
between younger and older patients or between doctors and therapists.  
In the rheumatology field, GCM has been used to design and develop interventions 
such as an online arthritis pain management programme (Trudeau et al., 2010), to 
prevent work disability in rheumatoid arthritis patients (Varekamp et al., 2005) and to 
understand their work requirements (Detaille et al., 2003). It has also been used to 
support the development of interventions in areas such as HIV/AIDS (Abdul-Quader 
and Collins, 2011) and public health, including health interventions for immigrants 
(Vaughn et al., 2016) and community relevant physical activity interventions (Kelly et 
al., 2007). 
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3.2.2 Description of concept maps 
Concept maps consist of point maps, cluster maps and cluster rating maps. Pattern 
matches and go-zones can also be generated from the software. A brief explanation 
for each term follows and a more detailed explanation provided in the results section 
in this chapter (Section 3.4). 
A point map is a visual representation of how all stakeholders have sorted their 
statements and is determined by the multidimensional scaling analysis. Each 
statement is represented by a point on the map.  
A cluster map shows the groups of statements as themed clusters and is generated 
following hierarchical cluster analysis.  
A cluster rating map demonstrates how a group of participants prioritise each 
cluster. Higher priority clusters have more layers (up to five) and clusters which are 
given lower ratings contain as few as one layer.  
A pattern match is a visual result demonstrating how different stakeholder groups’ 
opinions agree or differ about groups of ideas or clusters of statements.  
A go zone is a bivariate scatterplot, demonstrating how two different groups of 
stakeholders have rated the statements in a concept map, either at a cluster level or 
for all the statements within the concept map. Statements falling within the top right 
quadrant of the go zone have been given above average priority ratings by both 
groups. The quadrants are determined by the mean ratings for each of the 
comparative groups. These go zone statements are instructive for action planning. 
3.2.3 The concept mapping process 
GCM follows a distinct five-stage process: 
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1. Preparation for concept mapping: The key issue is identified, then a ‘focus 
prompt’ is developed and participants are identified. 
2. Idea generation: A brainstorming exercise takes place with stakeholders who 
have an interest and expertise in the area. Participants are each asked to 
provide their individual ideas in response to the focus prompt. 
3. Structuring the ideas: A refined list of statements from the brainstorming 
exercise is presented back to participants who are asked to rate each 
statement and to sort all of the statements into groups of ideas which they 
perceive to be similar in meaning. 
4. Representation: The collected data are analysed using a specialist software. 
Concept maps, ‘pattern matches’ and ‘go-zones’ are produced. 
5. Interpretation of the maps. 
 
The protocol for the study was published a-priori (Hackett et al., 2014). 
3.3 Method 
3.3.1 Stage 1: Preparation for concept mapping 
3.3.1.1 Study advisory group 
My study advisory group included my supervisory team and two people with PSS who 
serve on the committee of the local patient North East Sjögren’s Syndrome Association 
(NESSA). Further advice was sought from relatives and friends of patient members of 
the advisory group when deciding on a final list of ideas following the ideas generation 
stage. The advisory team contributed at the protocol development stage, during the 
delivery of the study and during the interpretation stage.  
3.3.1.2 Development of the focus prompt 
In order to ensure the aim of the study was achieved, an appropriate focus prompt 
was required. The focus prompt was going to be used in the brainstorming to generate 
the ideas/statements. It is therefore essential that this prompt was understandable. 
Many concept mapping studies use an incomplete sentence is as a prompt to elicit 
statement responses from participants (e.g. (McLinden, 2013; Stoyanov et al., 2014; 
Hackett et al., 2016b). The focus prompt emerged from discussions with members of 
the study advisory team and with experts in concept mapping during a five-day 
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concept mapping training course (Concept Mapping Incorporated, Ithaca, New York). 
The focus prompt I used in this study was: 
People with Sjögren’s could do more of the things they want to do or 
have to do if……………………………  
3.3.1.3 Ethical approval 
An ethical application was drawn up and included a study protocol, participant 
information sheets and participant documents (See Appendices (Section A.1)). The 
application was submitted for proportionate review and was granted by the Office for 
Research Ethics Committees Northern Ireland (13/NI/0190, IRAS Ref: 125562). 
Furthermore the study was accepted onto the National Institute of Health Research 
Comprehensive Clinical Research Network’s (CCRN) Portfolio of non-commercial 
clinical research studies (Study ID: 15939). Principle Investigators (PIs) from each of the 
Patient Identification Centres (PIC sites) in England for the UKPSSR (Ng et al., 2011) 
were contacted by the CCRN to see if they would be interested in supporting the study. 
12 PIs agreed and NHS Trust R&D approvals were sought and granted from each of 
these sites with support from the CCRN. 
3.3.1.4 Confidentiality 
To maintain confidentiality, each participant was assigned a unique code. Reply slips 
and consent forms were stored securely in a locked office at the Freeman Hospital, 
Newcastle upon Tyne NHS Foundation Trust. Electronic records were password 
protected and stored on an NHS computer. Participants opting to use the online 
system to complete the concept mapping exercises were allocated a unique username 
and password to ensure they were not identifiable on the web-based system. 
3.3.1.5 Sample size 
The recommended minimum number of participants for a GCM exercise is 40 (Rosas 
and Kane, 2012). In order to enable sub-group analyses and to allow for modest 
attrition rates (20%) at each step of the GCM exercise, I aimed to recruit approximately 
n=280 participants. I aimed to recruit 180 patients with PSS, 50 AHMs and 50 HCPs. 
This would allow me to detect a difference of the same order of magnitude as the 
background variability with 80% power. Subgroups within the patient group would 
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allow me to compare opinions of PSS patients with varying levels of fatigue, quality of 
life (QOL), perceived dryness, pain, cognitive symptoms, and mood disturbances. 
 
 
Figure 3:1 The a-priori flowchart of participants to be recruited to the GCM study, 
including estimated attrition rates at each step of the GCM process 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
180 PSS patients 
consent to study
 
120 PSS patients to 
complete 
brainstorming activity
 
80 PSS patients to 
complete sorting and 
rating activities
Functionally well and 
and functionally 
impaired n= 20:60 
Non-fatigued and 
fatigued n= 20:60 
Good QOL and 
poor QOL        
n= 20:60 
Examples 
of 
subgroups 
for 
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3.3.1.6 Recruitment 
The UKPSSR is a large database of patients recruited from different parts of the UK. All 
participants of the UKPSSR have provided their consent to be contacted for further 
research. 
Patients from the UKPSSR were invited to take part in this study as all participants of 
the UKPSSR are over 18 and diagnosed with PSS with the American European 
Consensus Critera (Vitali et al., 2002). The Patient and Adult Household Member 
(AHM) recruitment took place from 12 sites across England from February to August 
2014 via postal invitation. The location of the sites is shown in  
Figure 3:2. Within each invitation pack posted out to the potential participants was an 
envelope containing an invitation pack labelled ‘for the attention of an adult 
household member’. Health Care Professionals (HCPs) were invited to participate at 
professional meetings including a rheumatology staff meeting at the Freeman Hospital, 
Newcastle upon Tyne and a regional Primary Care Research Meeting in Gateshead. 
Health care professionals were contacted via email distribution lists, including a list of 
UKPSSR collaborators, a regional rheumatology email distribution list and the College 
of Occupational Therapists Specialist Subsection – Rheumatology email list. Informed 
consent was obtained from all participants according to the principles of the Helsinki 
Declaration. 
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Figure 3:2 Participant identification centre sites from where PSS and AHM 
participants were recruited 
3.3.1.7 Completion of the concept mapping study 
Participants were given the option of completing all stages of the concept mapping 
study on paper via the post, in prepaid envelopes or online after logging onto a web-
page using a unique username and password. 
3.3.1.8 Data collection 
Baseline demographics were collected from all participants. PSS patients and AHMs 
were asked to provide the following demographic information; age in years, gender, 
employment status, how long in years they have had a diagnosis of PSS or how many 
years had the person they live with has had a diagnosis of PSS. In addition PSS patients 
were asked to indicate if there were any further adults in the household, if they had 
any dependents, if they had paid for private therapy or complementary therapies in 
the past 6 months, level of education, household income, and whether they were in 
receipt of benefits. The PSS group also completed visual analogue scales for pain and 
fatigue and the Hospital Anxiety and Depression Scale (Snaith and Zigmond, 1986), the 
Cognitive Failures Questionnaire (Cogfail) (Broadbent et al., 1982) and a measure of 
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functional ability - the Improved Health Assessment Questionnaire (Improved HAQ) 
(Fries et al., 2009). The Improved HAQ consists of 20 questions which ask respondents 
to rate their ability to perform daily activities on a 5-point scale, where 0 = without any 
difficulty and 4 = unable to do. These questions are divided into 8 domains of physical 
function: dressing, arising, eating, walking, hygiene, reach, grip, and activity. The 
highest scoring question in each domain is used as the domain score. The total 
Improved HAQ score = ([mean domain score] × 25). Higher scores indicate greater 
functional impairment. 
Finally, PSS participants also completed the quality of life measure SF-36 version 2 
(Ware, 2000; Ware et al., 2000). SF-36 norm-based scores were calculated using 
United States (US) normative data as the Quality Metric Health OutcomesTM Scoring 
Software provided with the SF-36 licence uses the US normative scores to create these 
scores. It was a pragmatic decision to calculate normative scores rather than the actual 
scores as it is then possible to make comparisons between the results for each domain, 
between groups and with other population groups. The drawback is that there may be 
slight variations between the US and United Kingdom normative scores. However, a 
previous study on the original SF-36 demonstrated that there is little difference 
between the UK and US norms (Jenkinson, 1999). Furthermore, the Quality Metric 
Software works out a norm-based score for participants individually, based on their 
age and gender. I could have also compared the actual SF-36 scores with UK 
population norms, but a direct comparison would have been made at a group level, 
rather than making paired comparisons, and the participant scores would not have 
been made in direct comparison with norms of the same age and gender. The purpose 
of collecting both the demographic and symptom data was to provide an in depth 
description of the population.  
Family members were asked to complete short validated questionnaires to measure 
the impact of their spouse/relative’s disease on them. These measures included the 
Caregiver Strain Index (CSI) (Robinson, 1983) and the SF-36 version 2. The CSI is a 
thirteen item scale and respondents are asked to respond with a ‘yes’ or ‘no’ to each 
item. A score ≥7 out of 13 indicates high carer strain. Again, the purpose of collecting 
this information in addition to the demographic data, was to provide an in-depth 
description of the AHM population.  
 Katie L Hackett - May 2017   66 
HCPs were asked to indicate which professional group they belong to so comparisons 
could be made between different health care professional groups. These data 
therefore allowed additional subgroup analyses within the family and provider groups. 
PSS patient participants (n=122) were identified from 12 NHS sites in England. They 
were all participants in the United Kingdom Primary Sjögren’s Syndrome Registry (Ng 
2011) and as such fulfilled the American European Consensus Group (AECG) diagnosis 
criteria. Inside their postal invitation was an invitation to an adult household member 
(AHM). 43 AHMs took part in this group concept mapping study. In addition health 
care professionals (HCPs) who see PSS patients were invited to participate via email 
distribution lists and at professional meetings and 67 took part. The concept mapping 
study consists of three distinct stages. Not all participants undertook every stage. PSS 
patient and AHM participants were given the option of attending a face-to-face 
brainstorming meeting if they lived close-by to the meeting venue. All participants 
were given the option of completing the GCM exercises online via a web-based 
interface (Concept Systems Global MAX™) or on paper via the post.  
3.3.2 Idea generation 
3.3.2.1 Brainstorming 
In the first stage of the study participants were asked to complete the following 
sentence as many times as they could: 
“People with Sjogren’s could do more of the things they want to do and have to do 
if……….” 
Participants completing this exercise online or in a face-to-face meeting could see 
statements written by other participants meaning that duplication might be less than 
when completed in on paper, with no access to other participants’ responses. 
Brainstorming continued until data saturation was achieved (Trochim, 1989; Kane and 
Trochim, 2007). This was the point where no further unique ideas were being 
generated through the brainstormed responses (de Kok et al., 2007). The resulting 
statement set was reduced to a shorter list of unique ideas using a process described 
by Kane and Trochim (2007): 
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In the statement reduction process each statement was first given a key word. If more 
than one idea was contained within a statement, the statement was split. For example 
the statement “there was a structured support network from other patients and health 
care professionals which could be accessed when specific needs arose” was divided into 
two statements: “There was a structured support network from other patients” and 
“health care professionals could be accessed when specific needs arose”. These were 
then coded separately using an excel spreadsheet. I met with two members of my 
supervisory team (TR and VD) and the codes were verified. An example of a key word 
with statements which are very similar in meaning is: 
 Key word: Active 
 Statements: i) They keep their body active ii) They keep as active as possible 
At this stage duplicate statements were removed and I checked the statements for 
syntax and grammar. The wording was changed minimally for some of the statements 
to ensure they made sense and the grammar and syntax corrected when necessary. 
However care was taken to ensure that the meaning of the original statement was not 
lost. For example, the statement “Healthcare professionals knew about Sjogren’s” was 
changed to “There was education on Sjogren’s for healthcare professionals”. Any 
changes to the wording were checked with two supervisors (TR and VD) prior to the 
study advisory group meeting. 
Next, I grouped all remaining statements with the same key word together and listed 
the key words in alphabetical order in a Word document. The study advisory group 
met to decide which statements should be included in the final statement set and to 
discuss the wording of the statements. One patient study advisory group member was 
present at this meeting and four members of my supervisory team. Another patient, 
two AHMs and the remaining member of my supervisory team received the list 
separately and provided feedback via email. Groups of statements which had the same 
keyword were considered in turn. This process resulted in a synthesised statement list 
of 94 unique ideas which were reviewed independently by a small group of PSS and 
AHM representatives. 
The set of 94 refined statements were printed individually onto cards and packs of the 
cards were made up containing one of each statement. 
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3.3.3 Structuring the ideas 
3.3.3.1 Sorting the ideas 
Participants were instructed to sort the statements into themes in a card sorting 
activity. Each statement from the refined list was given a number and printed on a 
separate card. Participants were asked to sort the cards into groups or piles that were 
similar in meaning in a way that made sense to them. A sort recording sheet was 
provided and participants were instructed to give each pile a name and to record the 
statement numbers in each pile. The online option entailed a similar process with a 
drag and drop facility within the software. 
3.3.3.2 Prioritising the ideas 
Participants were asked to rate each statement for importance on a Likert 1-5 scale. 
The instructions were “rate each statement below on how IMPORTANT you think it is 
by putting a circle around a number”. 1 on the rating scale represented “relatively 
unimportant” and 5 “extremely important”.  
3.3.4 Representing the ideas 
3.3.4.1 Analysing the data 
Demographic, clinical and social scores were analysed in Minitab 17 and Graphpad 
Prism 6. Data distribution was classified as normal or non-parametric by plotting and 
interpreting histograms alongside the Anderson Darling normality test. Where data 
were considered as being normally distributed, they are summarized with mean and 
standard deviation (SD). Non-parametric data are described with a median and 
interquartile range (IQR). To determine whether SF-36 scores were comparable with 
the 1998 United States (US) published norms, the norm-based scores were calculated 
in Quality Metric software and one sample t-tests were then calculated in Minitab 17 
with the hypothesized mean of 50 and a confidence level of 95%. Parametric tests 
were applied to the SF-36 data irrespective of the data distributions as a large 
population study has demonstrated that the choice of statistical approach has no 
influence on results for these scores (Torrance et al., 2009).  
The GCM analyses were performed using Concept Systems Global Max™ software, 
specifically designed for GCM projects. Multidimensional scaling techniques were 
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performed on the card sorting data, which had been arranged into a similarity matrix 
to position each statement in relation to each other as a point on an x-y axis. This 
generated a point map with each point representing a statement. Points near to each 
other on the map will have been sorted together more frequently by participants in 
the sorting activity in comparison to statements which are further apart. The stress 
value, a statistic which reflects stability within the overall map was generated. Ideal 
stress values for concept mapping analyses are below 0.36 (Trochim, 1989).  
Secondly, hierarchical cluster analysis was performed using Ward’s algorithm created 
clusters of statements using the multidimensional scaling coordinates (Rosas, 2017; 
Rosas and Ridings, 2017). In Ward’s method, each statement is initially regarded as a 
cluster. These agglomerate together in such a way as to minimize the variability within 
a cluster. The software keeps combining clusters by choosing the two clusters which 
have the shortest distance between their central points until there is only one cluster 
left. Using a process described by Kane and Trochim (2007), I initially examined the 
content of 16 clusters and kept combining clusters and their content until there were 
as few as 4. In this process, the software was used to combine clusters one at a time. 
The statements within each were examined and interpreted to ensure the statements 
within conveyed an overall theme for the cluster. This is a qualitative decision and at 
the point where it no longer made sense to proceed to the next iteration as the 
contents of the cluster would be too conceptually broad is where the final cluster 
solution is agreed upon. Using this approach, a final cluster solution was agreed 
between me and my supervisory team. The software suggests names for the clusters 
based on the names participants gave to their piles in the sorting exercise and the 
cluster labels were chosen from these suggestions.  
Next, the rating data of the participants were considered. Importance ratings were 
compared for all participants in a cluster rating map. Next, comparisons in rating data 
were made between each stakeholder group at cluster level in “pattern matches”. The 
cluster rating map and pattern matches identified the most important clusters from 
the perspectives of each stakeholder group.  
The rating data were next compared in the “go-zones” for each cluster. Go-zones 
enable examination of rating values for specific statements between two stakeholder 
groups. There was a high degree of correlation between the rating scores for the PSS 
 Katie L Hackett - May 2017   70 
and AHM groups and their data were combined to allow comparisons with the HCP 
rating scores on the bivariate plot. The mean rating values are used as a cut-off on the 
go-zones and statements falling within the top right quadrant were considered as 
being of high importance by both the combined PSS and AHM group and the HCP 
group. As such, these statements were considered targets for planning future 
interventions. 
3.4 Results 
231 participants took part in the study including 121 PSS patients and 43 AHM from 12 
sites across England and 67 HCP from across the UK.  
From the 371 patients invited to participate in the study 49% replied indicating they 
would like to take part and overall 33% of patients invited to take part completed one 
or more stages of the GCM exercise. A flow diagram of PSS patient participants is 
shown in Figure 3:3. 
 
 
Figure 3:3 Flow diagram of PSS patient participants in the concept mapping exercise 
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Of the 60 AHMs who consented to take part, 43 went on to complete one or more 
stages of the GCM exercise (72%). A flow diagram of AHM respondents can be seen in 
Figure 3:4. 
 
Figure 3:4 Flow diagram of AHM participants in the concept mapping exercise 
 
Of the 70 HCPs who replied to the invitation about taking part in the GCM study, 96% 
completed one or more stages of the process, meaning 67 HCPs took part in the 
concept mapping exercise. A flow diagram of the HCP participants is shown in Figure 
3:5. 
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Figure 3:5 Flow diagram of Health Care Professional participants in the concept 
mapping exercise 
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The count of PSS and AHM participants who participated in the GCM study at each site 
is shown in Figure 3:6.  
 
Figure 3:6 Bar chart showing numbers of PSS and AHM who took part in the GCM 
study from each recruitment site 
 
Newcastle followed by Swindon and Birmingham have the largest numbers of patients 
recruited to the UKPSSR, which explains why recruitment was highest at these sites. 
Other sites have fewer registry participants, for example Harrogate had only three 
UKPSSR participants during recruitment for this study, one of whom opted to take part 
in the concept mapping study.  
A breakdown of the methods participants chose to complete the GCM study are shown 
in Figure 3:7. 
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Figure 3:7 Participants who completed the GCM: Method of completion 
 
The majority of PSS patient and the AHM participants opted to take part using the 
paper method of completion and a small proportion of local PSS patients opted to take 
part in a face-to-face brainstorming session. The majority of HCPs opted to take part 
online. 
3.4.1 Demographics of PSS participants 
A summary of the PSS patient participant characteristics can be viewed in Table 3-1. 
The mean age of the AHM participants (n=43) was very similar to the PSS participants 
at 63.81 (S.D. 9.49). The mean number of years since diagnosis of the people who they 
lived with who had PSS was also similar to the number of years since diagnosis for the 
PSS group at 10.41 (S.D. 7.39).  63% of the AHM group participants were male and 37% 
were female.  
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Possible 
score range 
Mean 
(SD) 
Median 
(IQR) 
% 
Age   63.01 
(9.96) 
  
Years since 
diagnosis 
  10.15 
(7.21) 
  
Gender Female    86.8 
Male  13.2 
Live with another 
adult 
Unknown    0.8 
No  25.6 
Yes  73.6 
Dependents at 
home 
Unknown    3.3 
No  81.8 
Yes  14.9 
Receiving disability 
benefits* 
Unknown    0.8 
No  77.7 
Yes  21.5 
HADs Anxiety  0-21  7 (6)  
HADs Depression  0-21  6 (5.7)  
Pain VAS  0-100 37.3 (27.4)   
Fatigue VAS  0-100 54.6 (29.2)   
Mental Fatigue VAS  0-100 38.1 (28.7)   
Dryness VAS  0-100 56.7 (30)   
Cogfail  0-100 43.2 (18)   
Improved HAQ  0-100  17.2 (36.7)  
*Personal Independence Payment/Disability Living Allowance/Attendance Allowance/Independent Living Fund 
Table 3-1 Summary characteristics of the PSS patient participants (n=121) 
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A breakdown of the employment status of the PSS group data can be viewed in Figure 
3:8 below. The proportion of retired participants was similar in both the AHM and PSS 
participant groups. A larger proportion of the AHM group were in full-time 
employment compared with the PSS group and a smaller proportion of AHM 
participants were in part-time work compared with PSS participants. 
 
Figure 3:8 Pie chart demonstrating employment status for PSS patient participants 
(n=121) 
 
The PSS participants had lower quality of life as measured on the SF-36v2 compared 
with the US norms mean. The PSS SF-36 scores for the PSS participants in comparison 
to the mean US population norms can be viewed in Figure 3:9.  
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Figure 3:9 SF-36 norm-based scores for PSS patients (n=121) 
 
The PSS patients scored lower than the norm-based scores for all domains of the SF-
36. This was calculated as being significant for all individual domains and for the 
Mental and Physical Component Summary scores (see Table 3-2). 
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SF-36 domain 
PSS Norm-based 
scores*† 
t-value p-value 
Physical Functioning 39.18 (10.88) -10.94 <0.001 
Role Physical 38.36 (10.90) -11.75 <0.001 
Bodily Pain 42.37 (9.93) -8.46 <0.001 
General Health 38.09 (11.94) -10.97 <0.001 
Vitality 39.70 (10.75) -10.50 <0.001 
Social Functioning 41.68 (11.31) -8.09 <0.001 
Role Emotional 42.65 (11.29) -7.14 <0.001 
Mental Health 46.01 (10.71) -4.08 <0.001 
Physical Component Summary 38.15 (11.03) -11.77 <0.001 
Mental Component Summary 45.04 (10.70) -5.08 <0.001 
*Mean (SD) †USA norms mean (SD) = 50 (10) for all domains 
Table 3-2 Differences between PSS patient SF-36v2 scores and norm-based scores 
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3.4.2 Demographics of AHM participants 
The proportion of retired participants was similar in both the AHM and PSS participant 
groups. A larger proportion of the AHM group were in full-time employment compared 
with the PSS group and a smaller proportion of AHM participants were in part-time 
work compared with PSS participants. The breakdown of employment status for this 
group can be seen in Figure 3:10. 
 
Figure 3:10 Pie chart demonstrating employment status for AHM participants (n=43) 
 
The proportion of retired participants was similar in both the AHM and PSS participant 
groups. A larger proportion of the AHM group were in full-time employment compared 
with the PSS group and a smaller proportion of AHM participants were in part-time 
work compared with PSS participants. 
The AHM norm-based SF-36 scores were compared with the US normative data and 
these can be visualised in Figure 3:11.  
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Figure 3:11 SF-36 norm-based scores for AHM participants (n=43) 
 
The comparisons with the normative data mean, using a one sample t-test can be 
viewed in Table 3-3. 
SF-36 domain 
AHM Norm-
based scores*† 
t-value p-value 
Physical Functioning 50.60 (8.28) 0.47 0.639 
Role Physical 50.94 (8.23) 0.75 0.456 
Bodily Pain 51.41 (9.43) 0.98 0.331 
General Health 54.37 (8.15) 3.51 0.001 
Vitality 54.33 (10.97) 2.59 0.013 
Social Functioning 53.84 (6.61) 3.81 <0.001 
Role Emotional 51.63 (6.90) 1.55 0.128 
Mental Health 54.88 (6.00) 5.34 <0.001 
Physical Component Summary 50.83 (8.75) 0.62 0.539 
Mental Component Summary 54.65 (6.95) 4.41 <0.001 
*Mean (SD) †USA norms mean (SD) = 50 (10) for all domains 
Table 3-3 Comparisons of AHM norm-based scores with US norms 
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The AHMs had SF-36 scores which were comparable with the US normative data for 
the Physical Functioning, Role Physical, Bodily Pain and Role Emotional domains as well 
as the Physical Component Summary. The AHMs scored significantly better than the 
US norms for the General Health, Vitality, Social Functioning, Mental Health domains 
and the Mental Component Score.  
The caregiver strain scores are shown in Figure 3:12. Although the median CSI score of 
1 demonstrates that most AHM participants experienced very little caregiver strain, 
14% of AHM participants did experience high levels (indicated with a CSI score ≥7).   
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Figure 3:12 Dot plot of Caregiver Strain Index scores for AHM participants (n=43) 
3.4.3 Demographics of HCPs taking part in the concept mapping 
The majority of the HCP group were doctors, including both hospital and general 
practitioners. Occupational therapists made up the next professional group in terms of 
numbers and nurses, psychologists, a podiatrist a physiotherapist and a service 
manager also took part. A breakdown of the professional groups within the HCP group 
can be seen in Figure 3:13.  
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Figure 3:13 Professional groupings of the health care professional participants 
 
3.4.4 Participation in each stage of GCM process 
Overall, 232 participants took part in one or more stages of the GCM process. 
Participation in the study has been broken down into participant group, stages of the 
concept mapping process and by participation type (online/postal or face-to-face). This 
breakdown can be viewed in Table 3-4.  
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Stage of concept mapping 
process 
Patients 
with PSS 
Adult house-hold 
members 
Health care 
professionals 
Total 
Brainstorming 93 31 48 172 
Sorting 61 22 46 129 
Rating – Importance 91 31 59 181 
Participation in any stage 121 43 67 232 
Table 3-4 Number of participants in each stage of Concept mapping study by 
participant group 
 
3.4.5 The statement reduction process 
The brainstorming exercise generated 463 statements, which were subsequently 
distilled to a final set of 94 unique statements. A complete list of the numbered 
statements can be viewed in the Appendices (Section A.3). 
3.4.6 Representing the ideas and initial interpretation: The concept maps 
Multidimensional scaling resulted in a point map with a stress value of 0.18 (See Figure 
3:14). Each numbered point within the map represents a statement.   
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Figure 3:14 Point map depicting the numbered statements 
Location and distance on the map have meaning: Statements which were frequently 
sorted together by participants are located close to each other on the map; statements 
which were rarely sorted into the same groups as each other are located further away 
from each other. Figure 3:15 demonstrates how statements, which are very differently 
to each other conceptually, are located some distance away from each other on the 
point map. 
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Figure 3:15 Point map demonstrating how statements which are very different 
conceptually, are distant from each other on the map 
 
Conversely, Figure 3:16 shows how statements which are similar in meaning have 
ended up being in close proximity to each other on the map.  
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Figure 3:16 Point map demonstrating how statements similar in meaning are located 
near to each other on the map 
3.4.6.1Arriving at a cluster solution:  
A 7-cluster solution was ultimately agreed upon. An example of an 8-cluster map is 
visible in (Figure 3:17). The next two clusters to be combined by Ward’s algorithm are 
circled and labelled ‘Mental wellbeing’ and ‘Wellbeing’. The statements within these 
two clusters are closely related conceptually to each other (see Table 3-5). It therefore 
made sense to combine them, creating one ‘Wellbeing’ cluster. 
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Figure 3:17 An 8 cluster map 
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Mental wellbeing cluster statements: Wellbeing cluster statements: 
6. They have a good diet 5. Could go out in the sun  
19. Could come to terms with their 
symptoms 
10. Were less stressed or worried 
30 Could continue to drive 21. Feel in control of their symptoms 
43. Have a positive attitude 46. They have better mobility 
47. Exercise regularly 49. Could improve their concentration 
63. Could come to terms with their 
limitations 
65. Learn to balance their activity and 
rest 
89. Develop good coping strategies 
90. Keep their body active 
92. Keep their mind active 
52. Their mood was better 
Table 3-5 Numbered statements within the two clusters which are next to merge 
 
After these two clusters were combined to create the ‘Wellbeing’ cluster, there were 
seven clusters. Following this iteration, the software next combined the ‘Public 
awareness and support’ and the ‘Family and friends support’ clusters to create six 
clusters. Although it made sense initially to combine these clusters, the statements 
within the ‘Family and friends support’ cluster related much more to how someone 
with PSS might relate to others and how they might relate to them. The statements in 
the public awareness and support cluster conceptually related to how society could 
support them within the context of their disease. Therefore, a unanimous decision was 
made to keep these as two distinct clusters and choose a final seven cluster solution. 
The seven cluster solution contained the following named clusters: (1) Access and 
coordination of healthcare; (2) Knowledge and support; (3) Public awareness and 
support; (4) Friends and family; (5) Symptoms; (6) Patient empowerment and (7) 
Wellbeing. The smallest cluster (Friends and family) contained 6 statements and the 
largest (Access and coordination of healthcare) 22 statements. The point cluster map 
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can be seen in Figure 3:18. Here each statement is again represented by a numbered 
point on the map and these points are grouped into the themed clusters.  
 
Figure 3:18 Point cluster map depicting the final 7 cluster solution 
 
Average importance rating scores for each cluster for all stakeholder groups were next 
examined and can be seen in a cluster rating map (Figure 3:19). The clusters with the 
greater numbers of layers were rated as being of greater importance by participants. 
As can be seen within Figure 3:19, the statements falling within the Patient 
Empowerment cluster received the highest priority ratings out of a possible 5 (mean of 
4.07) followed by the Symptoms cluster (mean of 3.98). The lowest rated cluster was 
Public Awareness and Support which had a mean rating score of 3.48.    
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Figure 3:19 Cluster rating map 
 
To determine if there were any differences between the three stakeholder groups’ 
importance ratings for the different clusters, a ‘pattern match’ was generated (see 
Figure 3:20). This demonstrated a high level of agreement between participant groups 
for the importance ratings for each cluster. PSS patients and AHMs both viewed 
Patient Empowerment and Symptoms as being the most important concepts. HCPs 
viewed Patient Empowerment and Wellbeing as being the most important, followed by 
symptoms. All groups agreed that Public Awareness and Support was the least 
important concept in the context of people with PSS being able to do everyday 
activities of their choosing. 
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Figure 3:20 Pattern match demonstrating importance ratings for each cluster by 
participant group 
 
‘Go-zones’ or bivariate plots of importance ratings for all statements were next 
examined for two participant groups at a time (see Figure 3:21). There was a higher 
correlation between rating data for the PSS and AHM group (r=0.89) compared with 
the PSS and HCP groups (r=0.68) and HCP and AHM groups (r=0.73). Therefore to 
examine the priority statements within each cluster, the PSS and AHM groups were 
combined. This meant the importance ratings were compared with the ‘lived 
experience’ group (PSS and AHM groups combined) and the HCP group. The similarities 
and differences were examined in go-zones which were generated for each of the 
clusters. Each cluster is discussed in turn, in decreasing order of importance as ranked 
by participants.  
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Figure 3:21 Go zones showing importance ratings for all statements comparing each 
of the participant groups 
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Cluster 1: Patient empowerment 
Participants who took part in the rating exercise rated Patient empowerment as the 
most important cluster. This cluster contains 8 statements. Table 3-6 shows the mean 
importance ratings given by all participants for each of the statements. Within the 
cluster statement #29 ‘There was a cure’ was seen as the most important followed by 
#80 ‘Felt they were being taken seriously’ and #25 ‘Have support to manage their 
symptoms themselves’. 
Statements 
Mean 
Importance 
Rating 
29 There was a cure 4.45 
80 Felt they were being taken seriously 4.34 
25 Have support to manage their symptoms themselves 4.22 
58 Take their medication as prescribed 4.07 
24 Have confidence to seek advice when needed 4.02 
22 Look after their physical, emotional and spiritual wellbeing 4.00 
92 Were taught relaxation techniques 3.74 
59 Have support with memory and concentration difficulties 3.73 
Cluster importance rating mean = 4.07 (SD 0.24) 
Table 3-6 Patient empowerment cluster: Statements and importance ratings 
 
In order to identify any differences in opinion between participant groups for the 
importance of each statement within this cluster, a go zone (explained earlier in 
Section 3.2.2) was created (see Figure 3:22). Here I made a comparison between two 
groups; those with the ‘lived experience’ of PSS (PSS patients and AHMs) and HCPs. 
The go zone has identified that the top three priority statements within the green zone 
are the same as those identified in Table 3-6. Similarly, the least priority statements 
within the table were those identified by both participant groups as being the least 
important (#92 ‘Were taught relaxation techniques’ and #59 ‘Have support with 
memory and concentration difficulties’). 
HCPs perceived that if people with PSS were able to look after themselves well (#22 
‘Look after their physical, emotional and spiritual wellbeing’) and have the confidence 
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to seek appropriate advice when required, they would be able to do more day-to-day 
activities of their choosing.  
PSS patients and AHMs perceived that it was important to ‘Take their medication as 
prescribed’ (#58). However, these statements were very near the cut off for the green 
go-zone areas and although they have highlighted some slight differences between the 
two groups, they were still rated at ≥4 out of 5 overall for all groups combined (see 
Table 3-6). 
 
Figure 3:22 Go zone identifying importance of each statement within the Patient 
Empowerment cluster 
 
Cluster 2: Symptoms 
The next most important cluster was the Symptoms cluster. This cluster contains 20 
statements which all relate to symptoms of PSS. Table 3-7 shows the mean importance 
ratings given by all participants for each of the statements. Statements relating to 
ocular dryness, pain and fatigue were rated as being the most important with skin and 
vaginal dryness being rated as the least important.  
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Statements 
Mean 
Importance 
Rating 
84 Their eyes were less dry 4.37 
50 Have less pain 4.34 
18 Were less fatigued 4.34 
76 Fatigue was better managed/treated 4.34 
32 Their vision was not impaired 4.32 
61 Their eyes were more comfortable 4.31 
71 Were able to sleep better 4.23 
68 Have healthy teeth and/or comfortable dentures 4.17 
69 Their throat was less dry 4.16 
34 Swallowing was easier 4.10 
82 Mouth and lips were less dry 4.07 
72 Gastrointestinal (stomach and bowel) problems were 
managed 
3.93 
8 Were less prone to getting infections 3.89 
31 Skin problems were treated 3.76 
74 Were less breathless 3.64 
77 Have more feeling in their mouth and lips 3.64 
3 Did not have mouth sores or ulcers 3.61 
36 Didn't have sexual problems 3.54 
27 Their skin was less dry 3.46 
26 Their vagina was less dry 3.40 
Cluster importance rating mean = 3.98 (SD 0.33) 
Table 3-7 Symptoms cluster: Statements and importance ratings 
 
In order to identify any differences in opinion between participant groups for the 
importance of each statement within this cluster, a go zone was created (see Figure 
3:23). This identified that symptoms relating to fatigue, pain, sleep and oral and ocular 
dryness were considered as being of highest importance. The ten statements within 
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the green go zone area were the same statements which were identified as being the 
most important in Table 3-7. 
 
Figure 3:23 Go zone identifying importance of each statement within the Symptoms 
cluster 
 
Cluster 3: Wellbeing 
The cluster, which was the third highest rated cluster to emerge from the concept 
mapping process, was the Wellbeing cluster. This cluster contains 16 statements. Table 
3-8 shows the mean importance ratings given by all participants for each of the 
statements. 
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Statements 
Mean 
Importance 
Rating 
91 Keep their mind active 4.41 
43 Have a positive attitude 4.41 
90 Keep their body active 4.36 
21 Feel in control of their symptoms 4.24 
89 Develop good coping strategies 4.17 
47 Exercise regularly 4.01 
65 Learn to balance their activity and rest 3.96 
46 They have better mobility 3.90 
19 Could come to terms with their symptoms 3.84 
6 They have a good diet 3.79 
63 Could come to terms with their limitations 3.78 
49 Could improve their concentration 3.75 
52 Their mood was better 3.73 
10 Were less stressed or worried 3.69 
30 Could continue to drive 3.68 
5 Could go out in the sun 2.86 
Cluster importance rating mean = 3.91 (SD 0.38) 
Table 3-8 Wellbeing cluster: Statements and importance ratings 
 
A go zone was created to identify the statements falling in the green priority area (see 
Figure 3:24). The top five statements within Table 3-8, all fell within the green area of 
the go zone. The HCP group saw certain statements as priorities. These include 
statements #19 ‘Could come to terms with their symptoms’, #63 ‘Could come to terms 
with their limitations’ and #52 ‘Their mood was better’. From the HCP group 
perspective, acceptance of the disease and its limitations and an improvement in 
mood could potentially result in people with PSS being able to carry out more daily 
activities of their choosing. Those in the lived experience group perceived that a good 
diet, better mobility and regular exercise could help a person with PSS to do more daily 
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activities. Both groups compared within the go zone identified that going out in the 
sun (#5) was a very low priority in comparison to the other statements. 
 
Figure 3:24 Go zone identifying importance of each statement within the Wellbeing 
cluster 
 
Cluster 4: Access and coordination of healthcare 
This cluster contained 22 statements. Statement #54 ‘There is good communication 
between clinicians’ was rated as the most important within this cluster (See Table 3-9). 
Other priority statements related to accessing good drug treatments and knowing who 
to contact when symptoms flared up and also having access to professional support 
during a flare. Statements relating to access to specific types of therapies were seen as 
lower priorities.  
A go zone was also created for this cluster (see Figure 3:25). The important statements 
within Table 3-9 can be seen within the green area of the go zone. HCPs rated some 
statements relating to specific things that health care professionals could do for their 
patients as being important. These include providing individualised treatment plans, 
signposting to appropriate support groups and charities and raising sensitive topics in 
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consultations. They also saw access to psychological support and a specialist nurse as 
being a priority. The PSS patients and AHMs did not see these as priorities. 
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Statements 
Mean 
Importance 
Rating 
54 There is good communication between clinicians 4.45 
2 Have access to a range of good drug treatments 4.39 
14 Have professional support during a flare up of symptoms 4.37 
1 Know who to contact when their symptoms flare up 4.32 
85 Associated conditions are diagnosed and treated 4.31 
15 Can see a consultant when needed 4.25 
93 Their healthcare is better coordinated 4.20 
4 Knew the range of available treatment options 4.18 
79 Diagnosis was quick 4.17 
66 There was more funding for specialist rheumatology 
services 
4.12 
7 There were "one stop" Sjögren's clinics with all relevant 
health care professionals available 
4.02 
62 Have access to a specialist nurse 3.91 
40 Have an individualised treatment plan 3.90 
45 There was better management of the side effects of drugs 3.88 
56 Health care professionals would raise sensitive topics  
(e.g. sex and vaginal dryness) during consultations 
3.71 
57 Professionals could direct them to support groups and 
charities 
3.66 
28 Have access to psychological support 3.49 
70 Have access to occupational therapy 3.46 
9 Have access to physiotherapy 3.39 
88 Have access to complementary therapies or alternative 
remedies 
3.23 
44 There were diaries for recording symptoms and problems to  
bring to appointments with health care professionals 
3.16 
81 Have access to hydrotherapy 2.96 
Cluster importance rating mean = 3.89 (SD 0.43) 
Table 3-9 Access and coordination of healthcare cluster: Statements and importance 
ratings 
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Figure 3:25 Go zone identifying importance of each statement within the Access & 
coordination of healthcare cluster 
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Cluster 5: Knowledge and support 
As can be seen in Table 3-10, the Knowledge and support cluster contained 13 
statements. The most important statements were those which related to the need for 
more research to develop and test treatments and research to understand the causes 
of the disease. This was closely followed by statements relating to education on PSS for 
both healthcare professionals and patients. The lowest priority statement was about 
there being appropriate aids and adaptations in the community. 
Statements 
Mean 
Importance 
Rating 
20 There was more good research to test and develop 
treatments 
4.45 
13 There was more good research to understand the 
underlying causes 
4.38 
53 There was education on Sjogren's for healthcare 
professionals 
4.28 
37 There was education on Sjogren's for patients 3.97 
75 There was information available on exercise and 
Sjogren's 
3.67 
60 Have access to support and advice from other people 
with Sjogren's 
3.66 
78 Have help with dental costs 3.65 
67 Felt a family member or supporter would be welcome at 
their appointments 
3.55 
48 Have access to appropriate aids and adaptations in their 
homes 
3.51 
23 Felt a family member or supporter could be included in 
their care planning 
3.48 
11 Have Sjogren's advice leaflets 3.44 
38 Could access support to help set personal goals 3.44 
12 There were appropriate aids and adaptations in the 
community 
3.17 
Cluster importance rating mean = 3.74 (SD 0.39) 
Table 3-10 Knowledge and support cluster: Statements and importance ratings 
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The go zone for this cluster (Figure 3:26) confirms that both groups considered the 
statements on research and education to be of most importance. Compared to other 
clusters, there was a lower level of agreement between the two groups (r=0.54). This 
reflected a difference in priorities for some of the statements between the HCPs and 
those with the lived experience of PSS. The PSS group considered having help with 
dental costs and having information on exercise as being a priority relative to other 
statements within the cluster, but these were seen as less important by HCPs. 
However, the HCP rated more highly statements around having support to set personal 
goals, welcoming family members to appointments and having access and support 
from others with the disease. Both groups considered having aids and adaptations in 
the community a lower priority.  
 
Figure 3:26 Go zone identifying importance of each statement within the Knowledge 
& support cluster 
 
Cluster 6: Friends and family 
The Friends and family cluster was rated as the second least important cluster and 
contained 6 statements which can be viewed in Table 3-11. The most important 
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statement was #41 ‘Have supportive family and friends’. The least important 
statement was #86 ‘On a bad day people could tell by looking at them how they are 
feeling’. Compared to other clusters, there was a lower level of agreement between 
the two groups (r=0.54). This reflected a difference in priorities for some of the 
statements between the HCPs and those with the lived experience of PSS. The lived 
experience group considered being able to describe PSS to others as being a priority 
relative to other statements within the cluster, but was not considered as being as 
important by HCPs. However, the HCP rated more highly - in relation to other 
statements in the cluster – the inclusion of people with PSS in events by their friends 
and family.  
Statements 
Mean 
Importance 
Rating 
41 Have supportive family and friends 4.12 
83 Family could understand the symptoms 3.83 
94 Can explain to others what they can and cannot do 3.78 
55 Could easily describe Sjogren's to others 3.66 
33 Friends and family include them in events 3.65 
86 On a bad day people could tell by looking at them how they 
are feeling 
3.10 
Cluster importance rating mean = 3.69 (SD 0.30)  
Table 3-11 Friends and family cluster: Statements and importance ratings 
 
The go zone for this cluster (Figure 3:27) confirmed that both groups considered 
having supportive friends and family as being of most importance in this cluster. Both 
groups also agreed that the lowest priority statement was about others being able to 
know how a person with PSS was feeling on a bad day. However, both groups 
considered being able to explain to others about their disease and having family who 
understood the symptoms as being important.   
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Figure 3:27 Go zone identifying importance of each statement within the Friends and 
family cluster 
 
Cluster 7: Public awareness and support  
The Public awareness and support cluster was rated as the least important cluster. 
There were 9 statements in this cluster (see Table 3-12). Priority statements for this 
cluster relate to education for people who fund services and being eligible for benefits 
if unable to work. Statements which were regarded as less important were #42 ‘Have 
assistance with shopping, cleaning etc.’ and #73 ‘Public transport was accessible’. 
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Statements 
Mean  
Importance  
Rating 
17 There was education about Sjogren's for people who fund 
services 
4.01 
87 Those unable to work and/or needed support to function, were 
eligible for benefits 
3.92 
64 Employers were aware of things they could do in the workplace 
that  are helpful for people with Sjogren's 
3.85 
51 There was education on Sjogren's for family members 3.59 
16 There was education about Sjogren's for the general public 3.38 
35 Public spaces were more Sjogren's friendly e.g. 
heated/lit/airconditioned differently 
3.28 
39 Have a disabled parking badge 3.14 
73 Public transport was accessible 3.09 
42 Have assistance with shopping, cleaning etc. 3.04 
Cluster importance rating mean = 3.48 (SD 0.36) 
Table 3-12 Public awareness and support cluster: Statements and importance ratings 
 
The go zone for this cluster (see Figure 3:28) showed that both groups agreed about 
priorities within this cluster and agreed about what was less important. Examples of 
priorities included education for those who fund services for PSS patients and for 
family members, benefits for people with PSS who are unable to function well or work, 
and awareness of employers to make appropriate adjustments within the workplace 
for employees with PSS. Lower priorities included accessible public transport, lighting 
and air-conditioning within public spaces, domestic support, and education about PSS 
for the general public. 
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Figure 3:28 Go zone identifying importance of each statement within the Public 
awareness and support cluster 
 
3.5 Discussion 
This concept mapping study has highlighted that PSS patients, AHMs and HCPs 
consider that in the context of people with PSS being able to participate more and 
carry out day-to-day activities of their choosing, the concepts of ‘Patient 
empowerment’ and managing ‘Symptoms’ are particularly important.  
3.5.1 Discussion of demographic results 
The PSS participants who took part in this exercise had a mean age of 63 years, which 
is similar to the average age in a study which included the majority of the UKPSSR 
cohort (mean of 61 years) (Lendrem et al., 2014).The average number of years since 
diagnosis in this study was 10. It is therefore possible that newly diagnosed patients 
and their family members may have given different responses to those in this study. In 
order to investigate this further, I conducted a subgroup analysis by creating a pattern 
match to compare the mean importance rating values at cluster level from those who 
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had a diagnosis of PSS (PSS patients and AHMs) of ≤5 years (n=34) and those who had 
a PSS diagnosis for >5 years (n=88). This revealed a high level of agreement (r=0.96). 
This result indicates that length of disease does not seem to influence how those with 
a lived experience of PSS prioritise the identified themes. However, it is still 
conceivable that ‘newly’ diagnosed PSS patients may have different needs and a 
separate study focussing on this subgroup of patients is needed to address this. 
13% of the PSS patients who took part in this study were male, which is slightly greater 
than the proportion of males (9%) reported in a recent meta-analysis of PSS studies 
which included 7888 participants (Singh et al., 2016). As the proportion of males in this 
study was greater than the proportion of males represented in other PSS studies, I 
compared the differences in importance ratings at cluster level between males and 
female PSS participants (males, n=10, females, n=83) by creating a pattern match. This 
revealed no differences in importance ratings between males and females (r=0.99). 
Therefore, despite a relatively greater proportion of male PSS patients taking part in 
this study, there was a very high level of agreement between males and females and 
the increased male representation did not influence the overall priority scores. 
The SF-36 norm-based scores for the PSS patients indicated that their quality of life 
was significantly reduced compared to the US norm scores. This is clinically as well as 
statistically significant as a difference of 3-5 below 50 is regarded as clinically 
significant (Saris-Baglama et al., 2011). PSS participants in particular had low mean 
norm-based physical component summary scores (38.15 SD 11.03). Low scores in 
domains which relate to activities of daily living and participation (Physical Functioning, 
Role Physical, Social Functioning and Role Emotional) further add to the body of 
literature (Hackett et al., 2012a; Hackett et al., 2012b), which proposes and 
demonstrates that people with PSS have difficulties performing daily activities and 
taking on life roles. 
Conversely, the AHM group had significantly better quality of life as measured by the 
SF-36 compared with the US norm scores for the Mental Health and Social Functioning 
domains. However, the low t-values for these domain scores indicates that the 
differences were minimal. Furthermore, the smaller AHM cohort, may not have been 
sufficiently powered and there may be differences in scores between people in the US 
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and those in England. To my knowledge, quality of life scores in family members of 
people with PSS have not previously been reported. 
Caregiver strain was present in 14% of AHMs and as would be expected, this is lower 
than CSI scores reported for those living with someone who had recently had a stroke 
(Blake et al., 2003), traumatic brain injury (Fortune et al., 2016) or recently discharged 
from a critical care unit (McPeake et al., 2016). However, the level of carer strain in 
adults living with someone with PSS, was similar to the levels reported by carers who 
live with someone who has Parkinson’s disease (Wade et al., 2003). Carer strain could 
be evident in AHMs living with someone who has PSS and clinicians should be aware of 
this possibility. 
3.5.2 Discussion of concept mapping results 
The point map had a stress value of 0.18. In multi-dimensional scaling, lower stress 
values are preferred as they reflect a better goodness of fit of the final point map 
representation with the original inputted similarity matrix (Kruskal, 1964; Rosas and 
Kane, 2012). Stress values for concept mapping studies should ideally fall below 0.39 
(Trochim, 1989) and a recent pooled concept mapping study analysis of 69 studies 
demonstrated an average stress value of 0.28 (SD = 0.04, range: 0.17–0.34, 95% CI 
[0.27, 0.29]) (Rosas and Kane, 2012).  
In general, this study has shown that HCP, PSS patients and AHM have similar 
priorities. However, there are some subtle differences and these were identified in the 
pattern match and the go zones. The main priority identified in this study by all 
stakeholder groups, was the need for patient empowerment. Patients can be further 
empowered by being key contributors in the design of services and symptom 
management programmes. 
3.6 Conclusions 
In order for people with PSS to improve their functional capacity and ability to 
participate in valued life activities, it is a priority that they are empowered and given 
support to manage their symptoms and improve their wellbeing. There was a high 
level of agreement between the participant groups regarding these priorities. 
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3.7 Summary 
In this chapter, I have reported the methods and results of a concept mapping study 
involving 232 participants. The participants included a range of health care 
professionals representing different professional groups from across the UK and PSS 
patients and adult household members from different sites across England. This is a 
large-scale concept mapping study and the results are likely to be representative of UK 
PSS patients and clinicians who treat them. In the following chapter, I discuss the 
concept maps further and I present a summary report resulting from the 
interpretation sessions of the concept mapping data, which took place with my study 
advisory group. 
 
 
 
 
  
 Katie L Hackett - May 2017   111 
Chapter 4. Intervention planning: Utilising the concept mapping 
results 
In the previous chapter, I reported the methods and results of a group concept mapping 
study involving 232 participants from three stakeholder groups. In this chapter, I 
discuss these results further and describe some group interpretation discussions held 
with members of the study advisory group. The purpose of these interpretation sessions 
was to identify future intervention targets and facilitators from the concept mapping 
data. I discussed these targets with clinical members of the study advisory group and 
some other experienced clinicians. I asked them to consider a number of priority 
statements from the concept map in turn and comment on whether it could be an 
intervention, an outcome or both. I also asked them to provide specific examples. I 
collated the responses to form the basis of a focus group outline plan for discussion 
with PSS patients and AHMs.  
4.1 Background 
In the previous chapter, I asked three stakeholder groups to identify factors (in the 
form of statements) preventing or facilitating people with PSS from being able to 
participate and perform daily activities. Participants ordered these statements into 
themes (or clusters) and ranked them for importance and the results can be seen in 
Chapter 3. Interpretation of these results is key and the final part of the concept 
mapping process (see 3.2.3). The results and interpretations from this broad 
stakeholder engagement concept mapping process and the appropriate subsequent 
interpretations can be reported back to stakeholders and used to guide future 
planning (Trochim et al., 2004). 
The reason for making further interpretations to the concept mapping results was to 
determine i)  the general themes and ii) the specific ideas from within the concept 
maps which will form both priority intervention target areas and specific components 
of a future intervention package. These interpretations will guide future non-
pharmacological interventions to support patients with PSS to improve participation 
and ability to perform their daily activities.  
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In GCM studies with large numbers of stakeholders, it is common for key study group 
members to have made some interpretations to the concept maps prior to presenting 
the results and interpretations back to other stakeholders (Kane and Trochim, 2007). 
Furthermore, some of the priority statements within the concept maps, identified by 
key stakeholders (in Chapter 3), might be regarded as either potential intervention 
components, outcome measures, or both. In this chapter, members of the study 
advisory group and clinicians specialising in the intervention target areas identify 
possible intervention components and outcomes from the concept maps. By 
highlighting the prioritised needs of the community and then further involving those 
who are likely to be part of the intervention delivery process, it maximises the 
potential implementation success of a future intervention package (Kelly et al., 2007). 
The initial interpretation of the concept mapping results produced in the previous 
chapter (Chapter 3) is used as a starting point in the utilisation of the concept mapping 
results as part of an intervention development process. 
4.2 Aims of chapter 
 To identify priority target areas from within the concept maps for future 
patient non-pharmacological interventions to improve participation and ability 
to perform daily activities for people with PSS.   
 To identify specific intervention components from within the concept maps 
which might form part of a future intervention package. 
 To provide a discussion framework for future focus group meetings with PSS 
patients and AHMs to discuss the intervention target areas and potential 
intervention components. 
4.3 Method 
The flow chart (Figure 4:1) gives an overview of the process which took place resulting 
in specific priority intervention targets and identified intervention components and 
possible outcome measures.  
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Figure 4:1 Flow chart demonstrating how the concept maps were utilised in the 
intervention development process 
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4.3.1 Identifying intervention targets from the concept maps 
a) Firstly, six steering group members (KH, TR, NK, VD, KD, W-FN) individually 
further examined the concept maps, in order to identify targets for a future 
intervention plan which will aim to improve participation and ability to perform 
daily activities for people with PSS. The same steering group members 
individually considered the clusters in the 7 cluster map (Figure 3:18) initially 
and drew logical pathways through the map. The pathways were a way of 
demonstrating how adjacent clusters within the maps may relate to each other. 
Clusters located near to each other are likely share some similarities with other 
clusters close by due to being near to each other on the map and it is possible 
that a cluster will influence its neighbouring clusters in some way. 
b) Secondly, several steering group members (KH, KD, TR, VD) individually 
considered the maps in light of the cluster importance ratings (Figure 3:19) and 
the importance of the individual statements within each of the three highest 
priority clusters (Figure 3:22, Figure 3:23 and Figure 3:24). The steering group 
members’ reported their individual interpretations during three study advisory 
group meetings. A further member of the steering group who had not been 
present at the two previous discussions (JN) attended the final group meeting. 
c) During the final steering group discussion meeting, the steering group reached 
consensus through discussion on the logical pathways through the map and for 
three specific intervention targets. 
4.3.2 Identifying intervention components and outcomes for each of the 
intervention targets from the priority statements 
Next, I created a go zone showing the importance of all individual statements within 
the concept map. Steering group members considered all statements within the green 
priority area of the go zone for inclusion as, either an intervention component (as part 
of a patient focussed intervention), or outcome within the context of each of the three 
identified intervention targets. Group members individually considered whether each 
statement explicitly related to each of the identified intervention targets and labelled 
each with one of four codes (Figure 4:2). Five steering group members took part in this 
process (KH, TR, VD, KD and JN).  
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 The statement relates explicitly to the intervention target - Include 
 The statement relates to the overarching theme but is not specific to the 
intervention target – Exclude 
 The statement is not patient focussed - Exclude 
 The statement is not relevant to this intervention target - Exclude 
Figure 4:2 Codes used to label each priority go zone statement 
 
We used the following inclusion/exclusion criteria to identify intervention components 
or outcomes from the priority statements. Statements that steering group members 
considered as being patient focussed and explicitly relating to the relevant 
intervention target were included. The statements that group members did not 
consider patient focussed (e.g. those focussing on political or organisational change) or 
those that did not explicitly relate to the relevant intervention target were excluded 
from the intervention component/outcome list. The individual results were discussed 
and a final list of statements which were labelled as ‘include’ by any steering group 
member involved in the coding exercise were listed for consideration by clinicians 
during the next stage of the process. We generated a final list following a discussion 
where disagreements over the coding were resolved. 
Once the main intervention targets and the priority statements which we considered 
to be explicitly related to the targets were identified from the concept maps, I 
presented them to clinicians with experience in at least one of the intervention target 
areas. The clinicians included physiotherapists (n=3), an occupational therapist (n=1), 
clinical psychologists (n=2), health psychologists (n=2) and consultant physicians (n=2). 
I asked the clinicians to consider the intervention targets in their clinical field. For 
example, clinicians working in the field of chronic pain only considered the priority 
statements in the context of the intervention target of pain. I asked the clinicians to 
consider whether each statement could form an intervention, an outcome measure or 
both. I also asked the clinicians to suggest specific interventions and/or outcome 
measures for each priority statement. Some clinicians examined the statements 
individually and fed back their comments. Others discussed their decisions as a group 
and fed back their ideas as one document. I collated these ideas and have presented 
them later in the results section of this chapter (see Section 4.4). Following these 
steps, the intervention target areas were presented to PSS patients and AHMs invited 
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to qualitative focus group discussions (Chapter 5) and at a patient support group 
where I was invited to present the results of the study (see Appendix A.7).  
The collated results formed the basis of a focus group discussion framework where the 
potential intervention targets and intervention components were discussed with PSS 
patients and AHMs (see Chapter 5). I held further discussions with members of the 
study advisory group to develop the focus group framework questions following the 
clinician validation exercise. 
4.4 Results 
4.4.1 Identifying the intervention targets 
Please refer to areas 1a, 1b and 1c in the flow chart (Figure 4:1). 
4.4.1.1 Interpretation of the map as a whole 
There were several ways of interpreting the maps. With this in mind, several members 
of the steering group first individually considered the cluster map and considered how 
each cluster related to the others. I presented my initial interpretations to the steering 
group first and other members shared their interpretations during a discussion. All 
disagreements were resolved through discussion and resulted in a shared 
interpretation. We divided the map up by four compass points (see Figure 4:3).  
The cluster map includes the Patient empowerment cluster at the centre. The clusters 
to the North of the map broadly relate to society’s response to the disease. To the 
South: A personal response to the disease; to the West: Environment; to the East: 
Health (see Figure 4:3).  
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Figure 4:3 The 7 Cluster map with broad theme areas depicted by compass points 
 
We drew several possible pathways through the map. Finally, we reconsidered the 
cluster rating map (Figure 3:19) and the most important statements within the two 
most important clusters (Patient empowerment and Symptoms) (Figure 3:22, Figure 
3:23). This influenced the direction of the pathways, which we then modified.  
4.4.1.2 Potential pathways through the map 
Several pathways were drawn through the clusters of the concept map (see Figure 
4:4). 
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Figure 4:4 Pathways through the concept map 
 
The pathways were split into four sections: 
1. In order to empower patients to ‘manage their symptoms themselves’ (#25) 
and for them to feel that they ‘were being taken seriously’ (#80) by clinicians 
they should be supported by clinicians to manage their priority symptoms. This 
in itself could have a positive impact on their wellbeing and result in them 
feeling more empowered. This section of the pathway is located in the South 
East corner of the map (see Figure 4:4). 
2. The priority symptoms could be addressed through an appropriate and 
accessible healthcare system. Having an appropriate system in place to help 
patients manage their symptoms, could be empowering to patients. This 
section of the pathway is situated in the North East corner of the map (Figure 
4:4). 
3. Through appropriate knowledge and support such as research ‘to test and 
develop treatments’ (#20), which would ultimately be delivered through a 
health care system. Furthermore, as the research and knowledge base 
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improves, there may be a spill over effect into public awareness of the disease. 
This section of the pathway is situated in the North West corner of the map 
(Figure 4:4). 
4. Friends and family are more likely to be supportive if they have a better 
understanding of the disease. Their support could ultimately further empower 
patients. This section of the pathway is located in the South West corner of the 
map (Figure 4:4). 
4.4.1.3 Identifying intervention targets from the priority clusters and 
statements 
Pathway 1 included the highest priority clusters. We therefore identified this pathway 
for identifying intervention targets, starting with the most important cluster within the 
concept map; Patient empowerment.  
The most important statements within the Patient empowerment cluster can be 
viewed in Figure 4:5. Firstly, we put statement #29 ‘There was a cure’, to one side, as 
there is currently no cure for PSS. Next, we considered statement #80 ‘Felt they were 
being taken seriously’. In order to take patients seriously, clinicians should consider 
what is of importance to their patients. Therefore #25 ‘Have support to manage their 
symptoms themselves’ is key.  
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Figure 4:5 Cluster rating map showing the Patient empowerment cluster priority 
statements 
 
Next, we considered which clusters related to these priority statements. In order to 
support patients to manage their symptoms themselves, it is necessary to establish 
which the priority symptoms are. Therefore statement #25 ‘Have support to manage 
their symptoms themselves’ immediately led us to consider the Symptoms cluster. The 
important symptoms (symptoms which fell within the green go-zone) within the 
Symptoms cluster were considered (see Figure 4:6). These priority symptoms included 
symptoms which relate to fatigue (#18 ‘were less fatigued’ and #76 ‘fatigue was 
better managed/treated’); sleep disturbances (#71 ‘were able to sleep better’), pain 
(#50 ‘have less pain’); oral dryness (#34 ‘swallowing was easier’, #68 ‘have healthy 
teeth and/or comfortable dentures’. #69 ‘their throat was less dry’) and ocular 
dryness (#32 ‘their vision was not impaired’, #61 ‘their eyes were more comfortable’ 
and #84 ‘their eyes were less dry’).  
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Figure 4:6 Cluster rating map showing Symptoms priority statements 
 
However not all symptoms actually ended up being located within the Symptoms 
cluster following the concept mapping process. Three statements, which could be 
considered as being mental health symptoms, ended up being located in the Wellbeing 
cluster. These included the #10 ‘Were less stressed or worried’, #49 ‘Could improve 
their concentration’ and #52 ‘Their mood was better’. All three of these statements 
were located within the concept map relatively close to the Symptoms cluster, but 
were not incorporated within this cluster during the cluster analysis. This is because 
the participants regarded these statements belonging conceptually to a Wellbeing 
theme. However, none of these statements (#10, #49 or #52) featured in the green go 
zone area of the Wellbeing cluster and therefore were not regarded as being priorities 
by PSS patients and AHMs. The priority statements within the Wellbeing cluster can be 
viewed in Figure 4:7. The steering group considered several of the statements within 
this third highest priority cluster, as being components of an intervention rather than a 
target. For example #65 ‘Learn to balance their activity and rest’ might be considered 
as a component of a fatigue intervention in other conditions e.g. chronic fatigue 
syndrome (White et al., 2011). 
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Figure 4:7 Cluster rating map showing Wellbeing priority statements 
4.4.1.4 Consensus on intervention targets 
During the third steering group meeting, members agreed that Section 1 of the 
pathway within the concept map (see Figure 4:4) was a priority area to focus 
intervention development goals as this area of the map contained the top priority 
clusters. Therefore, the intervention development focus should be on targeting priority 
symptoms in order to improve patients’ wellbeing and further empower them. 
Although five main symptom target areas were identified (sleep, fatigue, pain, oral 
dryness and ocular dryness), the group agreed that dryness symptoms are routinely 
addressed in clinics. There are systemic and topical treatments for both oral and ocular 
dryness and patients in the UK can be referred to an oral health physician or dentist 
and to an ophthalmologist for specialist care (Price, 2016a). Non-pharmacological 
treatments for sleep, pain and fatigue are not regularly addressed with PSS patients in 
the UK (Lord et al., 2009; Ng and Bowman, 2010; Hart et al., 2016) and therefore these 
 Katie L Hackett - May 2017   123 
needs remain unmet for many patients. The steering group therefore considered these 
three symptoms as being priority targets for an intervention plan (see Figure 4:8).  
 
Figure 4:8 Priority symptom targets and the priority statements referring to them 
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4.4.2 Identifying the intervention components for each symptom target 
Please refer to areas 2a, 2b and 2c in the flow chart (Figure 4:1). 
4.4.2.1 Selecting possible intervention components and outcome 
measurement tools 
The go zone highlights all the priority statements within the concept map. The 
statements within the green priority ‘go zone’ area can be viewed in Figure 4:9 below. 
 
Figure 4:9 Go zone of all statements with the most important statements highlighted 
in the green area 
  
4.4.2.2 Steering group interpretation session to reach consensus on 
intervention targets 
Following individual consideration of each priority statement within the context of 
each priority symptom target, the steering group identified a list of priority 
statements, which they considered as relating explicitly to fatigue, sleep and pain. 
These statements are identified in Table 4-1 (statements relating to a fatigue 
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intervention target), Table 4-2 (statements relating to a sleep intervention target) and 
Table 4-3 (statements relating to a pain intervention target) below.  
Potential components/facilitators or outcomes for a fatigue intervention identified 
from the priority concept statements within the concept map 
4. Knew the range of available treatment options 
6. They have a good diet 
10. Were less stressed or worried 
18. Were less fatigued 
19. Could come to terms with their symptoms 
25. Have support to manage their symptoms themselves 
38. Could access support to help set personal goals 
46. They have better mobility 
47. Exercise regularly 
50. Have less pain 
52. Their mood was better 
63. Could come to term with their limitations 
64. Employers were aware of things they could do in the workplace for people with 
Sjögren’s 
65. Learn to balance their activity and rest 
71. Were able to sleep better 
89. Develop good coping strategies 
Table 4-1 Priority statements identified by the steering group as explicitly relating to 
the fatigue intervention target 
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Potential components/facilitators or outcomes for a sleep intervention identified from 
the priority concept statements within the concept map 
4. Knew the range of available treatment options 
6. They have a good diet 
10. Were less stressed or worried 
18. Were less fatigued 
21. Feel in control of their symptoms 
25. Have support to manage their symptoms themselves 
38. Could access support to help set personal goals 
47. Exercise regularly 
50. Have less pain 
65. Learn to balance their activity and rest 
71. Were able to sleep better 
82. Mouth and lips were less dry 
89. Develop good coping strategies 
90. Keep their body active 
Table 4-2 Priority statements identified by the steering group as explicitly relating to 
the sleep intervention target 
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Potential components/facilitators or outcomes for a pain intervention identified from 
the priority concept statements within the concept map 
4. Knew the range of available treatment options 
10. Were less stressed or worried 
18. Were less fatigued 
19. Could come to term with their symptoms 
21. Feel in control of their symptoms 
25. Have support to manage their symptoms themselves 
46. They have better mobility 
50. Have less pain 
52. Their mood was better 
58. Take their medication as prescribed 
65. Learn to balance their activity and rest 
89. Develop good coping strategies 
Table 4-3 Priority statements identified by the steering group as explicitly relating to 
the pain intervention target 
 
4.4.2.3 Clinician validation 
Following the consultation with clinicians working in each of the relevant fields of 
chronic fatigue, sleep disturbances and chronic pain, the clinicians identified specific 
priority statements as being intervention targets and/or outcomes. The clinicians gave 
specific examples of interventions and outcomes. These can be seen in Table 4-4 (for a 
fatigue intervention target), Table 4-5 (for a sleep intervention target) and Table 4-6 
(for a pain intervention target). 
The clinicians regarded some statements as being a potential intervention 
component/facilitator for a particular symptom target and they regarded others as 
being an outcome. They considered some statements as being both an intervention 
component and an outcome and provided examples, which can be seen in the tables. 
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Go zone statements Cluster Intervention? Examples Outcome? Examples 
4. Knew the range of 
available treatment 
options 
Access & 
Coordination 
of Healthcare 
Yes At first appointment give 
information and make 
treatment plan in collaboration 
with patient 
No N/A 
6. They have a good 
diet 
Wellbeing Yes Advice on caffeine, sugar and 
fluid intake, general healthy 
eating, swallowing with a dry 
mouth 
Yes Food diaries for caffeine and sugar 
intake (when used to fight fatigue) 
10. Were less stressed 
or worried 
Wellbeing Yes CBT Yes Hospital Anxiety and Depression Scale 
(Snaith and Zigmond, 1986) 
18. Were less fatigued Symptoms No N/A Yes Fatigue VAS, ESSPRI (Seror et al., 
2011) 
19. Could come to 
terms with their 
symptoms 
Wellbeing Yes ACT Yes Acceptance and Action Scale II (Bond 
et al., 2011) 
25. Have support to 
manage their 
symptoms themselves 
Patient 
Empower-
ment 
Yes Activity management, pacing, 
GET, CBT 
 Fatigue VAS, ESSPRI  
1
2
8
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Go zone statements Cluster Intervention? Examples Outcome? Examples 
38. Could access 
support to help set 
personal goals 
Knowledge & 
Support 
Yes Goal setting Yes Canadian Occupational Performance 
Measure (Law et al., 2005a) 
46. They have better 
mobility 
Wellbeing Yes GET/exercises to activate 
specific targeted muscle groups 
Yes Increase in step count, Increase in 
timed physical activity, increase in 
mobility, SF36 physical function score 
47. Exercise regularly Wellbeing Yes Goal setting and GET Yes Increase in step count, Increase in 
timed physical activity 
50. Have less pain Symptoms Yes Pacing/balancing activity/GET/ 
CBT/ ACT/ Mindfulness 
Yes Pain VAS, ESSPRI 
52. Their mood was 
better 
Wellbeing Yes CBT, behavioural activation Yes HADs 
63. Could come to 
terms with their 
limitations 
Wellbeing Yes ACT Yes Acceptance and Action Scale II  
64. Employers were 
aware of things they 
could do in the 
workplace for people 
with Sjögren's 
Public 
Awareness 
Yes Personalised letter to give to 
employer with suggested 
reasonable adjustments, generic 
leaflet for employer 
No N/A 
1
2
9
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Go zone statements Cluster Intervention? Examples Outcome? Examples 
65. Learn to balance 
their activity and rest 
Wellbeing Yes Pacing/balancing activity/GET/ 
CBT 
Yes Activity diaries and activity monitor, 
activity balancing scale (Dur et al., 
2014), Work and Social Adjustment 
Scale (Mundt et al., 2002) 
71. Were able to sleep 
better 
Symptoms Yes CBT-Insomnia Yes Sleep diaries/activity monitor 
89. Develop good 
coping strategies 
Wellbeing Yes Goal setting, CBT, Mindfulness, 
Pacing 
Yes Brief COPE  (Carver, 1997) 
ACT = Acceptance and Commitment Therapy, CBT = Cognitive Behavioural Therapy, CBT-Insomnia = Cognitive Behavioural Therapy for Insomnia, ESSPRI = EULAR Sjögren’s Syndrome Patient Reported 
Index GET = Graded Exercise Therapy, HADs = Hospital Anxiety and Depression Scale, VAS = Visual Analogue Scale. 
Table 4-4 Intervention components and outcomes identified for a fatigue intervention target by clinicians 
  
1
3
0
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Go zone statements Cluster Intervention? Examples Outcome? Examples 
4. Knew the range of 
available treatment 
options 
Access & 
Coordinatio
n of 
Healthcare 
Yes At first appointment give 
information and make 
treatment plan in collaboration 
with patient 
No N/A 
6. They have a good diet Wellbeing Yes Advice on caffeine intake Yes Diary recording of caffeine intake 
10. Were less stressed or 
worried 
Wellbeing Yes Address worrying thoughts, 
notebook by the bed 
(component of CBT –Insomnia 
intervention) 
Yes HADs 
18. Were less fatigued Symptoms No N/A Yes Fatigue VAS, ESSPRI  
21. Feel in control of 
their symptoms 
Wellbeing Yes Behavioural changes as part of 
CBT-Insomnia intervention 
Yes Sleep diaries 
25. Have support to 
manage their symptoms 
themselves 
Patient 
Empower-
ment 
Yes CBT-Insomnia  Sleep diaries 
38. Could access support 
to help set personal 
goals 
Knowledge 
& Support 
Yes CBT-Insomnia Yes Sleep diary/ actigraphy 
47. Exercise regularly Wellbeing Yes Goal setting, GET, CBT No N/A 
1
3
1
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Go zone statements Cluster Intervention? Examples Outcome? Examples 
50. Have less pain Symptoms Yes Mindfulness, pain management 
techniques, relaxation, warm 
baths before bed, ACT 
Yes Pain VAS, ESSPRI  
71. Were able to sleep 
better 
Symptoms Yes CBT-Insomnia Yes Sleep diaries/ actigraphy 
82. Mouth and lips were 
less dry 
Symptoms Yes Glass of water by the bed/use of 
artificial saliva 
No N/A  
89. Develop good coping 
strategies 
Wellbeing Yes CBT-Insomnia Yes Brief COPE  
90. Keep their body 
active 
Wellbeing Yes GET, general exercise No  
Table 4-5 Intervention components and outcomes identified for a sleep intervention target by clinicians 
  
1
3
2
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Go zone statements Cluster Intervention? Examples Outcome? Examples 
4. Knew the range of 
available treatment 
options 
Access & 
Coordination 
of Healthcare 
Yes At first appointment give 
information and make treatment 
plan in collaboration with patient 
No N/A 
 
10. Were less stressed 
or worried 
Wellbeing Yes CBT, mindfulness-based stress 
reduction 
Yes HADs 
18. Were less fatigued Symptoms Yes Activity management, pacing Yes Fatigue VAS, ESSPRI 
19. Could come to 
terms with their 
symptoms 
Wellbeing Yes ACT Yes Acceptance and Action Scale II (Bond 
et al., 2011) 
21. Feel in control of 
their symptoms 
Wellbeing Yes CBT, GET, ACT Yes Revised Illness Perception 
Questionnaire (Moss-Morris et al., 
2002) 
25. Have support to 
manage their 
symptoms themselves 
Patient 
Empowerment 
Yes CBT, GET, ACT Yes Revised Illness Perception 
Questionnaire (Moss-Morris et al., 
2002) 
46. They have better 
mobility 
Wellbeing Yes GET/Physiotherapy targeted 
exercises 
No N/A 
50. Have less pain Symptoms Yes CBT, ACT Yes Pain VAS, ESSPRI 
1
3
3
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Go zone statements Cluster Intervention? Examples Outcome? Examples 
52. Their mood was 
better 
Wellbeing Yes CBT, behavioural activation Yes HADs 
58. Take their 
medication as 
prescribed 
 Yes If relevant, pain medication 
adherence therapy 
Yes Medication adherence scales 
(Nguyen et al., 2014) 
65. Learn to balance 
their activity and rest 
Wellbeing Yes Pacing/balancing activity/GET/ 
CBT 
Yes Activity diaries and activity monitor, 
activity balancing scale (Dur et al., 
2014) 
89. Develop good 
coping strategies 
Wellbeing Yes CBT, ACT Yes Brief COPE 
Table 4-6 Intervention components and outcomes identified for a pain intervention target by clinicians
1
3
4
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4.4.2.4 Focus group discussion framework 
After collating the feedback from the clinicians, I consulted with the study advisory 
group and drew up a framework of focus group questions to guide focus group 
discussions on the intervention target symptoms of fatigue, sleep and pain. It was 
important to ask people with the lived experience of PSS about their experiences of 
each of these symptoms prior to discussing potential intervention components. 
Therefore, focus group discussions on each of the areas started with asking people 
with the lived experiences of PSS about their individual experiences of the symptoms. 
The second part of the focus group discussion framework revolved around asking 
people about what kind of help they have sought for these symptoms (if any). The final 
part of the focus group discussion framework was for the facilitator to present some of 
the intervention components brought up during the clinician validation. The purpose 
was to ascertain whether these types of intervention components are likely to be 
acceptable and therefore be received well by people with PSS and their families. The 
outline of the discussion framework can be viewed in Table 4-7. 
Outline focus group discussion framework for each symptom target 
A i) Do people with PSS have difficulty with this symptom? 
   ii) What specific fatigue difficulties do you/your relative experience? 
   iii) Have the difficulties changed over time? How? 
   iv) Does this symptom impact on everyday life? How? 
   v) How do you/your relative currently manage this symptom? 
B i) Have you/your relative sought help for fatigue? From where or whom? 
   ii) Do you talk to others about it? Who? How do they respond? 
   iii) What kind of support/treatment have you had? Did this help? In what way? 
C i) Here are some possible non-drug intervention solutions. What do you think      
       about each? (Intervention components identified in Table 4-4, Table 4-5 and  
       Table 4-6) 
D) How would you like an intervention to be provided? e.g. in groups, one to one,  
      printed information etc. 
Table 4-7 Future focus group discussion framework for each symptom target 
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4.5 Discussion 
By carefully going through a process of examining the concept maps in detail with 
steering group members and careful interpretation of the results together, I have been 
able to identify priority intervention targets for PSS patients. Fatigue, sleep 
disturbances, pain, oral and ocular dryness have all been identified as symptoms which 
impact on patients with PSS ability to participate fully in daily life and carry out their 
daily activities. Dryness is a feature which is well recognised and there are established 
treatments which are recommended (Foulks et al., 2015; Vivino et al., 2015; Brito-
Zeron et al., 2016). However, fatigue, sleep and pain are needs which are infrequently 
addressed in the clinical setting and therefore they remain unmet (Segal et al., 2009; 
Ng et al., 2011; Hackett et al., 2016a). Consequently, we considered these three 
symptoms as being ideal intervention targets.  
Through discussing these intervention targets in more detail and considering further 
priority statements from all clusters within the concept maps, in collaboration with the 
steering group members, I have been able to identify some interventions (or 
facilitators) and outcomes from within the concept maps. The intervention 
components identified through the clinician validation process are more likely to be 
acceptable and feasible for delivery by clinicians within a clinical setting due to 
involving these key stakeholders in the process (Gitlin, 2013). The clinician validation 
process has fleshed out the priorities and given some realistic suggestions as to how 
each of these intervention targets might be addressed. The next step is to discuss 
these further with PSS patients and their family members to establish firstly whether 
they believe these intervention components and symptom targets should be 
addressed within PSS care. Secondly, if these intervention components are regarded 
by people with the lived experience of the condition as being both acceptable and 
important, it is important to establish how these components should be delivered.  
This next stage has addressed the high priority pathway within the concept map. There 
are alternative pathways, which are considered as being less of a priority. The lower 
priorities could also be addressed in a future intervention development plan. 
Alternative clusters (such as Access and coordination of healthcare) and pathways 
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within the map, could also be addressed to provide better holistic care and social 
support to improve the quality of life in PSS patients. 
4.6 Summary 
The work presented in this chapter has provided a focus group discussion framework 
to further explore the high priority intervention pathway. The following two chapters 
(Chapters 5 & 6) describe a focus group study and the emergent themes, which 
resulted from using this discussion framework with PSS patients and their family 
members.  
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Chapter 5. A qualitative focus group study to explore the 
experiences and impact of fatigue, sleep disturbances and 
pain/discomfort 
The previous chapter explained how the concept maps were utilised to identify specific 
unmet needs which could be targeted in future interventions to improve participation 
and the ability to perform daily activities. In this chapter, I describe the methods used 
to carry out several focus groups, in which I further discussed these unmet needs with 
patients and their spouses. I describe how I analysed the focus group data and present 
the results of how people with the lived experience of PSS, describe their fatigue, sleep 
disturbances and pain. I also discuss the impact of these symptoms on activities of daily 
living and participation.   
5.1 Method 
5.1.1 Aims 
The aim of this study was to discover more about the PSS symptoms of fatigue, sleep 
disturbances and pain from those with the lived experience of PSS.  
5.1.2 Study design 
I chose qualitative focus groups in order to meet the aims of this study. Focus groups 
use group interaction to collect data, as participants are encouraged to talk with each 
other, thus enabling them to comment on each other’s experiences and viewpoints, 
whilst being able to ask each other questions and provide anecdotes (Kitzinger, 1995). 
Group discussion is appropriate when the researcher has a series of open-ended 
questions, as participants are able to explore these with each other and focus on the 
issues they perceive as being important, using their own vocabulary (Kitzinger, 1995). 
Furthermore, focus groups can be used in the development phase of complex 
intervention development, particularly if a systematic review of the existing literature 
has not answered questions about the effectiveness of existing interventions (Craig et 
al., 2006). 
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5.1.3 Ethical approvals 
In order to conduct this study, I applied for a substantial amendment to the original 
concept mapping study approvals (13/NI/0190, IRAS Ref: 125562). I drew up new 
participant information sheets and consent forms for this section of the study which 
were submitted during the application process. This documentation including the 
letter from the ethical board granting this substantial amendment can be viewed in the 
Appendices (Section A.2). 
5.1.4 Recruitment and sampling strategy 
I posted invitation packs to 62 potential participants. The potential participants were 
44 PSS patients and 18 AHMs who had previously been recruited from the Newcastle 
upon Tyne site and had taken part in the earlier concept mapping study and had given 
consent to be invited to take part in future research studies. I did not send out 
reminder invitations. The pack included the participant information sheet, a reply form 
and a consent form (See Appendices, Section A.2.2 and A.2.3). As ethical and NHS Trust 
approvals were in place for the Newcastle site, participants were recruited from this 
site. The largest number of participants had also been recruited from this single site 
during the previous concept mapping study, as it is the host site of the UKPSSR and a 
regional specialist centre. This sampling strategy can be classified as criterion sampling 
(Patton, 2002) with location being the core sampling criteria.  However, in practice, it is 
more representative of convenience sampling. Convenience sampling, albeit 
commonly used in qualitative research is not an ideal approach (Patton, 2002). 
However, I should note that this was not a stand-alone qualitative study, but an 
exploratory phase, following on from the prior work. Also a previous PSS study which 
recruited patients from the Newcastle site demonstrated that the Newcastle patients 
who took part were reasonably representative of the whole UKPSSR cohort (Hackett et 
al., 2012a).  
I asked potential participants to reply using an enclosed reply form and to indicate 
whether they wished to participate in any of the focus groups. I also asked potential 
participants to suggest days of the week and times during the day when they would 
likely be available for a focus group. I subsequently planned the timing of the groups 
around the availability of both the facilitators and participants. Participants provided 
informed consent and signed consent forms prior to attending the focus groups. 
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5.1.5 Structure of the focus groups 
The focus group meetings took place during a weekday morning in a meeting room in 
the Newcastle upon Tyne Hospitals NHS Foundation Trust. I allocated two hours for 
each focus group. This allowed time for participants to settle and help themselves to a 
drink. At the beginning of each meeting, I briefly explained the results of the previous 
concept mapping study to participants then introduced the questions which guided the 
topic discussions (see Table 5-1).  
The conversations where structured around exploring: 
 Their experiences of the symptoms of fatigue, sleep disturbances and pain,  
 The strategies patients use to manage them 
 The impact these symptoms have on participation.  
The focus of this chapter is on experiences of symptoms.  I present the results of the 
other two elements, together with participants’ thoughts on potential intervention 
strategies suggested by clinicians and potential modes of delivering future non-
pharmacological interventions in the following chapter (Chapter 6 and 7).  
Topic guide  
Do you (or your relative) experience any difficulties with fatigue? 
What are they? 
Do you (or your relative) experience any difficulties with sleep? 
What are they? 
Do you (or your relative) experience any difficulties with pain? 
What are they? 
 
Table 5-1 Topic guide used to explore symptoms of fatigue, sleep disturbances and 
pain 
 
At the beginning of each focus group, I gave participants handouts with the outline 
structure of each session and a pen. I explained to them that they could write anything 
down on the paper and these would be collected in at the end. I divided each focus 
group session into two phases with a 15-20 minute break in the middle. Each phase 
lasted between 30 and 50 minutes. The meetings were audio recorded and these 
audio recordings were transcribed verbatim. Participants were reimbursed for their 
travel and drinks and snacks were available throughout the sessions. Participants could 
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attend more than one focus group meeting if they wished, as the discussion topics 
were different at each meeting. 
I facilitated the three focus group sessions, which I structured around the following 
topics: sleep disturbances; fatigue; pain and potential modes of delivering future 
interventions. Dr Vincent Deary co-facilitated the meetings with me and took field 
notes. Dr Deary and I both work as clinicians in the Newcastle CRESTA Fatigue clinic 
(Hackett et al., 2016b), and we both have extensive experience of working clinically as 
therapists with patients with chronic fatigue, chronic pain and long-term conditions. Dr 
Deary had not met any of the participants prior to the focus groups. I had previously 
met several participants during the course of my clinical work and had met two 
participants during the earlier concept mapping study, at the face-to-face group 
brainstorming session. At the end of each focus group, I summarised the topics of the 
conversation as an informal way of checking my interpretation of the conversations 
with the group members: this represents a modest version of ‘member checking’ 
(Lincoln and Guba, 1985). 
5.1.6 Data analysis 
I used thematic analysis to analyse the data (Braun and Clarke, 2006; Braun and Clarke, 
2013; Braun and Clarke, 2014) as it allows for the identification and analysis of 
patterns within the data. I use thematic analysis as an essentialist, or realist method in 
order to report the experiences, meanings and the reality of participants (Braun and 
Clarke, 2014). 
I use thematic analysis to reflect the reality of the participants’ viewpoints and 
experiences in the following chapters (Chapters 6 and 7), I attempt to apply the 
participants’ reality to the wider context of how services might be delivered for PSS 
patients in the future, within an NHS setting. I have addressed my analysis from a 
critical realist standpoint (Pawson and Tilley, 1997; Willig, 1999). This approach 
acknowledges that our experiences, perspectives and theories shape our 
understanding of the world (Maxwell, 2012), therefore there is no possibility of 
accurately obtaining a ‘God’s eye view’ (Putnam, 1989). 
I conducted the thematic analysis in six phases, as described by Braun and Clarke 
(2006):  
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1. I familiarised myself with the data by listening through the audio recordings 
and reading through the transcripts. Whilst doing this I noted down my initial 
ideas.  
2. Next, I generated initial codes from the data. I recorded the codes in an Excel 
spreadsheet and pasted in sections of transcript, which related to those codes 
in adjacent cells. 
3. I then examined the codes and grouped those together which conveyed similar 
meanings. This resulted in the generation of higher order themes.  
4. I reviewed these themes in relation to the coded extracts of text from the 
transcripts to ensure that they worked within the context of the whole dataset. 
These themes and the codes within them, were then reviewed by a second 
researcher (Dr Tim Rapley) and regularly discussed with him. They were also 
reviewed by other members of the supervisory team to improve analytical 
rigour (Fernald and Duclos, 2005). 
5. I continued to analyse and refine the specifics of the themes and the overall 
story, which the analysis presents. 
6. I wrote up the analysis, which went through several iterations. I selected 
appropriate sections of text to describe the themes, which I had interpreted 
from the data. 
5.2 Results 
I received postal responses from 27 out of the 62 PSS patients and AHMs who I had 
invited to take part (44% response rate). Nineteen respondents indicated that they 
would like to take part in a focus group. Thirteen were able to attend one or more 
focus groups, including 10 patients with PSS (8 female and 2 male) and 3 AHMs (2 
female and 1 male). Table 5-2 shows the demographic details of the focus group 
participants and indicates which meetings they attended as well as the fatigue, pain 
and dryness symptom scores for the PSS participants. These scores were recorded 
during the previous concept mapping study. The focus groups all took place late 
morning during the week. A second table provides demographic data for those who 
provided consent to take part in the focus groups, but were unable to attend (see 
Table 5-3). 
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I observed few differences between those who were able to attend a focus group 
meeting and those who were not. Of note, one PSS patient who provided consent but 
was unable to attend was in full-time employment. The patients in the non-attendance 
group also seemed to have higher dryness scores than those who were able to attend. 
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Participants Gender Age 
Employ-
ment status 
Attend 
FG1 
Attend 
FG2 
Attend 
FG3 
Years 
since   
diagnosis 
Pain  
(0-100)† 
Bodily 
Pain* 
Fatigue  
(0-100)† 
Vitality* 
Dryness 
(0-100)† 
PP1 Patient M 62 Unemployed Yes Yes No 4 49 34.2 53 31.8 69 
PP2 Patient F 73 Retired Yes No No 26 34 46.7 72 46.7 58 
PP3 Patient F 46 Unemployed Yes Yes Yes 10 16 51.51 96 28.8 49 
PP4 Patient F 74 Retired Yes No No 11 23 42.6 82 22.9 69 
PP5 Patient M 59 Emp P/T Yes Yes Yes 4 12 55.5 39 46.7 11 
PP6 Patient F 54 Unemployed Yes Yes Yes 2 82 26.5 90 22.9 37 
PP7 Patient F 65 Emp P/T Yes Yes Yes 7 16 46.3 28 52.6 33 
PP8 Patient F 77 Retired No Yes Yes 12 23 42.6 93 22.9 66 
              
PP9 Patient F 75 Retired No Yes Yes 31 23 46.7 29 52.6 45 
PP10 Patient F 68 Retired No No Yes 4 30 42.2 74 40.7 59 
AHM1 Spouse F 66 Retired Yes Yes No 4       
AHM2 Spouse M 60 Retired No Yes Yes 12      
AHM3 Spouse M 77 Retired No Yes Yes 31      
Mean (SD)   66 (10)  Total 8 Total 10 Total 9 12 (10) 28 (21) 45 (8) 66 (26) 36.8 (12) 50 (19) 
† VAS *SF-36 domain norm-based scores (US norms = 50 (SD 10)), FG = Focus Group, Emp P/T = Employed part-time 
Table 5-2 Focus group participants' attendance and demographics 
 
 
1
4
4 
 Katie L Hackett - May 2017    
Participants Gender Age 
Employ-
ment status 
Years 
since   
diagnosis 
Pain  
(0-100)† 
Bodily 
Pain* 
Fatigue  
(0-100)† 
Vitality* 
Dryness 
(0-100)† 
PP11 Patient F 60 Retired 4 81 34.6 100 22.9 99 
PP12 Patient F 52 Emp F/T 26 7 55.6 26 46.7 84 
PP13 Patient F 70 Retired 31 29 47.5 71 40.1 79 
PP14 Patient F 56 Emp P/T 8 63 30.6 53 31.8 88 
PP15 Patient F 77 Retired 9 21 46.7 22 46.7 52 
AHM4 Spouse M 67 Retired 8      
Mean (SD)   64 (9)  14 (11) 40 (31) 43 (10) 54 (33) 38 (10) 80 (18) 
† VAS *SF-36 domain norm-based scores (US norms = 50 (SD 10)), FG = Focus Group, Emp F/T = Employed full-time, Emp P/T = Employed part-time 
Table 5-3 Demographic details who provided consent, but were unable to attend a focus group 
 
 
1
4
5
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In the following text, each participant is referred to by their code number in Table 5-2; focus 
group facilitators are referred to by our first names and the groups are coded according to 
the session number; e.g. FG1A is the first half of focus group 1 and FG3B is the second half 
of the third focus group. 
5.2.1 Living with symptoms of PSS 
5.2.1.1 Symptoms as a whole 
The previous concept mapping study (see Chapter 3) demonstrated that symptoms of sleep 
disturbances, fatigue and pain were all deemed to interfere with participation in daily 
activities, in addition to oral and ocular dryness. Focus group participants concurred with 
these findings.  
In explaining what the terms sleep disturbances, fatigue and pain meant to them, 
participants worked to question and deconstruct this terminology whilst attempting to 
explain specifically the impact these symptoms had on their daily lives.  
Prior to giving a detailed description about each individual symptom, patients explained 
what it was like living with a range of PSS symptoms. They explained that this was 
challenging for a variety of reasons. Firstly, these symptoms can seem as though they are 
invisible to others. One patient described how even during a flare of symptoms, her friends 
would say to her: 
PP8 “Well, you look alright [Yeah]. You know, you look fine,” they’ll say, don’t 
they? (FG2B 607-609) 
If others could not visualise the flare of symptoms, as they would if it were ‘a broken leg’ 
(AHM2 FG2A 265), this would mean that people they meet on a daily basis ‘don’t know that 
you’re not well’ (PP7 FG3A 710). 
Due to the invisible nature of the symptoms, patients often struggled to meet the 
expectations of others. This was in part because other ‘people think that you should be able 
to keep doing everything you used to do’ (PP5 FG1B 1469-70). Others sometimes struggled 
to understand that the impact of the symptoms means that their colleague, friend or 
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relative with PSS, may no longer have capacity to do some of the things they used to do with 
relative ease.  
Another important feature of PSS symptoms was that they rarely occur in isolation. Patients 
often found that their symptoms could influence each other. For example, a flare of pain 
and discomfort might also occur alongside fatigue. Furthermore, other factors such as stress 
could also influence these symptoms. Despite the fact that more than one symptom is often 
present at any one time, in the following sections for ease of presentation, I summarise the 
results of the focus group discussions on each of the individual symptoms of fatigue, sleep 
disturbances and pain. However, the overlapping nature of the symptoms is evident in the 
following sections. 
5.2.1.2 The experience of fatigue 
Fatigue was a symptom experienced regularly by all the patients in the focus groups. Some 
patients experienced fatigue as being ever-present, with flares of more severe fatigue. 
Others experienced fatigue intermittently, with periods of time when they had very little 
fatigue followed by flares of moderate and severe fatigue. However, flares of more severe 
fatigue could come on quite rapidly for all patients and I give an example of this at the end 
of the current section, in the context of physical fatigue. 
During the discussions, participants described a clear distinction between ‘physical’ and 
‘mental’ fatigue. These phenomena were experienced both simultaneously, or separately, 
as one patient explained: 
PP3 I get, er, physical fatigue a lot … during the day it’ll come on. You mightn’t 
have the mental fatigue at that time. (FG1B 96-109) 
Mental fatigue was described as ‘a great cloud kind of building up in your head’ (PP7 FG1B 
36-37) and as ‘brain fog’ (PP8 FG2B 350). For one patient in particular, mental fatigue was 
much more of a problem than physical fatigue and affected her concentration. 
Consequently, it was sometimes difficult for her to achieve deadlines at work, such as 
written reports. Furthermore, mental fatigue, seemed to influence patients’ cognition which 
affected their perception of verbal expression and memory: 
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PP8 [Sometimes] I just can’t [think]. Some of the things I say are just 
ridiculous. … 
AHM2 She’ll say something and deny saying it. If I pull her up and say, “You’ve 
said X, Y, and Z.” 
PP8 “You said so and so.”   
AHM2 “No I didn’t.”  … She did it the other day and my son was round and he 
says, “You did Mum.” …“You said that, Mum.” (Laughter) 
PP8 And, I, I don’t realise I’ve done it or I, I forget things. (FG2B 360-378) 
Participants therefore regarded any cognitive difficulties they might have as being a 
consequence of their mental fatigue.  
Physical fatigue was described very differently; as a heavy sensation ‘like somebody’s 
putting bags of potatoes on your body’ (PP3 FG1B 99-100) as though ‘everything’s weighing 
your down’ (PP3 FG1B 110-111). This sensation could strike quite suddenly, and when it was 
present, it felt like an effort to lift limbs or move. This sudden onset of a severe fatigue was 
also depicted as a sensation of being deflated: 
PP9 You just think someone had stuck a needle in me and drained. 
PP3 Drained you, mhm.  
PP9 Everything out of you. It just – 
PP3 Like a vampire sucking the life out of you.  
PP7 I just, sort of, just go limp. (FG3A 550-558) 
This sudden onset was a common experience amongst patients and it could be present for 
varying lengths of time. For one it often meant that he has to stop and rest; ‘I get to a point 
where I’ve now just got to switch off’ (PP5 FG1B 733). After a while, however he felt able to 
continue again, but others were restricted for much longer periods, sometimes for several 
days. This severe fatigue was described as being ‘overwhelming at times’ (PP3 FG1B 187). A 
patient’s husband could identify when his wife was experiencing a sudden fatigue episode, 
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as he would observe the colour of her face changing to white. During those moments, she 
explained how she felt: ‘I’m just like a rag doll’ (PP8 FG3A 575). 
5.2.1.3The consequences of fatigue on functional ability and participation 
In general, the symptom of fatigue was a huge problem for patients as it ‘dominates your 
life’ (PP3 FG1B 213) and consequently permeated all areas of their existence, including 
work, self-care, domestic, family and social activities of daily living. 
First, fatigue had become a huge barrier to being able to ‘do’ many activities: 
PP3 I know you shouldn’t allow it [to dictate your life], I know, but it’s very 
hard when you want to do the things and you, you can’t physically do 
them. (FG1B 213-218) 
Some had completely ruled out certain activities, as they felt physically unable to take part 
in them despite wanting to. Considering an activity, which consumes a lot of energy, was 
described felt like observing a huge mountain from its base:  
PP6 You’re in the car park, you see all those other climbers go up. And your 
mind’s saying, “Yes I can do that.” But your body’s just saying, “No.” 
(FG1B 285-287) 
Physical fatigue seemed to affect functional mobility. One patient described how he could 
no longer keep the same pace as his wife if they were walking somewhere. Previously he 
said that he would have been the one who would be walking ahead. It was hard ‘just getting 
your head round the mental fact you can’t do it’ (PP1 FG1B 1538-1539) whenever they came 
across an activity that fatigue was preventing them from doing. 
Participants considered fatigue as being the biggest factor preventing people with PSS from 
being able to engage fully in certain activities. However, one patient had been reflecting on 
her own reduced participation and had wondered whether it was her own ‘inertia’ (PP4 
FG1B 236) or reduced motivation which was preventing her from engaging fully. This view 
was not shared by others, who explained that they were motivated, but repeatedly were 
prevented from doing things due by their fatigue.  
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The mental fatigue described earlier, which could affect work productivity, also had 
implications for engagement even in some sedentary activities. A participant described 
strategies she had used to try and take her attention off her physical fatigue, but her mental 
fatigue prevented her distraction techniques from working: 
PP3 You can’t even concentrate on the TV to take your mind off it. … You can’t 
even read a book because if you read a book, I’ll have read a, three 
chapters and think, “What the hell have I just written [read]?”.  And then 
if I’m watching the television, and I’ve done it many a time, I’ll come to 
the end and I’ll think, “Aye, what was all that about?”. And it can be one 
of me favourite shows. (FG1B 115-130) 
Therefore, instead of being able to redirect her attention from her physical fatigue to far 
less demanding activities, her focus was on her own reduced functional capacity.  
Mental fatigue also had implications for activities requiring concentration. Consequently, 
some patients were reliant on others for certain things. One patient gave a description of 
how he now relied on his wife to sort out his medicines into a Dosette box, so he knows 
which medicines he needs to take when. His mental fatigue means that he is no longer able 
to attend to this task himself: 
PP1 I mean I take- … About 16 tablets a day. Now I can’t put them up, I just, I, I 
haven’t got the mental facility to, “I take one of them, and I take one, two 
of them. I take one of them.” She sits on a Friday night for about two 
hours and puts all the tablets up for the week. (FG1B 1908-1915) 
This participant was very aware his mental fatigue and reduced concentration meant his 
wife was taking on some caring responsibilities to support him. He regarded this as evidence 
of his decreasing independence.  
The changeable nature of the fatigue also meant that arrangements often had to be 
changed or cancelled and this clearly affected others. A man whose wife has PSS described 
how the fatigue could put a stop to any plans that they both might have together: 
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AHM2 With fatigue, when it gets to, say, four o’clock, five o’clock, and, and [my 
wife] wants to go out or we’ve planned to go out somewhere and she 
ends up in bed. There’s nothing you can physi- you can do about it. (FG2A 
1382-1385) 
Therefore, it was not just patients who regularly had to place their lives on pause, or 
frequently alter their plans; the lives of their spouses and their broader social networks had 
also become disrupted. 
Since having a diagnosis and being aware of the limitations the fatigue has put on them, for 
some, part of their identity had changed. They had given up careers, hobbies and life roles 
due to the fatigue. One participant said ‘I’ve never been someone with a weakness, I’ve been 
the sportsperson’ (PP5, FG1B 1711-1712). He was trying to deal with his altered identity and 
living with a symptom, which he saw as a ‘weakness’.  
The effects of the fatigue meant that patients often found it a real effort to go out and 
engage in activities in the world and therefore began to feel socially isolated. Some had 
found that their world had become smaller. This social isolation was also due to ‘the lack of 
understanding’ (PP7 FG1B 2073-2074) and ‘because you are fighting this alone’ (PP7 FG1B 
2084). When patients felt that they did not have understanding from other people, it could 
have a negative effect on their mood.  
5.2.1.4 The experience of sleep disturbances 
All patient participants reported experiencing sleep disturbances, which post-dated the 
onset of their PSS. A clear example of this is from someone who described being able to 
‘sleep on a washing line’ (PP7 FG1A 892) prior to developing her PSS. For her, getting off to 
sleep and staying asleep had been relatively effortless before PSS. After diagnosis however, 
she had perceived a reduction in sleep quality and an increase in the effort which she 
needed to put into falling asleep, such as ensuring her sleeping environment was right. This 
was a story to which other participants could also relate. 
Some participants thought their disease caused their sleep problems and all believed that 
their sleep disturbance had become worse over time due to the effects of their PSS. In a 
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discussion where they considered why the disease might affect their sleep, one conclusion 
was that given that ‘It’s with you 24/7’ (PP3 FG1A 754), it would naturally impact sleep.  
PP3 The thing is it affects you so much during the day, realistically when you 
think about it, why would it switch itself off at night when you went to bed 
to sleep? 
PP6 Mhm. 
PP7 Mhm. 
PP5 Good point. 
PP3 It doesn’t go when you go to bed 
PP2 No 
PP3 The Sjögren’s is still there, so it just obviously it manifests in a different 
way, which is not letting you sleep basically.  
PP2 Yeah, that's it. (FG1A: 722-737) 
In this way, patients relied on their lay reasoning to make sense of the impact of the 
disease. For example, one person considered how her co-morbidities further contributed to 
her sleep difficulties, including her hypothyroid problems and the menopause.  
PP6 The thyroid’s upset if the Sjogren’s is upset and they’ll upset each other. If 
I’ve got the flushes and the weird mood-swings and whatever’s going on 
up here in the head; then I start having nightmares and disturbed sleep.  
(FG1A: 124-127) 
She also found that if one condition was symptomatic, it would affect her other conditions, 
such as her menopause or thyroid disease, causing a flare of those symptoms, resulting in 
further sleep difficulties and creating a vicious cycle. 
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However, the idea that sleep problems were somehow tied to PSS, was not an association 
that all patients had considered automatically. Furthermore, they had not been informed by 
health professionals about any potential impact on their sleep. As they noticed a change in 
sleep, they were left to ask ‘What’s going on? Is it to do with this mad crazy disease …?’ (PP6 
FG1A 165-166). One participant had previously reasoned her sleep disturbances were due to 
the ageing process: 
PP4 I’ve only recently, sort of, realised that … [my sleep disturbance] actually 
might be Sjögren’s related rather than age related (Laughter), which 
everything is when you get to my advanced years. (FG1A: 264-266) 
This patient had reached this conclusion after discovering an article about sleep and PSS on 
the internet. 
We have just seen that sleep disturbances were common amongst participants since the 
onset of their disease. The specific types of sleep disturbances however, varied. 
Unrefreshing sleep was commonly experienced and for one patient, even on the occasions 
she was able to sleep for 8-9 hours per night, it meant she would ‘wake up and feel as if 
[she’d] never been to bed’ (PP4 FG1A 247). For someone else, it felt as though he had done a 
‘night shift as opposed to having a sleep’ (PP5 FG1A 449) due to feeling so exhausted when 
he woke up. This non-restorative sleep was seen as an ‘emotional disappointment’ (PP7, 
FG1A 451) due to having an expectation of feeling refreshed in the morning, only to find 
that this need was not being met. 
Difficulty with sleep onset was a distinct problem raised during focus group discussions. A 
participant explained that although occasionally he was able to get to sleep relatively 
quickly, he regularly struggled to initially get off to sleep. He described an example of what 
this meant for him in practical terms, from a couple of nights previously: ‘I was lying awake 
at half past one thinking, “When am I going to go to sleep?”’ (PP5 FG1A 409-410).  
Another form of sleep disturbance were regular night awakenings, which were a commonly 
experienced problem by patient participants. One lady often found herself awake for ‘two to 
three hours’ (PP4 FG1A 257) in the middle of the night before falling asleep again and 
consequently would wake up feeling as though she had not slept at all. Similarly, another 
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participant would eventually doze off after waking during the night. However, she described 
the sleep she experienced following a long spell of lying in bed awake as ‘not exactly sleep, 
sleep’ (PP7 FG1A 238) and that this (dozing) sleep was dissatisfying as it was perceived as 
being inferior to regular sleep. Another participant who regularly experienced night 
awakenings was usually able to fall back to sleep again but only to continue to wake 
frequently during the night such as ‘at one, and half past two, and five’ (PP5 FG1A 1781). 
Interestingly, one person shared how his problems were different to those described by 
other participants with PSS. He did not experience sleep onset difficulties or regular night 
awakenings. However, he regularly experienced what he considered a short sleep duration. 
‘If I get four hours sleep/five hours sleep a night I, I’ll be lucky (PP1 FG1A 33). As well as 
experiencing a short sleep duration, he also gave the impression of an altered circadian 
rhythm as he both went to sleep and woke up very early. 
PP1 I mean I usually go to bed round half past seven/eight o’clock. And I’m up 
again at 1:00, and that’s it. And I’m there, one o’clock and I’m there ‘til 
half past seven the next; eight o’clock the next night. (PP1 FG1A 23-29) 
This had implications for his wife: 
AHM1 Unfortunately that, sort of, buggers me up for the day as well. (Laughter) 
Kate: Yeah. 
AHM1 ‘Cause he, he gets up, disturbs me. I don’t go to bed at eight o’clock, I go 
to bed about half past ten/eleven o’clock, so after a couple of hours I’ve 
just got into a deep sleep and this one gets up. (FG1A 37-44) 
Patients’ sleep disturbances did have consequences for bed partners. For one participant, it 
had meant ‘I’ve thought about saying to my other half, “We’ll have separate rooms”, we 
already have separate beds’ (PP6 FG1A 116-118). The impact of poor sleep on relationships 
was not explored in detail, but the possible implications of poor sleep on relationships are 
clear. 
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A range of sleep problems were reported by participants and they also described that 
although they may experience one particular sleep problem at one time, these can change. 
For example, a particular problem, such as difficulty with sleep onset, may not consistently 
be present, but it can be replaced by another sleep disturbance instead. One participant 
explained how this played out for him: 
PP5 It’s just an inconsistent thing with me, other nights I can fall asleep 
virtually as soon as I put my head on the pillow, but then wake up several 
times during the night. (FG1A 421-423) 
Another lady frequently experienced inconsistency in her sleep and no longer took for 
granted a full night’s sleep. 
PP2 I still have erratic sleep pattern. … I can go to bed at 11 o’clock and not 
get to sleep at all. … I can go to bed at 11 o’clock and sleep until about 2, 
and that’s it. … And occasionally, very, very, very occasionally I sleep right 
through, and that’s always something to look forward to. (FG1A 67-80) 
When she did occasionally experience a good night’s sleep, this was very satisfying and 
somewhat of a relief. 
Patients explained that other symptoms influenced their sleep. Pain was a factor, which 
occasionally seemed to disrupt sleep; however, it was unclear whether this specifically 
related to PSS or to other comorbid musculoskeletal problems: 
PP10 Two nights ago I never slept all night ‘cause of the [neck] pain and it had, 
it went down me arms and me hands. (FG3A 193-4) 
Discomfort relating to dryness seemed to have a greater impact on sleep than pain. Oral and 
ocular dryness in particular caused a huge amount of discomfort for some people and they 
felt the dryness was responsible at times for waking them in the night: 
PP3 I really struggle with the dryness in my eyes and my mouth during the 
night. … I wake up like three of four times, like somebody’s put a hairdryer 
in your mouth. … And sometimes it catches your throat and you can wake 
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yourself up trying to swallow. … It’s a horrible feeling. And as much as you 
try to get a glass of water, a second later it’s still like you’ve been in the 
desert. … And then the dryness, I put Lacri-lube in my eyes, and I can put it 
in three or four times during the night and I’ll still wake up like they’ve got 
sand in them. (FG1A 294-315) 
It is entirely possible that someone waking to use the toilet during the night could be more 
attentive to their dryness symptoms once they have woken up, rather than it being the 
cause of their waking. However, participants did not raise this scenario and they concluded 
that the dryness had been the factor, which had disturbed their sleep.  
Discomfort in the legs was another factor, which participants said, could interfere with 
sleep. The various types of leg discomfort described, related specifically to poor peripheral 
circulation and reduced sensation. The specific discomfort of cold legs during the night was 
shared by several participations: 
PP3 I get discomfort in my legs ‘cause I have bad circulation. I’ve thermals on 
in the summer all the time. 
PP1 Yeah, yeah. 
PP3 My friends laugh, it’s crazy, I canne keep the heat in my legs. Erm, I’ve got 
an electric blanket as well which does help. But it’s, I get a lot of 
discomfort in bed until I actually get off, erm, to sleep and stuff. And, er, 
erm, but it’s more so in my legs I get the discomfort. (FG1A 939-947) 
Sleep disturbances did have consequences for other PSS symptoms, making them seem 
worse. Fatigue was a natural consequence of poor sleep, which meant the ability to 
participate and perform daily activities was restricted.  
PP4 Yes, you could see, erm, sort of, link too isn’t there between disturbed 
sleep or inadequate sleep and fatigue the next day so you can’t do the 
things you want to do during the day.  
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PP1 Mhm yeah. 
PP4 And you wander about like a zombie. (FG1A 764-766) 
Unsurprisingly, another impact of sleep disturbances was daytime sleepiness. The wife of a 
patient described how she regularly observed her husband falling asleep inadvertently 
during the day: 
AHM1 And he’ll be sitting on a chair and then I’ll be talking to him and I’ll, “Are 
you listening?” and he’s asleep (Laughter), you know, during the day he’s 
nodded off 10 minutes, and I’m talking away to meself. (FG1A  558-560) 
Other participants also regularly experienced falling asleep during the day, for example 
while sitting down to watch television in the afternoon. However, inadvertently falling 
asleep during the day, whilst in the company of other people could be embarrassing at 
times. 
PP5 I was actually at a friend’s yesterday afternoon, we’re chatting, and I 
actually fell asleep. (Laughter).  
PP8 Mid-conversation?  
PP5 Yeah, literally, almost. (Laughter).  
PP8 I’ve done that. (FG3A 975-982) 
Another participant fell asleep during one of the focus group discussions despite being 
actively involved in the discussion before and after she dozed off. Daytime sleepiness, was 
therefore, both observed and described as being a real problem, which impacted on 
patients’ daily function and participation. 
It was felt that sleep disturbance resulted in an increase in fatigue, but that fatigue also led 
to daytime sleepiness. However frustratingly for participants with PSS, fatigue did not 
always lead to sleep at night, and one participant highlighted a reason for this paradox was 
because ‘the fatigue is a different thing to tiredness’ (FG1A, PP3, 392). 
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Sleep was regarded as a precious resource. It was something that people no longer took for 
granted. It was also considered a linchpin, in the fact that is was seen as a strong influencing 
factor on other symptoms such as fatigue and depression: 
PP4 If that one’s wrong [sleep] a lot of the other ones’ll fall. I suppose it’s 
like … the domino theory’. (FG1 821-822) 
If they did not sleep well, patient participants would feel fatigued, consequently feel low in 
mood and experience more worry. 
5.2.1.5 The experience of pain and discomfort 
Although pain was a priority symptom identified within the concept mapping study (see 
Chapter 3, it was not immediately a term which patients fully related to in the discussions. 
They explained; ‘It’s a funny one. Pain? Discomfort?’ (PP6, FG3B 18); ‘It isn’t pain pure and 
simple’ (PP7 FG3B 24). There was a strong feeling that the word ‘pain’ was not always an 
adequate term for the broad spectrum of symptoms they believed that this word was 
supposed to cover. First of all this phenomenon was experienced ‘on a sliding scale’ (PP7, 
FG3A 20):  
PP7 It can be anything from a mild irritation, as it were, right the way through 
to absolutely excruciating. (FG3A 28-29) 
Patients used the descriptive terms ‘irritation’ and ‘discomfort’ for what they experienced at 
the lower end of this spectrum. Further up the scale, they might experience ‘a nagging 
pain … aching pain’ (PP5 FG3B 947) and at the top end was severe pain. It also became clear 
during the discussions that some participants preferred the term discomfort to pain, as they 
were better able to relate to it. Some peoples’ experiences of pain only went so far up the 
spectrum as they tended to live with discomfort and not pain. One person did not relate to 
having pain at all, in the context of her PSS. She considered pain in the context of a previous 
biomechanical injury: 
PP8 I don’t have the pain. I mean I’ve had discs out of my back so, I mean, I 
know what pain is. (FG3A 936-937) 
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Location of the pain and discomfort was an additional factor, which influenced how it 
patients described it: 
PP7 Well for me it depends on A) where it is. … So, for example, my eyes are 
rarely what I would describe as painful. But they’re very often extremely 
uncomfortable. … Whereas my neck… And the, and the arthritic bits are 
extremely painful when they flare up. ….  
PP9 That’s a good point actually. (FG3B 37-50) 
The discussions demonstrated that the experiences of pain and discomfort were diverse 
between individuals. Pain was not a symptom which was present for everyone, or that was 
present for all the time. In those who did have pain their experience varied. When pain was 
present it could vary, both in location and severity.  
Some patients described having joint pain in different areas of their bodies, particularly in 
upper limbs and spine. One patient said she was ‘in constant pain’ (PP10 FG3A 187) in her 
neck, and another said she often had pain in her hands, wrists and elbows. A spouse of a 
patient thought that the articular pain people were describing was due to having arthritis 
rather than PSS: 
AHM2 I think the pain’s possibly might be to do with the arthritis side of it rather 
than the Sjögren’s, … the Sjögren’s is more discomfort. (FG3A 72-73) 
It is possible that people were describing pain from co-morbid arthritis, but despite its 
cause, articular pain was present in several patients and this pain was viewed as ‘proper 
pain’ (PP7 FG3A 921) on the irritation/pain spectrum. One person also explained how her 
neck pain was worse during bad weather because ‘when it’s good [the weather] it’s not too 
bad [the pain]’ (PP10 FG3A 198). 
Headaches were another type of pain which were commonly experienced amongst 
participants. The type of headaches varied between individuals but there were some 
similarities in the pain distribution for some people: 
PP9 I get a headache here that goes down into the neck. 
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PP7 Yes. 
PP9 And then along the shoulder. 
PP7 I get that as well. (FG3A 1231-1237) 
Some people’s headaches were more localised such as ‘at the top of the head’ (PP10 FG3A 
1245) and ‘behind my left eye’ (PP5 FG3A 1250).  
Peripheral tingling sensations, particularly in the hands and feet were present for some 
patients.  Although this seemed to be an unpleasant sensation as ‘sometimes it’s quite 
numb’ (PP6 FG3A 1314); no-one identified it as being painful. It could occur during activity 
and without warning; ‘all of a sudden it comes. It, it’s peculiar’ (PP6 FG3A 1330). This 
particular patient explained how she had previously been investigated for multiple sclerosis 
prior to her PSS diagnosis because of her tingling sensations. 
Gastrointestinal symptoms were another type of discomfort raised during the discussions. 
For example, nausea sometimes accompanied headaches. Furthermore, bowel pain, 
discomfort and occasional lack of control were a further problem for some people. Several 
patients experienced both nausea and discomfort in their abdominal region when they were 
feeling particularly fatigued. These sensations could affect their appetite: 
PP9 If you’ve got that nausea feeling it just feels as if you’re hollow inside and, 
erm…  
PP3 Yeah, it’s like an empty feeling isn’t it? Yes.  
PP9 Yes, it’s, it, I don’t know whether that’s pain or a deep ache or… But it’s, 
erm, it’s when you’re really tired. … And, erm, probably pushed too 
hard. … And, erm, you just feel nauseous and you don’t fancy to, anything 
to eat. (FG3A 326-345) 
Nausea, in addition to being present alongside fatigue, could manifest quite suddenly and 
be accompanied by a heavy sensation ‘like you’ve been at the gym for the full day. … like, er, 
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you’ve done a marathon’ (PP3 FG3A 352-356). However, it did not necessarily follow 
exercise. Other patients could relate to this diffuse, heavy feeling: 
PP6 I sometimes feel like somebody’s poured lead. I always say to me GP, it’s 
my legs, right at the tops of me legs. … And it’s like somebody’s poured 
lead into the legs and they’ve very heavy and it feels as if you’re walking 
through treacle. (FG3A 984-994) 
Following a fatigue episode, another patient described how initially the nausea would start, 
followed by joint pain: 
PP3 When my fatigue comes on and I feel like really heavy, and to me it’s like a 
sickly feeling. I get like a sickly heavy- … A sickly heaviness like a- … like a, 
just like a nausea feeling comes over you. ... That’s what I get. And then 
these start to burn, the joints and the wrists. (FG3A 242-257) 
For the patient participants, the combined unpleasant experiences of nausea and 
widespread discomfort and pain rarely occurred in isolation, but would often manifest 
themselves following the onset of a sudden extreme fatigue episode.  
Pain and discomfort associated with dryness was another common problem. As has already 
been mentioned, discomfort was the term which was seen as a more accurate description 
for the sensations associated with dry eyes.  
Oral dryness seemed to result in very specific types of pain and discomfort as one lady 
explained: 
PP9 I mean my dentistry history has been terrible, you know, I’ve had them all 
filled and capped and then recapped.  
PP8 Oh mine is the same, yes.  
PP9 And then extracted. So now I’ve got, er, dentures. Top one’s fine ‘cause 
there’s a bit of suction, bottom one just floats ‘cause I’ve got no gum 
and ... it’s not pain exactly but it’s certainly discomfort. And there has 
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been a lot of pain, when I had extractions and things like that. ... So there 
is that level of pain there, which everybody would have with having 
extractions and caps and recaps... dentistry is, erm, it’s a, it’s a well-
known thing, I mean, er, er, from the fact of being a Sjögren’s [patient] 
because your mouth is so very dry. (FG3A 118-141) 
Oral dryness creates an ideal climate for tooth decay, gum disease and tooth loss. The 
dryness had resulted in dental work being necessary for some of the participants. These 
dental treatments could be very painful.  
Another very specific pain, experienced in the mouth area, was a severe cramp-like pain in 
the parotid glands: 
PP7 When this flares up- (pointing to side of face). … Wow, that is the end.  
PP6 Yes, yes.  
PP10 Yes, it’s so sore.  
PP9 Yes, mine’s here. (Pointing to salivary glands on side of face)  
PP7 It’s absolutely excruciating, there’s no other word for it. … And you get like 
a spasm and it all comes right out here. 
PP3 It goes rock hard.  
PP7 It does. .... And it’s so, so, so, so painful.  
PP3 I get that. ... It doesn’t last does it?  
PP7 No, it doesn’t take long. ...  
PP9 About four/five minutes.  
PP3 It’s really painful isn’t it?  
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PP9 Yeah. (FG3A 1639-1716) 
Although this pain occurs temporarily for short periods, it is severe when it strikes and most 
unpleasant. Discussing this shared experience seemed to be important to those involved in 
the above conversation. For some it was the first time they had been able to talk about this 
particular sensation with others who had first-hand experience of the same phenomenon. 
A further presentation of discomfort was the inability to tolerate particular sounds or loud 
noises as someone explained: 
PP6  And I love music … there are certain things that I’ve loved from, you know, 
since I was knee-high to the grasshopper. And then there’s certain times 
when the noise stimulus is just too much. And I think that’s peculiar. 
(FG3A 779-780) 
This person, who had always enjoyed playing her music, had found that at times she was 
unable to listen to it and enjoy it, now she is living with PSS. Intolerance to noise was a 
problem, which several of the patients experienced, but this occurred intermittently; it was 
not a constant state.  
Intolerance to light was another sensory disturbance affecting one patient. She described 
having to close her eyes in natural light and consequently either always sunglasses or 
glasses with lenses which react to light. 
From the above descriptions of pain and discomfort experienced by PSS patients, it can be 
seen that the presentation of these symptoms in PSS is heterogeneous and that these 
symptoms can vary considerably both within and between patients. The sliding scale of pain 
described by participants, with specific examples along the continuum can be seen in Figure 
5:1. 
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Figure 5:1 The sliding scale of pain with specific examples along the continuum 
 
5.3 Discussion 
The focus group discussions revealed that fatigue, sleep disturbances and pain and 
discomfort were all experienced by PSS patient participants. Furthermore, these symptoms 
greatly impacted on their lives and those of their family members. Problems encountered by 
patients, resulting from their symptoms included increased social isolation, reduced ability 
to perform physical and mental activities and the sense that they were misunderstood by 
those around them. All of these factors could impact upon mood. There was an overlap of 
symptoms and one symptom often seemed to affect another. For this reason, it was 
sometimes difficult for participants to discuss one symptom in isolation. Furthermore, 
symptoms were not always present and could vary. ‘Symptom complexes’ are not unique to 
PSS and the interactions of symptoms and their palindromic nature have been previously 
described in seropositive and early rheumatoid arthritis patients (Stack et al., 2013; Stack et 
al., 2014). 
Participants found it particularly useful to discuss their individual experiences with others. 
Although the focus groups were not designed to be therapeutic in any way, patients 
reported that it was helpful to be able to share experiences and talk through specific 
difficulties with others who understood. Patients with rheumatic diseases (including PSS) 
who took part in another qualitative study investigating the impact of written fatigue 
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information similarly, found the qualitative interview process itself to be therapeutic, 
despite it not being intended that way (Hart et al., 2016). 
It is essential that symptoms are believed and acknowledged by HCPs during appointments 
and that they are not easily written off, for example as a symptom of old age, as this can be 
devastating to patients. In the general population fatigue may be more prevalent in older 
age groups (Avlund, 2010). However in PSS, increased fatigue is actually associated with 
younger age (Overman et al., 2016). HCPs can often feel reluctant to dwell on a symptom, 
particularly fatigue when they are not certain of its aetiology or available treatments 
(Repping-Wuts et al., 2008). Educating HCPs about PSS, its symptoms and their 
management would therefore be of benefit to patients, if it resulted in more understanding 
clinicians. 
Mental fatigue was an aspect of fatigue which was discussed. Participants described some 
symptoms of cognitive impairment, which included difficulties with concentration and poor 
memory. These cognitive symptoms are a known problem in PSS patients (Segal et al., 2012; 
Blanc et al., 2013) and although patients did not perceive them to be constant, they did 
affect their ability to fully engage in some daily activities. Although patients explained 
mental fatigue could occur in isolation, they described it often occurring with physical 
fatigue, or following an episode of over-exertion. The experience of both physical and 
mental fatigue taking place together, has been reported previously in qualitative studies of 
other fatiguing conditions, including chronic fatigue syndrome (Keech et al., 2015) and 
fibromyalgia (Stamm et al., 2014). 
Physical fatigue was described as a distinct heavy feeling which could strike suddenly and at 
times was overwhelming. The sudden onset of fatigue (which was sometimes accompanied 
with pain) is similar to the ‘boom and crash’ pattern described in a qualitative study of 
CFS/ME patients (Pemberton and Cox, 2014). During the crash phase, usual activity had to 
stop.  
Levels of fatigue were both variable, often unpredictable and at times overwhelming. 
Similar qualitative findings have likewise been reported in other arthritic conditions 
including RA (Hewlett et al., 2005), fibromyalgia (Vincent et al., 2016) and SLE (Connolly et 
al., 2014). 
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Fatigue had far reaching implications for people’s lives. Focus group participants had been 
forced to give up careers and roles and had placed their lives on pause because of it. This 
biographical disruption was identified in the literature many years ago, following the onset 
of a chronic disease and its associated symptoms (Bury, 1982). This study also raised the 
issue that life was often interrupted with smaller intermittent pauses during a flare of 
fatigue, where it became necessary to stop activity. This is similar to the consequence of 
fatigue in both RA and SLE patients (McElhone et al., 2010; Thomsen et al., 2015) and 
affected others. Social isolation was also raised as a problem, which was a consequence of 
fatigue. Social isolation in people who develop a chronic illness has previously been 
discussed in the literature and is in part due to the impact of an illness disrupting previous 
life roles (Bury, 1982; Charmaz, 1983). 
Motivation was a concern for one participant who experienced fatigue regularly, particularly 
during poor weather. Reduced motivation is a symptom of low mood and depression, which 
has an increased prevalence in PSS (Valtysdottir et al., 2000; Harboe et al., 2009; Kotsis et 
al., 2014). Furthermore, depression is a predictor of PSS fatigue and if identified, should be 
addressed in clinical settings (Karageorgas et al., 2016). 
Sleep disturbances were evident amongst the PSS participants during the focus groups. 
Sleep disturbances are seen in seen in a range of chronic diseases (Kamath et al., 2015) and 
there are broad similarities between the sleep difficulties experienced in PSS and in other 
conditions such as primary insomnia (Frankel et al., 1976; Reynolds et al., 1991), 
fibromyalgia (Katic et al., 2015) and chronic pain (Tang et al., 2015). Not all participants had 
made an association with their sleep disturbances and their PSS. This is possibly due to the 
prevalence of sleep disturbances until recently, being relatively under-recognised in PSS 
(Hackett et al., 2016a). 
Participants perceived that some of their other symptoms interrupted their sleep, including 
pain, discomfort and dryness. The specific types of sleep difficulties they experience have 
recently been summarised in the PSS literature (Hackett et al., 2016a). They include 
problems with sleep onset, night awakenings, altered circadian rhythm, dryness, and short 
sleep duration (Gudbjornsson et al., 1993; Hay and Morton, 2006; Hilditch et al., 2008; 
Theander et al., 2010; Usmani et al., 2012; Hackett et al., 2016a). In this study, patients’ leg 
discomfort and altered sensation were specific symptoms interfering with sleep. It is 
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possible that these may be due to peripheral neuropathy or restless leg syndrome, which 
both occur within PSS populations (Hening and Caivano, 2008; Carvajal Alegria et al., 2016). 
It is essential that the specific problems are picked up in a consultation as the individual 
treatment modalities for each may vary. For example restless legs syndrome may be 
successfully treated pharmacologically with dopaminergic therapies (Zak and Walters, 
2015). Furthermore, if a primary sleep disorder is suspected (such as obstructive sleep 
apnoea), patients should be referred to the appropriate specialist for further investigations 
(Hackett et al., 2016a). 
Night awakenings were a particular problem, occurring alongside dryness and discomfort. 
Furthermore, sleep onset difficulties were identified by several focus group members. Both 
these problems are symptoms of insomnia and as such, should be amenable to CBT-I (Trauer 
et al., 2015). However, due to the unique feature of oral and ocular dryness also interfering 
with sleep in PSS, a dryness management component may form a useful adjunct to a CBT-I 
intervention. 
Participants in this study described an overlap between their sleep and fatigue symptoms. 
This is neither surprising nor unique to PSS, as this overlap is recognised in both primary 
insomnia and in other fatiguing conditions (Buysse, 2013; Brass et al., 2014; Gotts et al., 
2016). Furthermore, participants saw sleep as a precious resource, which, if disrupted 
resulted in an exacerbation of their other symptoms. It therefore makes sense that sleep 
could be appropriate symptom target, and if successfully treated, might have a positive 
influence on other symptoms, including fatigue, anxiety, depression and pain (Thorndike et 
al., 2013; Tang et al., 2015). 
Although patients recognised pain as being a symptom of their PSS, not all had it. 
Furthermore, the term ‘pain’ was not necessarily regarded as being appropriate to describe 
the symptom and should be used interchangeably with the term ‘discomfort’. The terms 
pain and discomfort covered a range of experiences and symptoms which could be viewed 
on a sliding scale.  
The gastrointestinal symptoms may be related to irritable bowel syndrome (Bengtsson et 
al., 2011) or other complications such as dysautonomia (Newton et al., 2012). These 
features may require a coordinated approach, with the involvement of an appropriate 
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clinician. Headaches were also identified in this study. A previous study demonstrated an 
increased prevalence of headaches in PSS patients compared with healthy controls 
(Tjensvoll et al., 2014). An intolerance of light and noise by some participants was also a 
problem for some. These features are also described in fibromyalgia and CFS (Soderlund et 
al., 2000; Meeus and Nijs, 2007; Clauw, 2014).  
Little is known about pain in PSS. In one cross-sectional study of 100 PSS patients, 
fibromyalgia was identified in 31 individuals (Choi et al., 2016) using the American College of 
Rheumatology (ACR) 2010 Criteria (Wolfe et al., 2010). This is much greater than the 5% 
prevalence of fibromyalgia (determined using the same criteria) in the general population 
(Vincent et al., 2013). The characteristics of fibromyalgia identified by Clauw (2014) can be 
seen in Table 5-4. There are many similarities between these characteristics and symptoms 
described by patients during the focus groups. Fibromyalgia has been described as a 
centralised pain state (Clauw, 2014). The pain is regarded as being centralised as it is 
assumed to relate to a dysfunction of the central nervous system or pathology which 
contributes to both the development and the maintenance of chronic pain (Williams and 
Clauw, 2009; Phillips and Clauw, 2013). 
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Characteristics of Fibromyalgia and other centralised pain syndromes  
Character and quality of pain 
 Diffuse or multifocal, often waxes and wanes, and is frequently migratory in 
nature  
 Often accompanied by dysesthesia or paraesthesia’s and described as more 
"neuropathic" (e.g., with terms such as numbness, tingling, burning)  
 Patients may note discomfort when they are touched or when wearing tight 
clothing 
History of pain in other body regions earlier in life  
Accompanying comorbid symptoms also of central nervous system origin  
 Often fatigue , sleep disturbances, memory, and mood difficulties accompany 
centralized pain states such as fibromyalgia  
 Several of these symptoms will typically improve along with pain when 
individuals are successfully treated with appropriate pharmacological or 
nonpharmacological therapies  
Symptoms suggesting more global sensory hyper-responsiveness  
 Sensitivity to bright lights, loud noises, and odours and even many visceral 
(autonomic) symptoms may be in part due to a global sensory hyper-
responsiveness seen in conditions such as fibromyalgia 
Table 5-4 Characteristics of fibromyalgia and other centralised pain syndromes (adapted 
from Clauw, 2014) 
 
The term ‘fibromyalgianess’ has been coined to describe a spectrum of the intensity of, or 
sensitivity to, fibromyalgia symptoms which was identified in RA patients in response to 
completing a symptom questionnaire (Wolfe, 2009). At one end of the spectrum, no 
fibromyalgia symptoms are evident, whereas at the other end, a person may experience 
high levels of all symptoms. The spectrum highlights the problem of dichotomising patients 
into having a diagnosis of fibromyalgia or not, as many people are likely to score somewhere 
between both extremes of the scale, therefore experiencing a level of fibromyagianess 
(Wolfe, 2009). The discordance between subjective and objective symptom scores in PSS 
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has been highlighted by a group in Newcastle previously (Robinson et al., 2014), and pain 
centralisation in some patients may be one possible explanation for this discordance. 
Due to the range of experiences associated with the term pain, standard measures used in 
clinics (such as a pain VAS), may not pick up all the details. Therefore, appropriate 
measurement is needed in order to identify the specific issues of pain and discomfort and 
their severity as this may help guide clinicians towards appropriate interventions.  
Pain and discomfort levels were variable between and within participants. Patients also 
made their own association with pain and fatigue. The Newcastle group has recently 
highlighted the close association of these symptoms in a large cohort study of UK patients. 
This study identified four specific phenotypes of PSS patients and was further validated in 
two international cohorts (Lendrem et al., 2016). Patients who experienced pain, also 
experienced fatigue and these patients were likely to belong to two out of four clinical 
phenotypes; specifically, the ‘high symptom burden’ group and the ‘low anxiety and 
depression’ group. Therefore, PSS patients who experience pain or fatigue, may benefit 
from different clinical management from those who do not. However, this study has 
suggested that patients perceive that their pain is often worse following a period of raised 
activity levels. Therefore, the implementation of fatigue activity management strategies 
such as problem solving, planning, prioritising and pacing (Arthritis Research UK, 2011), may 
also support with pain management. 
There are several limitations to this focus group study. The focus groups were conducted 
during a weekday morning from a convenience sample of a relatively small number of 
patients. This meant that none of the PSS group members worked full-time and some useful 
insights may have been missed. However, there was representation from patients and 
family members who worked part-time, were unemployed and were retired. This study 
discussed several symptoms in depth and was conducted with people who had a lived 
experience of the symptoms. Finally, the participants were recruited from a North East clinic 
and as such some insights might have been missed from patients from different regions.  
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5.4 Summary 
This chapter has described both methods and results from focus group discussions with PSS 
patients and spouses of patients about symptoms of fatigue, sleep disturbances and pain. In 
the following chapter, I discuss further results from the focus group discussions, including 
the types of self-help strategies patients have found useful for managing these symptoms. 
Furthermore, I present feedback from patients about intervention components which were 
suggested by clinicians (in Section 4.4.2.) and report participants’ thoughts and reactions to 
potential modes of delivering future symptom management interventions.  
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Chapter 6. Developing a new care package for PSS symptoms: A 
qualitative study  
In the previous chapter, I described how I conducted focus groups with PSS patients and 
family members to explore the symptoms of fatigue, sleep disturbances and pain in more 
detail. In this chapter, I present further results from the same qualitative focus groups. 
Firstly, I describe the strategies patients have implemented to self-manage these symptoms. 
Secondly, I describe their responses to the interventions proposed during the previous 
clinician validation process (in Chapter 4). Finally, I describe a model of delivering future 
symptom management following feedback from patient and family stakeholders in this focus 
group study. 
6.1 Method 
6.1.1 Aims 
 To determine which strategies patients use to manage their symptoms of fatigue, 
sleep disturbances and pain and discomfort. 
 To explore the acceptability of potential intervention components with patients and 
their family members. 
The focus groups and analysis were conducted in the same way as described in Chapter 
Chapter 5 (Section 5.1). The specific items covered in this aspect of the study are reported in 
the topic guide (Table 6-1). Each of these items was presented to participants on sheets of 
paper during the focus groups with space for participants to jot down any written responses 
onto the handouts if they wished. These were separated out for each topic. For example, 
when the topic of sleep disturbances were discussed, the handouts only included questions 
on sleep and possible intervention components to help manage sleep disturbances. 
Similarly, when the handout materials for the fatigue focus groups only included questions 
and intervention components relating to this topic. The same was true for the pain topic. 
The intervention strategies were explained by myself and Dr Deary, the focus group co-
facilitator. 
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Topic guide 
How do you (or your relative) currently manage your:  
 Fatigue? 
 Sleep difficulties? 
 Pain? 
Here are some possible non-drug intervention solutions. What do you think about 
each?  
Fatigue (a brief verbal description was given of each strategy or approach): 
Cognitive behavioural therapy (CBT) 
Pacing 
Planning 
Prioritising 
Delegating 
Strength/balance exercises 
Gradually increasing physical activity/grading exercise 
Online course/therapy 
Individual therapy with a health care professional 
Group fatigue management programme 
Sleep (a brief verbal description was given of each strategy or approach): 
Cognitive behavioural therapy for insomnia (CBT-I) 
Establishing a bedtime wind-down routine 
Removing all activities such as computers/crafts/books from the bed 
Restricting time spent in bed 
Keeping a record of sleep in a sleep diary 
Talking through any unhelpful thoughts about sleep with a healthcare professional 
Getting up after 15 minutes if haven’t managed to fall asleep 
Online course/therapy 
Having 6 individual therapy appointments with a health-care professional  
Pain (a brief verbal description was given of each strategy or approach): 
CBT 
Acceptance and commitment therapy 
Pacing or balancing activities with rest 
Increasing activity gradually 
Identifying unhelpful thoughts about pain 
Doing daily targeted exercises prescribed by a physiotherapist 
Taking part in an exercise group 
Using meditation or relaxation techniques 
Understanding more about why and how we experience pain (education) 
Doing an online course to help with managing pain 
Having some individual appointments with a health-care professional for specific 
support with pain management 
Attending a group to share experiences of managing pain with other people who 
have Sjögren’s 
Table 6-1 Topic guide for intervention focus group discussion and modes of delivering 
interventions in the future 
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6.2 Results 
6.2.1 Strategies currently used by patients to manage their fatigue, sleep 
disturbances and pain 
A variety of strategies were utilised by participants to manage their symptoms. Many were 
adopted through trial and error and they generally continued to use those which provided 
benefit. However, not all strategies were helpful or necessarily received a positive response 
from friends, family or others, yet patients continued to use them. The strategies described 
by participants are discussed separately for each of the symptoms of fatigue, sleep 
disturbances and pain in the following sections. This is followed by a short section where I 
show how patients manage several symptoms collectively. 
6.2.1.1 Strategies used to manage the symptom of fatigue 
A variety of strategies were used to try to manage fatigue. Through accepting some help 
from others, one patient had succeeded in maintaining a previous role. He enjoyed being 
part of a local brass band. However, his fatigue meant that it was too much physical effort 
for him to carry his own heavy instrument, meaning he regularly received some assistance 
from another band member.  
PP1 I play a tuba in a brass band, I can still play it but I can’t carry it. But it’s 
never stopped us. I’m always getting one of the lads to, to hump the 
instrument around for us and I’ll sit and I’ll play it all day. (FG1B 477-486) 
Through accepting help, he was able to continue with an activity which he enjoyed and 
which was important for his well-being.  
Some participants felt that they did not want to be beaten by their disease or their fatigue. 
In effect despite feeling ‘totally inert and you can’t even get up out of a chair or even pick up 
a cup of, a cup of tea’ (FG1B 174-175), they had pushed themselves to continue doing 
things. There was a sense that living was a daily battle which ‘at the end of the day you 
either give into it or you don’t’ (PP1 FG1B 466). In this way, fatigue imposed restrictions, 
which could be difficult to accept. The friends of one patient had advised her to listen to her 
body and accept its limitations. However, she did not want to admit defeat: 
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PP6 You’re thinking, “Look, I’m not old.” I’d accept, if I was 93 or something 
(Laughter) I’d be like, “Okay.” I’d accept that. (FG1B 411-412) 
However, this strategy of constantly fighting the fatigue did not always end with positive 
results. If they pushed themselves to continue an activity, it could result in an exacerbation 
of symptoms at a later point.  
PP2 And sometimes you force yourself to do things. … And then you suffer for 
it afterwards. (FG1B 161-167) 
A specific example was given when choosing to continue with physical exercise despite 
experiencing excessive fatigue. This could result in a ‘detrimental effect’ (PP1 FG1B 1060) 
with even worse symptoms following the period of over exertion. 
Medication was another strategy used by some patients to try and alleviate their fatigue. 
One participant talked about her experiences of the drug hydroxychloroquine: ‘It does help 
with my fatigue, but it doesn’t eradicate it, doesn’t take it away’ (PP3 FG1B 664-665). 
Overall, the effects of this drug (which is commonly prescribed to PSS patients), were 
perceived as being minimal by those who had experience of taking it.  
Several people had tried alternative medicines to help with fatigue including Shiatsu, which 
one patient believed had helped her mental fatigue. 
PP7 I have to say, that the Shiatsu has put me to pre-Sjögren’s levels of 
concentration normally, in a normal day-to-day basis. And, and, and that 
mental clarity that I had before is there most of the time. … And it, it’s 
been a lifesaver. (FG1B 47-60) 
Several others had tried acupuncture and homeopathy but were less convinced about it 
having a positive impact on their fatigue symptoms. A further participant had searched for 
answers to his fatigue and investigated possible remedies which might help, but he said ‘I 
haven’t found anything [that helps] to be perfectly honest’ (PP5 FG1B 988). 
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Despite having significant problems with fatigue, patients were reluctant to seek help from, 
and talk about it with their general practitioners (GPs). Generally, there was a perception 
amongst group participants that GPs did not understand this symptom:  
PP2 I’ve brought it up [the topic of fatigue with a GP] and I just read a blank 
stare. … They don’t, they don’t understand.  
PP7 They don’t get it. 
PP2 No. 
PP1 And- 
PP2 You just, you just can’t get through. (FG1B 600-616) 
Although another participant mentioned that she would talk to her GP about her painful 
joints; when I asked her if she had mentioned her fatigue to her doctor she replied; ‘no, I 
just wouldn’t’ (PP4 FG1A 594). This was because she felt that her GP had previously blamed 
some of her other symptoms, including her pain and poor sleep down to ageing. Fatigue was 
a huge symptom to her and the prospect of having this symptom, which was a dominant 
factor in her life, dismissed as a sign of old age, was enough to avoid mentioning it 
altogether.  
Patients did not only avoid discussing their fatigue with health care professionals. Some also 
described keeping it from many people they came in regular contact with in their daily lives. 
The invisible nature of this symptom (described earlier in Section 5.2.1.1) was a barrier to 
talking about their fatigue. One patient felt it was necessary for her to present herself in a 
certain way to others, which in itself was exhausting: 
PP6 I’ve got to look healthy and look fine … You put the face on. ... It’s like you, 
you, you, you’re wearing a mask ... And you get sick and tired of wearing 
the mask. (FG1B 1632-1641) 
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Due to the negative responses this person had previously experienced from her family 
regarding her fatigue, she worked extra hard to keep it hidden from them, possibly to avoid 
further negative reactions. 
However, hiding fatigue from others could create additional problems, including raised 
expectations in others. This could result in feeling as if ‘you’re being pushed all the time’ 
(PP2 FG1B 1768). Some thought that it would be helpful for others to know more about the 
disease and the specific symptoms, in particular, fatigue. However, as they found it difficult 
to explain the impact of their fatigue, a suggestion was made that some appropriately 
written information, or a booklet describing PSS and fatigue might help. One patient said 
she had come across a book which was simply written with illustrations which described 
chronic fatigue syndrome (CFS) to people who did not have CFS: 
PP6 And I flicked through the preview and I thought, “It’s such a good idea” 
but just to say to people, or your boss or whatever, to say, “Look, this is 
how I feel. It’s not a, a good night’s sleep will not cure all.” (FG1A 776-
779) 
There was a sense that patients would feel empowered by something as simple as having 
appropriately written information to give to others, which would eliminate the pressure of 
them verbally trying to explain it, every time someone asked. 
One participant had previously undertaken a course of CBT for her chronic pain. She found 
that it had equipped her with useful strategies, which she now used to pace her daily 
activities in order to minimise the effects of her fatigue. She described how the therapy had 
provided her with an ability to examine patterns in her life and to consider how these might 
interact with her physical symptoms, such as fatigue. One such strategy was to use a visual 
cue: 
PP6 I have an egg cup on the mantelpiece at home, which is one of me 
prompts, and it was, she [her CBT therapist] taught us to say, “That’s your 
egg cup” she put it on, on the mantelpiece, “That is my energy for today. 
How are you going to use that energy effectively?” ... And I found that 
was a good, ‘cause I like, I think visually and I like that prop... And 
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thinking, “Right [participant's own name], if you drain the egg cup by 10 
o’clock in the morning don’t be surprised if you’re, you’re crashed out.  
Vincent  Yeah, okay. So that helped you manage your energy?  
PP6 Yes. (FG1B 1189-1205) 
Following the completion of her CBT intervention, she also continued to keep a diary of her 
symptoms as she considered it to be a useful tool to help her map what was going on in her 
life; not only her pain, but also flares of her comorbidities, daily events and her fatigue.  
For the purpose of the group discussion, pacing was described by the facilitators as dividing 
up activities/tasks, into smaller, bite-sized chunks and interspersing them with rest. Another 
patient had applied pacing techniques herself without the support of a health care 
professional and through doing this was successfully able to continue with the hobbies she 
found enjoyable, including gardening. 
PP10 I do a bit of gardening. I do five minutes and then I have to sit down.  
PP6 And then stop, yes.  
PP10 And things, and then get up and do another five. But I have, if I pace 
meself it’s great.  (FG3A 2202-2213) 
This patient had also gone on to apply pacing to exercise which meant she was able to 
continue walking her dog and do some very gentle exercise at her local gym. ‘If I pace meself 
I find that is better for me with the exercise.’ (PP10 FG3A 2226)  
However, although pacing was a relatively easy concept to grasp, some people said they 
would need support to apply the principles to their own lives. Solely being aware of the 
concept of pacing was not always enough to being able to implement the strategies. Other 
factors also could influence the practical application of strategies such as pacing. A patient 
who was involved with several committees found that if she was chairing a meeting, she 
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was better able to control it, and instigate breaks. However, if someone else was in charge, 
this could become more difficult as:  
PP2 ‘There’s an awful lot of people who just want to get on and they just don’t 
want the breaks. … You feel you’re being pushed all the time’. (FG1B PP2 
1753-1754) 
Outside influences, particularly in work or more formal situations could make it difficult to 
apply the principles of pacing activity or planning rest breaks, especially if other people were 
involved in the activity. 
Exercise was a strategy used by other patients to help actively manage their fatigue. One 
participant explained how he found exercise to be beneficial, but his ability to carry it out 
depended on how much energy he had at the time. He also thought that if people with PSS 
were advised by professionals to try and manage their PSS fatigue, then the advice should 
be appropriate and specific for the individual. Another patient who had previously been 
advised by a health care professional to do some very gentle exercise had followed through 
on this advice. She had taken up Qi Gong, which is similar to Tai Chi, and found it to be 
beneficial; ‘I try to do it … every morning. And that helps me start the day’ (FG1B 1077-
1082). 
6.2.1.2 Strategies used to manage sleep disturbances  
One participant had now resigned himself to having poor sleep for the rest of his life. ‘It’s 
just something you live with; you can’t do anything else’ (PP1 FG1A 50). However, other 
people had implemented their own range of strategies to try and improve their sleep. 
Daytime naps were one such strategy that some people drew on to help them manage 
symptoms of both their daytime sleepiness and fatigue.  
PP5 I, I get to a point where I’ve now just got to switch off for a little while. … 
And it might not be sleep, it might just be sitting quickly, resting my 
eyelids but then I, I can have another go.    
Kate Mhm. 
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PP7 A powernap.  
PP3 Just creeps up on you, yes. 
PP7 A powernap. 
PP5 Yeah. Yes it is, yeah. (FG1B 733-755) 
Daytime napping offered some refreshment which participants were not able to experience 
from a night-time sleep. However not everyone was able to sleep during the day despite a 
poor night’s sleep. One lady believed that if she were able to have a nap, she would feel 
better, but despite trying, she was unable to sleep at all during the day. Consequently, she 
constantly felt more fatigued. 
Some participants had sought help from their GP who had subsequently offered to prescribe 
them sleeping pills. However, none had opted to use them. One reason given by one was 
that she thought hypnotic medication may be addictive and she did not want to become 
reliant on such a drug. Another said her reason for refusing it was ‘I want control of me, not 
drugs’ (PP2 FG1A 1114). 
Alternative medicines, including Chinese herbs, Shiatsu and acupuncture had been used by 
some people. One participant regularly had acupuncture for her pain and described her 
night’s sleep following an acupuncture session; ‘I sleep like a baby. It’s a wonderful, 
wonderful deep restorative sleep, and I can go all the way through’ (PP6 FG1A 139-141). This 
phenomenon was not unique to acupuncture as someone else also described experiencing 
restorative sleep the night following a Shiatsu treatment.  
Relaxation or meditation techniques to help sleep were an avenue which had been explored 
by some people. One patient told the group how she regularly enjoyed using meditations to 
help her relax at bedtime. She had sourced the tracks on the internet and downloaded them 
onto her iPad. However, despite noticing some relaxation benefits from listening to them, 
she did not always find that she could get off to sleep whilst listening to them. Another 
patient found that relaxation helped her to ‘calm down and take [her] mind off … worrying 
things or churning thoughts’ (PP4 FG1A 1649-1653). Therefore, although these techniques 
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did not necessarily induce sleep, they did seem to help distract from anxieties and promote 
a sense of well-being.  
One patient described how he struggled with thoughts going through his mind while he was 
trying to sleep: 
PP5 When I’m lying awake, and my mind’s churning over goodness knows 
what, and I can’t get back to sleep, the only thing that actually gets me 
back to sleep was putting my TV on because that occupies my mind. And I 
fall asleep to the TV. (FG1A 1389-1392) 
Another patient used the radio as a similar distraction technique in order to fall asleep. 
Discomfort interfered with sleep and patients addressed this in a variety of ways, depending 
on the source of the discomfort. One person had been able to alleviate the discomfort she 
experienced in her legs by propping up the end of her mattress in the hope that she would 
sleep better. Feeling cold at night in bed, particularly experiencing cold legs meant, perhaps 
unsurprisingly, that some people took a great deal of care ensuring that their sleep 
environment was warm and stayed warm, using electric blankets, hot water bottles, and 
extra blankets. However, these strategies could also affect a bed partner. One patient’s wife 
described how her husband’s use of hot water bottles in the bed was ‘a bone of contention’ 
(AHM1 FG1A 896) as she liked to remain cool in bed.  
6.2.1.3 Strategies used by participants to manage pain and discomfort 
Patients used a variety of strategies to help manage their pain and discomfort. One such 
strategy was to push through the pain, to ‘push it to the back of your mind’ (FG3A PP10 
2307) and focus on something else, because ‘if you concentrate on the pain it seems to get 
worse’ (FG3A PP10 2303). Music was an example of a welcome distraction. If it were 
possible to redirect attention onto something enjoyable, such as music it meant that pain 
would seem to reduce. However, if they also had difficulties with tolerating noise, music 
might not be the most appropriate distraction. Using other activities, which required 
physical or mental effort as a distraction from pain and discomfort, could also be more 
difficult to achieve during an exacerbation of fatigue.  
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Patients had sought help from their GPs for their pain and had encountered a range of 
responses. They described that, after finding a doctor who was sympathetic to their needs, 
they would prefer to go back and see the same doctor rather than risk receiving a negative 
response from a doctor who they perceived as not having a lot of understanding about their 
condition or symptoms. However despite being on the receiving end of some negative 
attitudes from GPs, (this was discussed previously in the context of fatigue in Section 
6.2.1.1) there were incidences of positive responses to patients’ experience of pain. One 
patient had been referred for ‘Exercise on Prescription’ (Ayres and Pocock, 1995) by her 
doctor. Another patient described how a more sympathetic GP in her practice had: 
PP10 prescribed the rare codeine and paracetamols for us. …. She said, “Oh no, just 
take them when … when it’s necessary.” (FG3A 1780-1786)  
This patient had been empowered by her GP take control of her pain medication, and taking 
it when she felt it would be appropriate, which for her was ‘only if it’s really bad’ (FG3A 
PP10 205). 
Transcutaneous electrical nerve stimulation (TENs) devices were used by a couple of people. 
One patient needed help from her husband with a device which: 
AHM2  Looks like a thick pen. Erm, and you click the end and it gives you, it’s like an 
electric shock. … And it stimulates. You’ve got to click it about 25 times, I 
mean when [his wife (PP8)] wants clicking I end up with thumb ache because 
(Laughter) it takes that much clicking, but it does help at times doesn’t it?  
PP8 Yeah. (FG3A 1403-1422) 
Another patient also found benefit from wearing a TENs machine on his back and shoulders 
as this helped to relieve his musculoskeletal pain. 
Two patients mentioned their use of alternative therapies in the context of managing their 
pain. As was mentioned in the previous section (Section 6.2.1.2), one participant found 
acupuncture to ease her pain and consequently help her sleep better. Another patient 
explained that as well as helping with many of her other PSS related symptoms, Shiatsu had 
helped to decrease her pain. 
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Support from family members was considered to be particularly important when the pain 
was a problem. Supportive significant others could be very helpful, when pain was 
particularly bad. One patient’s daughter often would often encourage her during a pain flare 
by saying: 
PP10 “You’ll be alright.” … Just, er, just take a few deep breaths and we’ll just 
start again” (FG3A 2586-2590) 
Having supportive friends and family, who understand the variability of PSS pain, could 
therefore be very useful for patients, when trying to cope with an increase of this symptom. 
It can be seen that patients use a variety of strategies to manage symptoms of fatigue, sleep 
disturbances, pain and discomfort. Several of these strategies were also recommended 
during the clinician validation process. This will be discussed further in Section 6.2.2. 
6.2.1.4 Generic strategies used by participants in the context of several 
symptoms 
During the discussions, patients often found it hard to separate their symptoms and talk 
about one in isolation. This was because the different symptoms seemed to interact with 
each other. Furthermore, some strategies seemed to help with more than one symptom. 
For example, patients therefore often employed similar strategies to managing their pain 
and discomfort as to those they used for managing their fatigue, in part due to these 
symptoms often occurring together. Pacing was one such strategy used for both symptoms, 
which meant that pre-planned activities could happen without a severe exacerbation of 
symptom, or ‘crash’.  
Pre-planning pleasurable activities was considered as being an important strategy for 
general well-being, despite the presence of symptoms as one lady explained: 
PP7 Something that you anticipate that’s a pleasure.  
PP3 Mhm, mhm.  
PP7 Which I’m sure is, is right.  
PP3 Mhm.  
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PP9 I think that’s very major actually. … In my ten tips I wrote … [I say] try and 
have something to look forward to either daily or weekly. I think you really 
can. (FG3A 2250-2266) 
This lady (PP9) explained to the group how she had previously written a list of helpful tips to 
help other people with PSS and this recommendation was in her list.  
Planned exercise was something that one patient found particularly helpful for her fatigue, 
pain and mood: 
PP10 Well I do a regular exercise and I’ve been doing it for three years. … And, erm, 
I’ve always found it good because it, otherwise I, if I just sat there I wouldn’t 
get up in the morning and do anything. (FG3A 2175-2180) 
Another patient who was taking part in an ‘Exercise on Prescription’ scheme for her pain 
(see Section 6.2.1.3) explained that this scheme provided her with ‘a free membership to, er, 
[a local] leisure centre’ (PP7 FG3A 2101). Subsequently, she had been using the gym under 
the guidance of an instructor and having swimming lessons. As well as helping her pain, the 
regular exercise had resulted in the added benefit of improving both her fatigue and her 
mood. She described feeling more confident and positive which she attributed to taking this 
step in supporting her own health. However, a couple of patients had experienced a 
‘detrimental effect’ (PP1 FG1B 1060) from carrying out exercise: 
PP5 It’s like also if you try and do some sort of exercise, even if it’s just, you know, 
30 minute walk a day, the, the, the repercussions sometimes … is worse than 
actually doing it. (FG1B 1050-1056) 
Symptoms could be exacerbated by doing too much exercise and it was difficult for people 
to gauge how much the right amount was.  
We have seen that having supportive people around can be helpful and conversely we saw 
previously (in Section 5.2.1) that having unsupportive family or friends who did not seem to 
understand the symptoms of fatigue and pain could be unhelpful. One focus group 
participant explained that she had found a source of support through social media. She 
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regularly used the social network internet resource Health Unlocked (Health Unlocked, 
2016) and discovered: 
PP7 It’s just somewhere you can just vent your spleen a bit and you get 
information, you get ideas.  
AHM2 You get support.  
PP6 Yes- and you get bits, it fills in the blanks where the medical practitioners, 
maybe, leave off. (FG3B 2005-2011) 
Although this patient did not receive much understanding from her immediate family 
members, she had found support amongst strangers on the internet who mutually shared 
their lived experiences of living with chronic symptoms. 
6.2.2 Responses of participants to strategies proposed by clinicians to 
manage their symptoms 
For each of the symptoms, various potential intervention components, which related to the 
particular symptom were described to participants as outlined in Table 6-1. Overall, 
participants responded positively to these suggested strategies. Details of their responses 
are provided for fatigue, sleep disturbances and pain and discomfort. 
6.2.2.1 Fatigue 
Several patients had already tried, or continued to use, some of the fatigue management 
strategies including pacing and exercise. This in itself demonstrates that patients were 
generally accepting of such interventions. Several patients understood the theory behind 
pacing but explained that it could be ‘difficult to apply’ (PP6 FG1B 1023) however ‘it’s worth 
pursuing’ (PP6 FG1B 1027) because they could see the benefits. Providing the information 
wasn’t always enough for people to be able to actually practise this skill and some people 
felt they would require further support to implement information that was provided in 
written form. Others felt confident that as long as they had the information at hand, they 
would be able to apply the principles. Different patients therefore require different levels of 
support. 
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Earlier, (see Section 6.2.1.1) we saw that one patient used a diary to help her map her 
symptoms. Within the context of planning and pacing, activity diaries were also discussed as 
a potential component of a fatigue intervention. Diaries were seen as an acceptable and 
potentially useful intervention component to help patients self-monitor their fatigue. 
Exercise was again an acceptable intervention, but some people found it difficult to know 
where to start and how to pace it appropriately (see also Section 6.2.1). Therefore, 
appropriate individualised guidance is needed.  
CBT was an intervention which had previously been recommended to some focus group 
participants as previously seen in Section 6.2.1. Further aspects of CBT interventions were 
also discussed as a future possible intervention for fatigue. I asked participants whether it 
might be useful to examine some of the thoughts which are likely to drive unhelpful 
behaviours. This was something which resonated with one patient in particular: 
PP5 I’ve always been a workaholic so I have a problem that I’ll, I’ve got something 
to do so I go at it and I’ve got to finish it. … But the result of forcing myself to 
finish it is that I’ve got nothing left in the tank. (FG1B 1303-1314) 
Spending time to examine the beliefs behind unhelpful behaviours or habits was seen as 
both acceptable and appropriate by all, including those who believed they were less driven 
by their premorbid standards. However, all participants could relate to these ‘all or nothing’ 
(Vincent FG1B 1325) behaviours and believed CBT would be an acceptable and helpful 
intervention which would provide patients with opportunities to examine unhelpful 
thoughts and behaviours. 
Within a CBT intervention, it was also seen as important to have the opportunity to consider 
the reactions of others in society towards their disease and symptoms, particularly when 
these were negative. It was also felt that some PSS patients might need support to function 
and manage their symptoms, particularly fatigue, in social and work situations. It would 
therefore be advantageous to have the opportunity to explore these scenarios during a 
future fatigue intervention. 
Participants remarked on how an inability to participate fully in every-day activities due to 
their fatigue, impacted on their mood. Having specific goals to enable them to participate 
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more fully in activities was seen to be helpful, in both managing the fatigue and improving 
mood. A patient’s husband gave an example where his wife’s fatigue was affecting her 
mood due to the fact her activity and participation had reduced so much: 
AHM2 And I had to really nag you to come with me just to take him 
[grandchildren's dog] for a walk didn’t I? But it did help you, I 
think, when you got out.  
PP8  Yeah (FG3A 2546 – 2548). 
Having support to set and implement specific goals, could therefore seem difficult when it 
came to implementing them, but the effort required could be really beneficial. Setting 
personalised goals was therefore seen as an acceptable component of a fatigue 
management intervention. 
6.2.2.2 Sleep 
Many of the poor sleep experiences described by patient participants were not unique to 
PSS, but, as discussed in the previous chapter, (Section 5.3) share similarities with other 
conditions. Several components from a cognitive behavioural therapy for insomnia (CBT-I) 
intervention, (see Table 6-1) were described to participants in order to appreciate how well 
they might be received as a potential intervention to improve their sleep. Although only 
some components of a CBT-I intervention were discussed, including some stimulus control 
elements (Bootzin et al., 1991), due to the time constraints, this was deemed enough to 
introduce the concept of CBT-I treatment. The stimulus control elements which were 
discussed included only using the bed for sleep and sex (hence removing other activities 
such as crafts and computers from the bedroom), getting up if not asleep after 15 minutes, 
anchoring the wake up time and avoiding day-time napping (Bootzin et al., 1991).  
A discussion around sleep hygiene and CBT-I components followed. Some participants had 
already tried some components and one lady had previously received one-to-one CBT-I over 
several weeks. 
Sleep diaries are used in CBT-I to measure outcomes and monitor sleep efficiency (the 
percentage of time spent in bed being asleep). Some patient participants had previously 
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been asked to complete sleep diaries at their clinic appointments. Although the purpose of 
collecting the sleep diary data at the clinic was primarily to measure sleep outcomes and 
plan treatment, it had surprising benefits:  
PP6 That sleep diary, er, that I’ve done for [clinic] - that was incredible. That really 
made me think, ‘cause … we’re trying to find answers about patterns and all 
this. ... And I think all of a sudden when you start to … log your sleep and ... 
you focus on it … it sort of raised lots of things that I thought, “Ah, maybe 
there are some things I could do...”. I found that sleep diary very, very useful. 
(FG1A 654-665) 
This patient found that by documenting her sleep for a couple of weeks, she formed an 
awareness that her sleep problems were actually part of her disease. The process of 
completing the diary also helped prepare her to make changes after seeing patterns emerge 
in her sleep diary. She subsequently felt ready to implement any suggested behavioural 
changes to try and improve her sleep.  
Another technique proposed to the group was to remove clutter and activities from the 
bedroom including books, work, mobile phones, televisions, crafts etc. The participant who 
had undertaken CBT-I had already been advised to do this as part of her therapy and had 
subsequently carried out this advice and continued to implement it after she had completed 
her therapy. Another participant who was hearing this advice for the first time during the 
focus group started to make immediate plans to practically change her bedroom 
environment when she returned home:  
PP6 It’s made me look at our bedroom, which is basically like a warehouse ‘cause 
we’re putting a Velux window in and…our bed is ancient, it’s 15 years old and 
it desperately needs changing. … I even thought about those just practical 
things like maybe, “Yes, we need to get the bedroom more comfortable.” So 
things like taking out those, you know - gadgets and things … you’re doing as 
much as you can - practical things. (FG1A 1591-1611) 
For this patient, completing the sleep diary and having access to this information was 
enough for her to make changes to her bedroom environment. 
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Although other participants had not formally had CBT-I, a few participants recognised some 
of the components discussed as they had previously tried to implement them themselves. 
Anchoring the time that someone would wake up in the morning was one such strategy that 
had been put into practice by one participant who gets up at the same time daily for her 
work. This is where the wake up time is set the same every morning e.g. 7am and means 
rising at this time every day, including weekends, regardless of how well the person had 
slept the previous night. Other people also indicated that they would be willing to try it if it 
was part of an intervention which aimed to improve their sleep. However, one participant 
had a different reaction. He said he would ‘find it difficult fixing a time because it depends 
on the sort of night [he’d] had’ (PP5 FG1A 1447-1448). He explained;  
PP5 if you do eventually get to sleep what’s the point of deliberately waking 
yourself up? You’re having some sleep, thank God. Let me, let me keep it. 
(FG1A 1676-1678) 
As shown in the previous chapter, sleep is regarded as a finite resource which on first 
thoughts he did not want to squander, even as part of an intervention to help him in the 
longer term. He seemed resistant. However, after being given the rationale behind some of 
the intervention components being mentioned he agreed that he could see the reasoning 
behind it, but if he were to try these techniques he would have ‘to see some, erm, success’ 
(PP5 FG1A 1844-1845) after implementing any such strategies in order to continue with the 
treatment. 
With regards to sleep onset difficulties, a technique which is recommended to patients is 
that they get up after 15 to 20 minutes if they have not fallen asleep. Participants generally 
said they would see this advice as being acceptable. Two people already did this, one of 
whom had received the CBT-I intervention previously. However, one person who regularly 
implemented this advice and gets up to read in a chair if she is unable to get to sleep, 
encounters a problem: 
PP2 Next thing I know it’s two hours, three hours later. … I haven’t gone back 
to bed. I’m just sitting in the chair. … And I’ve just fallen asleep. 
Kate Oh, you’ve fallen asleep in the chair?  
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PP2  Yeah. (FG1A 1574-1586) 
Despite intending to return to bed when she feels sleepy, she regularly finds that she has 
fallen asleep in the chair. There were also others in the group who disagreed with this idea 
and said that they would prefer to stay in bed as in their experience, they would eventually 
doze off. 
Another technique; sleep restriction (Spielman et al., 1987) was proposed to the group. In 
this technique, the average amount of sleep someone has each night over week is 
calculated. Thirty minutes is added to their average sleep time and this is the amount of 
time that they are permitted to be in bed. The exception to this is if someone is 
experiencing on average less than 4.5 hours sleep per night meaning the minimum amount 
of time a person would ever be restricted to is 5 hours, even if they were getting on average 
a lot less than this per night ordinarily. This suggestion received a mixed response from 
participants. It initially seemed counterintuitive to the group; ‘The thing is, if, if you’re not 
sleeping what’s the point in not going to bed?’ (PP1 FG1A 1671). For this reason participants 
felt that again, they needed a good rationale as to why this might be advised. They 
understood the rationale which was to be able to regulate their sleep and for them to begin 
to associate being in bed with being asleep, not awake. After being presented with a good 
rationale, they acknowledged that ‘the patient too has to be willing to experiment’ (PP4, 
FG1A 1830). Most participants in theory would be willing to try these techniques if they 
thought that their sleep would improve as a result of the changes that they had made and if 
they were able to see some improvements relatively quickly after applying these 
techniques.  
6.2.2.3 Pain 
The discussion which took place around pain management strategies, included components 
of activity management, CBT (Ehde et al., 2014) and acceptance and commitment therapy 
(ACT).  
As with the other symptoms of fatigue and sleep, patients viewed symptom diaries as being 
an acceptable and potentially useful tool for managing their pain symptoms.  
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The focus of ACT helps the patient accept their pain, to refocus their attention towards 
opportunities in the present and to realise valued goals (the commitment) (McCracken and 
Vowles, 2014; Veehof et al., 2016). Strategies including meditation, exercise and balancing 
activities and rest were not covered in great detail, as they had been discussed as part of a 
fatigue strategy management plan (Section 6.2.2) or had previously been raised by 
participants as being useful coping strategies which they already use.  
Following a description of ACT, one lady described how accepting her breast cancer 
diagnosis several years previously had helped her while she was undergoing treatment. She 
said in the early stages following her diagnosis; 
PP6  I reeled and reeled and reeled against the disease because I was … getting 
worse and worse and worse. (FG3A 2416-2417)  
However, following a conversation with someone who had encouraged her to try and 
accept her diagnosis and stop fighting, she came to the realisation that if she could accept it, 
she would expend less energy and redirect her energies to getting through the next stages 
of her treatment. Furthermore, she was able to apply this acceptance to her PSS diagnosis 
and the pain and discomfort that came along with it. Through accepting her disease and its 
associated symptoms, she felt better in herself. Another participant shared this view:  
PP6 If you could, if you could … train your brain to accepting of the disease … life 
would be so much easier I think. … It really would. … Acceptance is the key 
word’ (FG3A 2469-2489). 
The commitment aspect of ACT echoed with some of the strategies patients already used 
(see Section 6.2.1.3). It could mean choosing to do a valued activity, rather than avoiding it. 
Avoidance can take place to prevent experiencing further unwanted symptoms. One focus 
group member could see how it would be easy to avoid activities which seem to heighten 
her pain. She explained that her back pain is aggravated whenever she attempts to move 
logs in her log pile. However she had made the choice to continue with the activity and 
found ‘eventually it [the pain] goes away’ (PP7 FG 3A 2401). Patients found that if they 
allowed their pain to receive their full attention, rather than a task at hand, it meant that 
they were less likely to complete the activity and that their pain would be more intense. 
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PP10 I think if you think more of the pain it, the pain’s worse.  
PP6 It, it gets on top of yous.  
PP10 It gets on top of you, yes.  
PP8 Mind over matter.  
PP7 It is- …. You just learn to, kind of, shove it.  
PP8 I think if you’ve got a job to do as well, you’ve got to get it done.  
PP5 Well if you’ve got something to do. 
PP8 Yeah, you have to get it done (FG3A 2329-2354). 
CBT, meditation and ACT were all interventions that patients would welcome, if offered, as 
part of a plan to help them reduce manage their symptoms. Furthermore, some patients 
already used several of the strategies themselves, therefore had ‘bought into them’ but they 
would value specific and appropriate support to better self-manage.  
6.3 Discussion 
Participants had experience of a range of interventions, and were mostly willing to try out 
new ones, particularly if they were individualised and time was taken to explain the 
rationale behind them. 
Starting an activity and seeing it through to completion was a self-management strategy 
which several patients had adopted. In a self-management book written for people with 
CFS, the author describes people who push through activities to completion without 
stopping for rest as being ‘starter finishers’ and how this behaviour can be self-defeating 
(Pemberton, 2009). Pushing through the fatigue was seen as a way of fighting the symptom 
by some participants, despite repeatedly experiencing negative consequences from 
implementing this strategy. Conversely, in the context of pain this strategy was seen as 
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potentially being helpful. Patients reported how committing to a task and seeing it through 
to the end could help distract from their pain. However, committing to an activity did not 
mean that it cannot be broken up and interspersed with rests. Several patients had reaped 
the value from pacing their activities by breaking down them into smaller chunks and taking 
regular rests. This strategy is used within in both fatigue and pain management 
interventions (Hewlett et al., 2011; Hewlett et al., 2015; Andrews and Deen, 2016). 
However, pacing was a skill which could be difficult to apply, in part due to self-defeating 
behaviours. Therefore investigating these self-sabotage behaviours (Hewlett et al., 2015) 
may be a helpful component of an intervention to manage pain or fatigue. 
In addition to using pacing strategies, some patients had already used diaries to self-monitor 
their symptoms, found them to be useful and regarded them as an acceptable intervention 
component which patients could use to observe patterns in their own behaviours. Diaries 
are a tool which used within symptom management interventions for fatigue (Hewlett et al., 
2011; Hewlett et al., 2015) and insomnia (Mairs and Mullan, 2015) and could be used in a 
future PSS symptom management intervention. 
Some patients used exercise to help with their fatigue, pain and general well-being. Exercise 
is recommended in the management of PSS fatigue (Price et al., 2016). This qualitative work 
begins to show that patients need support to tailor their exercise and to start at a level 
which is appropriate for them. Some patients were able to work this out for themselves, 
while others require more individualised support and guidance. 
It can therefore be seen that patients require different levels of support. In this study, some 
patients recognised that making some specific changes to their behaviours helped them to 
better manage their symptoms. They were able to implement these behaviour changes if 
they had access to the information which explained what to do. However, information itself 
was not enough for others to feel that they would then be able to independently make 
lifestyle changes and they require more support than purely information alone. One study 
(which included PSS patients) found that written self-management information for fatigue 
may have more impact with supporting patients to manage their own fatigue if the 
information is handed to the patient directly by a healthcare professional and they are given 
a follow-up appointment to discuss the written advice. This extra support may provide more 
opportunities for behaviour change to occur, in the context of fatigue management (Hart et 
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al., 2016). The following chapter (Chapter 7) discusses different levels of support in more 
detail.   
This study has begun to show the importance of providing patients with a rationale for 
interventions where they are able to see improvements in their symptoms or functioning as 
a result of carrying out an intervention. Conducting a ‘behavioural experiment’, where a 
new behaviour is tested for a trial period may be a useful intervention component. There is 
some evidence that this strategy is beneficial in anxiety disorders (McMillan and Lee, 2010) 
and may be particularly useful if a patient is anxious about changing a behaviour or sceptical 
about its potential for benefit.  
This study has provided some evidence that once a self-management skill is learnt for one 
symptom, patients are able to apply the same strategy to other symptoms. This is 
important, because if a patient has several symptoms, it may not matter which is addressed 
first in a symptom management program, as the technique may have a carry-over effect and 
help them with managing other symptoms, improving their autonomy in managing their 
own disease. This concept could also be considered as patient activation, which is ‘an 
individual’s knowledge, skill, and confidence for managing their health and health care’ and 
can be measured with the Patient Activation Measure (Hibbard et al., 2005).  
This qualitative study has provided direction on which specific strategies and intervention 
approaches could help with symptom management in PSS. For example, when patients hid 
their fatigue from those around them, it often resulted in increased expectations from 
others. A cognitive behavioural approach could therefore be used to challenge unhelpful 
beliefs around fatigue and equip patients with the skills required to describe or explain their 
disease and its symptoms (including fatigue) to others, when appropriate (Rimes and 
Chalder, 2005; Hewlett et al., 2011; Dures et al., 2012; Knoop et al., 2012). 
Patients reported that sometimes support for their fatigue symptoms from other people 
could be enabling. Conversely, sometimes seeking support from others was regarded as 
being disabling. Context and individual beliefs therefore determined when support from 
another person with fatigue symptoms might result in either increased independence, or 
greater dependence. A tailored level of support with acquiring this skill may therefore be 
appropriate.  
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Exercise, particularly exercise which was paced or gentle, was also used by patients to 
manage their fatigue. This is in line with evidence in the literature for physical activity 
interventions for fatigue in fibromyalgia (Macfarlane et al., 2016), RA (Cramp et al., 2013) 
and CFS (White et al., 2011) as well as evidence from a small study of aerobic exercise in PSS 
(Strombeck et al., 2007). 
Some patients had naps during the daytime to manage their daytime sleepiness. However 
daytime naps, particularly when taken during the afternoon, are associated with reduced 
cognitive functioning in CFS (Gotts et al., 2015) and are generally discouraged as part of a 
CBT-I intervention (Perlis et al., 2005). Therefore, daytime naps are not necessarily an 
appropriate coping strategy. 
One patient who had completed a course of CBT-I, continued to carry out the techniques 
including stimulus control, yet still continued to have poor sleep. CBT-I will not provide an 
effective solution to everyone with PSS-related insomnia. 
Patients accessed support from others, including their family members and internet support 
groups in order to help them cope with their pain and discomfort. Group support, provided 
either online or through face-to-face group interventions or patient support groups, may 
also be beneficial. Interventions which include an element of peer support have shown 
positive results on a range of outcomes in patients with a range of conditions who 
experience chronic fatigue, insomnia and chronic pain (Hewlett et al., 2011; Thomas et al., 
2014; Matthias et al., 2015; Kothari et al., 2016). 
Influence of others can prevent people from pacing. Assertiveness training is a skill which 
might be beneficial to some people. This has been recognised by others who have 
developed and tested fatigue and pain interventions. Assertiveness training is incorporated 
into CBT fatigue management for RA (Hewlett et al., 2015) and communication skills form a 
module of an online self-management tool for fibromyalgia (Sparks et al., 2016).  
Patients found it useful to monitor their symptoms using symptom diary. Self-monitoring is 
a behaviour change technique which has been used in interventions to promote physical 
activity in RA (Larkin et al., 2015), is likely to be acceptable to PSS patients and could be 
used as a component of a symptom self-management intervention. 
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This study has begun to show that partner involvement in future symptom-management 
interventions could improve understanding and therefore support. Previous research has 
found differences between how couples relate to each other in the context of one partner 
having RA and couples were categorised into one of three groups: 1) ‘The shared illness 
management’ group, where both partners would attend appointments and make decisions 
together about how to manage the condition, 2) ‘The ill partner in charge’ group, where the 
person with RA made autonomous decisions about their own disease management and 3) 
‘The conflict over management’ group. In the third group, there was conflict in the 
relationship as the partner was dissatisfied about how the person with RA was managing 
their condition (Mann and Dieppe, 2006). Providing opportunities for partner involvement 
and supporting patients to communicate their needs effectively and assertively may 
therefore mean less conflict and result in the person with PSS feeling more understood and 
supported by their family. Further research would be required to investigate illness-related 
interaction in couples and families with PSS, but it is possible that those who have 
understanding partners (in the context of how they manage their PSS fatigue) experience 
less conflict than those whose partners did not support the way they managed their PSS 
symptoms. However, relatives should be included in face-to-face interventions and 
literature could also be made available for friends, relatives and employers which gives 
further information about the disease and symptoms. Increased awareness amongst friends 
and family may result in increased support and ultimately have a positive effect on mood.   
The way a person with PSS perceives their support from friends, family and health care 
professionals may have an impact on their mental health. A recent study has demonstrated 
that PSS patients who had either functional or self-reliant psychological profiles had lower 
fatigue scores than those who had dysfunctional or alexithymic (alexithymia is difficulty 
differentiating emotions) psychological profiles (van Leeuwen et al., 2015). The self-reliant 
group did not generally have good social support but they did not demonstrate negative 
thinking styles or display avoidant behaviour and were able to both describe and identify 
their feelings. Perhaps the perception of poor social support becomes a self-fulfilling 
prophesy. Addressing both negative thinking styles and avoidant behaviours within a CBT 
intervention could benefit patients with PSS and ultimately impact on their fatigue levels. 
Equipping patients with assertiveness skills and helping them with being able to 
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communicate with others about their fatigue could also be beneficial and making literature 
available to patients to pass on to others could help increase self-efficacy. Educating health-
care professionals about the impact of PSS should also be considered. Support from a 
healthcare professional was also seen as being really important. ‘Believe my symptoms’ was 
a priority statement in a concept mapping study identifying the needs of patients (including 
some with PSS) attending a generic fatigue clinic (Hackett et al., 2016b). It is essential that 
symptoms are believed and acknowledged by HCPs during appointments and that they are 
not easily written off, for example as a symptom of old age as this can be devastating to 
patients. 
6.4 Summary 
In this chapter, I have summarised the strategies patients used to manage the symptoms of 
fatigue, sleep disturbances and pain as well as the response of patients and partners on 
potential future self-management intervention components. In the next chapter, I 
summarise potential modes of delivering future intervention components. 
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Chapter 7. A future model of care 
7.1 Introduction 
This chapter reports further findings from the focus groups and discusses a model in which 
intervention might be delivered to manage fatigue, sleep disturbances and pain for PSS 
patients. In this study a partially formed intervention model was presented to patients due 
in part to iterative process of the focus groups. It had already been suggested by 
participants that different patients require different levels of support (see Section 6.2.2). A 
model offering different levels or steps of care, with increasing intensity has a theoretical 
basis having already been developed and applied in other areas such as in chronic pain (von 
Korff, 1999) and in mental health (Bower and Gilbody, 2005). In order to shape an 
intervention model further, it is essential engage in a dialogue with stakeholders as this will 
give an indication as to whether such a model is likely to be implementable (Craig et al., 
2006). 
7.2 Aim 
To determine how a future intervention package might be delivered within an NHS setting 
7.3 Method 
The methods used for data collection and analysis are the same as reported in Section 5.1. 
Participants were asked at the end of each focus group discussion topic about possible 
modes of delivering the intervention components for each of the symptoms of fatigue, sleep 
disturbances and pain. There was also dedicated time to discuss modes of delivering future 
intervention components for all three symptoms, specifically allocated at the end of the 
third focus group. Participants were asked how this might look in an overall structure for a 
future model of care.  
The rough model presented to participants incorporated a low intensity Level 1 intervention 
(such as written information and access to local peer support) which would be available to 
PSS patients in addition to their ‘usual care’. The consequence of such an approach would 
mean that at diagnosis, everyone would be offered Level 1 care. This first step intervention 
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might include with written information about the condition as well as information on local 
support groups and appropriate websites and the option to attend a group session for 
recently diagnosed patients.  
It was proposed that a Level 2 intervention might be specific computerised or face-to-face 
group therapies targeting the specific symptoms of sleep, fatigue, pain and discomfort. Over 
time, according to patient needs, the range of therapies could be expanded to include other 
specific symptoms which are important to patients and impact on their lives, such as anxiety 
and worry, low mood and dryness.  
It was suggested that a Level 3 intervention could be individualised therapies for these 
symptoms, to be made available to those who require one-to-one, face-to-face 
interventions. All levels of intervention could be available within rheumatology services or 
some components be made available via other specialist services such as pain management 
teams. 
Participants were asked to contribute their opinions and ideas about these ideas, to suggest 
any additional ideas or to add further to this proposed model further that they would 
consider as being particularly helpful.  
7.4 Delivering symptom management interventions 
In the first instance, patient participants expressed a need for personalised care, where they 
were able to make an informed choice about their care. The main reason for a menu of 
options was that symptoms manifest themselves differently in different people. They are 
‘like a bag of liquorice all sorts. … Everybody’s got different flavours.’ (PP5 FG3A 1192-1198).  
AHM2 This is the trouble because for some fatigue’s the worst problem and some 
it’s, er, depression that’s the worst problem.  
PP8 There’s no two alike are there? (FG3B 424-427) 
Patients did not want their treatment pathway to be decided solely by clinicians. Instead, 
this was something they wanted active control over, providing the treatment or support 
they required was available. One participant described that he would like ‘a list, a menu for 
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the whole thing but then in, in each subsection a menu’ (PP5 FG3B 787-788). Another noted 
that they wanted ‘a support mechanism in place … that enabled [them] to decide what 
[they] needed’ (PP7 FG2B 945-946).  Patients wanted to have a conversation with a health 
care professional about the available options in order to make an informed choice about 
their care. There was a perception that choice and availability of different therapies and 
options ‘would go a huge way towards helping with moods and the confidence.’ (PP5 FG3A 
950-951). Thus, providing options where the patient could access what they perceived 
would be helpful for their individual circumstances, would be empowering. 
The possible modes of delivering interventions for the range of symptoms were discussed. 
Following patient feedback in Chapter 6 (Section 6.2.1.1), it was suggested that differing 
levels of support would be needed for different patients. 
7.4.1 Level 1 – Information provision and access to peer support 
In the first instance, the participants stressed the importance of having access to general 
information about the condition at diagnosis. The information is not only important for the 
person with the diagnosis, but can also empower the patient to educate others about their 
disease, including health care professionals, friends, family and colleagues. However, there 
was a major drawback, to receiving information verbally at diagnosis.  
PP7 ‘Cause I think when you’re diagnosed the words you hear are, “Incurable, 
but we can treat, but the treatment’s iffy.”  
PP8 That’s right.  
PP3 Yes.  
PP7 That’s all you hear, you don’t hear anything else. (FG3B 1628-1635) 
Patients felt limited as to how much information they were able to absorb at this time, as 
they were processing the fact that they have a systemic, incurable disease. They stressed 
the importance of also being provided with written information about their condition, 
including information on benefits and contact details of patient organisations and web 
addresses for further information which they could access as and when issues arose. Having 
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accessible written information was also empowering, as it can be given to others and used 
as a tool to help explain about the disease and how it can affect people with PSS.  
Furthermore, participants believed it would be beneficial for them to access others with the 
same diagnosis for some kind of support and this would be an opportunity to acquire 
further basic knowledge or ‘guidance’ (PP9 FG3B 1849) about their disease. One lady 
described her desperation to meet other people with PSS 30 years previously when she 
could think of no other way of meeting others who shared the same diagnosis. 
PP9 I agreed to one or two tests that I shouldn’t have agreed to really, just to see 
what other people [with PSS] looked like. (FG3B 1667-1668)   
Most participants thought that a group offering information on their disease, some basic 
self-management advice and the opportunity to meet others with PSS should be available 
several months after being told they had PSS, which would give them space to process their 
diagnosis. They thought newly diagnosed patients may have more questions and 
opportunities for further exploration of these ideas in a facilitated group could be more 
useful at this point. However, one patient had a differing view about the timeframe that this 
should be available ‘I think I’d want to know straight away’ (PP7, FG3B 1827-1828) and she 
said she would have been keen to have the information about such a group from her 
consultant at the time of diagnosis. 
In the implementation of such education groups, participants thought that it is critical to 
provide enough information, whilst at the same time giving patients space to consider any 
new information about their condition and to decide how they wish to manage it. This is a 
fine balance as participants felt that they did not want to be frightened by being provided 
with too much detail about possible future outcomes. 
PP7 You’ve got to give them that space to understand what’s going on themselves 
and realise how they might want to manage it. So really it’s the support to 
them to learn how to manage it rather than to tell them what might or might 
not happen in any great detail.  (FG3B 1892-1895) 
Participants proposed that a second follow-up group at this point, would provide an 
opportunity to ask further questions about the condition as well as providing a further 
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opportunity to meet others who were sharing the experience of coming to terms with their 
diagnosis. 
People taking part in the focus groups thought that the advantage of having access to 
groups with facilitated discussion by a knowledgeable health care professional could help 
them process their own thoughts about the disease through the discussion process and 
reflection between group sessions. This finding implies that a purely didactic approach may 
not be appropriate.  
PP7 Because you can be asked a question and you can either answer with thought 
or spontaneously but as the conversation goes on, that question in your mind 
is still churning away and so eventually you are going to get to the root, 
perhaps, of what the problem is, or something you’d never thought about. ... 
So you’re going to get a far more, erm, satisfying… Response to yourself, as it 
were, if that makes sense. (FG2B 1827-1838) 
Some participants explained that they would also have valued meeting an “expert patient” 
soon after diagnosis. This would be a patient who had been diagnosed for longer and was 
willing to share their experiences. One patient described how he had once been admitted to 
hospital for major surgery and had experienced meeting an expert patient; 
PP5 And someone else who had gone through that before me was a volunteer to 
come into the hospital when I was in there and sit with me and talk to me 
about their experience and their, their life post-bowel surgery. Erm, now 
whether there is a transference between that sort of approach and Sjögren’s, 
I don’t know. (FG2B 1657-1660) 
The participants liked the idea of having access to a patient who, with more experience, had 
already walked a similar path to them ‘As long as they are, they are able to be reasonably 
positive about it’ (PP5, FG2B 1668). They thought it could ‘depress you’ (AHM2, FG2B 1672) 
if the person attending the focus group had relatively mild symptoms but the experienced 
patient had many kinds of problems associated with their disease, as they might think ‘this 
is what’s going to happen to you.’ (PP1, FG2B 1675). 
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It was therefore important to carefully select a patient who had been diagnosed for some 
time, to be certain that they would strike the right balance of sharing experiences but not 
overburden newly diagnosed patients with frightening stories. 
While the focus group participants were very much in favour of groups, they had opted to 
come along to the focus group in the first place and may be more at ease in group situations 
than others. They acknowledged that there may be some patients who after receiving a PSS 
diagnosis may not want to access a group. Some people may find that a written information 
pack provided at diagnosis including contact details of patient organisations and web 
addresses for further information is sufficient. They thought such a pack should contain 
details on where patients could access further support as and when issues arose. 
Participants discussed the pros and cons of accessing support via an online forum. One 
patient (as discussed earlier in Section 6.2.1.4) had first-hand experience of this for one of 
her comorbidities, as well as a PSS specific forum and clearly found these forums a useful 
source of support; 
PP6 The forum takes up where the medical side leaves off, or where if your 
family don’t want to discuss it, or whatever. And we go on and we 
exchange lots and lots of ideas and things, we get lots of, you know, I 
mean everybody says, “We’re not there...” Nobody’s there to give medical 
advice. But it’s just somewhere you can just vent your spleen a bit and you 
get information, you get ideas.  
AHM2 You get support.  
PP6  Ye- and you get bits, it fills in the blanks where the medical practitioners, 
maybe, leave off. (FG3B 1994-2004). 
Therefore, although professional-based expertise and knowledge is useful, it can be 
supplemented by expertise and shared experiences from other patients who also live with 
the disease and/or symptoms. 
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7.4.2 Level 2 – Accessible therapy to manage specific symptoms: 
Computerised therapies and group symptom management support 
Although having access to information about PSS, participants felt that further specific 
symptom management support would be required for patients at different times. As there is 
such heterogeneity of symptoms between patients and because a particular symptom could 
be more troublesome at a particular time for the same individual, it was again, important to 
have choice. A menu of different specific digital therapy interventions which could be 
accessed via a website was one such potential option that was put forward in the focus 
groups. There were different views about this potential mode of delivery.  
There were some benefits that members of the focus groups identified regarding digital 
therapy interventions. One participant saw the potential of this kind of support being 
available to more people than face-to-face therapy might be. She also though ‘one has to be 
careful about costs’ (PP4 FG1B 1998) and saw this as a cost-effective way to deliver an 
intervention to many people, which was also realistic to achieve.  
Although the idea was new, participants generally thought that they would be willing to try 
this sort of intervention and ‘If it works fair enough, if it doesn’t well you can move onto 
something else’ (PP1, FG1A 2023-2024). One participant said she saw the attraction of a 
computer intervention to people who were planning and designing interventions and was 
positive about it herself as she liked to use computers.  
A husband of a person with PSS saw further advantages with computerised interventions, as 
it is possible to improve and modify them; ‘when you do something on a computer it’s there 
and it can be improved’ (FG3B 924-925). He also thought that it would be relatively easy to 
refer patients for such interventions. For example, a GP could refer patients during a 
consultation, thereby making it immediately accessible to a person with PSS as it is required. 
Another participant thought that it would require less ‘manpower’ (PP9, FG3B, 821), and 
thereby increase accessibility. 
There were also less favourable opinions regarding computerised therapies. One household 
member pointed out the age demographic of a sizeable proportion of those with PSS and 
how this could be a barrier to accessing computerised therapies.  
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AHM2 A lot of people with Sjögren's are, are older and a lot of people, erm, either 
don’t want to or haven’t got the knowledge for computers and stuff like that. 
(FG2A 1666-1667) 
Another patient participant who worked with computers was willing to try such a therapy, 
but for him ‘face-to-face is still the preference’ (PP5, FG2B 1703-1704). The reason for the 
reservations were  
PP6 Because you don’t get any feedback at all on a computer.  
PP5 Yeah, because if you are telling everybody face-to-face, you can see 
looking at their face whether the eyes and the mouth agree. (FG2B 1710-
1713) 
One participant’s reason was simply ‘I hate computers’ (PP8, FG3B 879). Participants 
thought that computerised therapies would require commitment and motivation from 
patients. One participant considered herself as ‘too lazy’ (PP9, FG2B 1869) to work through 
an intervention on a computer without a therapist. 
One way around the potential problem of lack of commitment was that digital therapies 
could potentially be offered with additional face-to-face, Skype or telephone appointments 
to give additional support or coaching to a person who was working through a computer 
therapy. This was met with a favourable response, with one patient participant seeing a 
potential active role for himself, in supporting people through the process: 
PP5 I can imagine that if – this is just me – I can imagine because of my, erm, 
my push to volunteer for things, if there was a digital pathway, I could see 
I could offer to be a digital advisor and take people through it. I’ll sit in 
front of the computer with you.  
AHM2 Yeah, you could be a digital buddy for everybody. (Laughter) 
PP5 I could do that.  
PP9 I’ll come along with you. (FG2B 1942-1950) 
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Although there are some potential disadvantages of computerised therapies, there have 
been many advantages highlighted. This is potentially an intervention which would require 
less manpower than some traditional face-to-face therapies and could be made accessible 
to large numbers of people who needed it quickly. Refinements could be made to constantly 
improve it and it could be enhanced by additional support being provided by expert patients 
or clinicians. It could be a lower level intervention which could be made available to people 
who are experiencing particular difficulties, such as with sleep (e.g. CBT-I). If this 
intervention does not help to improve their symptoms, there is potential for a higher 
intensity intervention to be offered (face-to-face individual appointments). 
7.4.3 Level 3 – One-to-one therapies 
Participants highlighted the advantages of having face-to-face therapy. These included 
‘human contact’ (PP6 FG1B 1953) and the fact that it was ‘more personal’ (PP1 FG1B 1961). 
Another participant explained the reason face-to-face suited her was ‘you can connect and 
you can, I think you can open up and express more when you’re face-to-face’ (PP3 FG1B 
1963-1964). 
Participants had particular expectations of face-to-face therapies. Being able to have ‘faith 
in the other person’ (PP9 FG3B 886) and ‘the attitude of the person’ (AHM2 FG3B 894) were 
essential prerequisites, alongside listening skills and the knowledge of the therapist. 
Participants are able to tell if a therapist genuinely believes what they are recommending, 
or if they believe what their patients are telling them.  
AHM2 I mean you sat there, I mean I can read your face and, you know, I know if 
you’re telling me something and, that you believe it, sort of thing, you know, 
through your eyes and your expressions. (FG3B 906-908). 
I anticipated that for those having to travel long distances to access therapy, that this may 
be a problem. However when this was put to participants, no one saw it as a difficulty. 
However, again, the participants who had chosen to take part in the focus group were 
motivated to travel to a face-to-face meeting and this viewpoint may not be representative 
of the PSS population as a whole. The major disadvantage of face-to-face therapies was 
thought to be the resources that would be required. 
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One participant was very pragmatic about provision of therapies, and making them available 
for all who could benefit from them. 
PP4 Cause I think one has to be careful about costs … of therapies and what is 
available … and not create expectations … that would be unrealistic. … And if 
you can come up with a, a lower cost recommendation that might actually be 
delivered... (FG1B 1998-2021). 
She saw potential in rather than making a therapy that, although desirable, may only be 
available for a small proportion of people who might benefit, it may be better to look at 
alternatives which could be accessed by more people and that could be deliverable. 
Having the option to have a partner or relative present during health care appointments 
was important for some patients. There was a perception that involving family members in 
any therapy would help the family member understand more about the condition and their 
attendance would be indicative of their support. A spouse of a patient echoed this and said 
she would like to be present during any face-to-face CBT her husband might have in the 
future, as this could help her gain further understanding of his symptoms and emotions.   
7.5 Discussion of stepped model of care and PSS care pathway 
An illustration of the model can be seen in Figure 7:1. There is support for managing each of 
the symptoms of fatigue, sleep disturbances and pain, with the intensity of the intervention 
increasing with each level of the model. 
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Figure 7:1 The intervention model 
During the focus group discussions, patients explained that it was very difficult to absorb 
information at the time they received their diagnosis. The literature shows that type 2 
diabetes patients also find it difficult to process the information they are given at the time 
they are given their diagnosis as at this time they may be experiencing a range of reactions 
including shock, despair and anxiety (Beeney et al., 1996; Gillibrand and Flynn, 2001). 
However, despite potential difficulties processing information, type 2 diabetes patients still 
feel it is important to have detailed information at diagnosis (Peel et al., 2004). In this PSS 
study, patients said they would also receive an invitation to one or more face-to-face group 
meetings where they could access further information about the PSS, to meet a patient who 
has lived with the diagnosis for some time, the professionals who may be involved with their 
care as well as meeting others who have also been recently diagnosed with the same 
condition. It should be noted once more however, that the patients who saw the value on 
this approach, had themselves opted to take part in a focus group. Within the written 
information which would be provided at Level 1, might also be information about 
information groups for people who have recently been diagnosed. Furthermore, it would 
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contain information explaining what is available in terms of specific symptom management 
support at Levels 2 and 3, and how to access it if required.  
Level 2 interventions (digital therapies and groups for symptom management support) could 
be made available to those who were experiencing problems with specific symptoms 
including pain, fatigue and difficulties with sleep. This could take place with guidance 
initially from a trained allied health professional who would take on a coaching role. 
Patients in the focus groups were keen to have support from other patients and some were 
even keen to provide that kind of support to newly diagnosed patients themselves. 
Experienced patients therefore, have a potential role to play in the delivery of these 
interventions. This possibility of patients delivering interventions is not a new concept. 
Patients have a history of delivering self-management interventions to other patients in 
schemes such as the Expert Patient Programme in the UK NHS. This was based on the 
Chronic Disease Self-Management Programme which was developed in the US. This was a 
lay-led, training programme for long-term physical conditions which demonstrated some 
cost reductions, improvement in self-efficacy and health distress (Lorig et al., 1999; Lorig et 
al., 2001). The UK Expert Patient Programme also demonstrated an improvement in self-
efficacy in the short term, although this programme did not result in improvements in 
overall quality of life or reduce access to health services (Foster et al., 2007; Griffiths et al., 
2007; Greenhalgh, 2009). A further study by Lorig and colleagues compared a lay-led 
approach with a non-lay-led tailored self-management programme in arthritis patients 
which was delivered via the mail and ‘usual care’ (Lorig et al., 2004). Both the lay and non-
lay interventions had significant benefits over usual care and it has therefore been argued 
that many people do not need to access a group or a face-to-face programme to attain the 
capability to self-manage (Taylor and Bury, 2007).  
Focus group participants stressed the importance of having choice available at Level 2. This 
would mean that if computer modules or groups which target specific symptoms were 
available, patients would have the option to choose the module(s) or group(s) that they felt 
would be the most helpful for them. Internet-based interventions have been criticised for 
having high attrition rates (Todkill and Powell, 2013). However two systematic reviews of 
adherence to anxiety and depression web-based CBT interventions found that attrition rates 
are similar to face-to-face interventions for these conditions (Christensen et al., 2009; van 
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Ballegooijen et al., 2014). If a patient chooses a digital intervention, a health care 
professional or trained patient might offer support at the beginning, midway and after 
completion of the module, as my findings show that patients think this accountability would 
motivate them to complete the work within the module. However, a recent trial of 
computer-based CBT to improve physical activity with and without additional coaching 
demonstrated similar improvements in both groups (Alley et al., 2016). Further research is 
required to determine whether additional coaching is likely to increase the effectiveness or 
adherence to a digital intervention in this patient group. 
The focus group participants had vocalised their awareness of stretched resources in the 
NHS and saw both digital and group symptom management as being a way of striking the 
balance between potential cost and reach to patients who need the support. A tailored one-
to-one clinic-based intervention for PSS patients with fatigue, which incorporated behaviour 
change techniques (e.g. goal setting) resulted in clinically meaningful and statistically 
significant improvements in fatigue (Hackett et al., 2016b). However, most UK PSS patients 
do not have access to such clinics (Hackett et al., 2016b). Internet-based health 
communities e.g. patientslikeme© (PatientsLikeMe, 2016) can offer peer/social support but 
they are not designed specifically to support PSS symptom management/behaviour 
changes. Internet-based behaviour change interventions have shown improvements in self-
management behaviours and symptoms across a range of conditions (Bantum et al., 2014; 
Eccleston et al., 2014; Hou et al., 2014; Zachariae et al., 2015) and therefore, such Level 2 
interventions offer a potential solution to PSS patients who currently have little support to 
self-manage. Furthermore, such interventions would fulfil the forthcoming BSR and BHPR 
Guideline for PSS, which recommend that patients have access to appropriate online 
resources for symptom self-management (Price, 2017).  
One participant expressed concerns about computer literacy in older patients with PSS. 
However, a recent report demonstrates that 89% of those aged 45-54 and 82% of 55-64 
year olds accessed the internet daily or almost every day during 2016 (Office for National 
Statistics, 2016). With the average age of PSS onset being in the early 50’s (Qin et al., 2015), 
most newly diagnosed patients are likely to have internet access, and the proportion of 
those who do regularly access it is likely to increase. However higher levels of disability, as 
well as lack of skills and equipment are two of the main barriers to internet usage (Office for 
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National Statistics, 2016). Training and devices could also be made available to those who 
do not use the internet regularly. 
Group self-management for fatigue, sleep and pain would also be made available as a Level 
2 intervention. This might be more attractive to those who are less familiar with computers 
and provide further opportunities for face-to-face peer support.  
If patients complete a Level 2 intervention and yet still require further support 
subsequently, or for those who are identified at assessment as needing additional support, 
Level 3 individual therapy would be offered. Further research is required to determine the 
ideal way of selecting appropriate individuals at assessment for individual therapy.  
Appropriate assessment may mean that these patients can be matched to the appropriate 
level of care for their individual requirements. However, certain patients who have 
undertaken symptom management at Level 2, may still require some individual support 
(Level 3). Again, appropriate assessment following a Level 2 intervention is likely to 
determine those individuals. 
Although different levels of intervention have been proposed, the proposed stepped model 
of care will support patients to self-manage aspects of their disease, regardless of the level 
of support that is required for an individual. Self-management programmes should be built 
on patient perceived problems and should include medical/behavioural management, role 
management and emotional management tasks (Lorig and Holman, 2003). The bio-
psychosocial model (Engel, 1977) addresses these areas and as I mentioned in Chapter 1 
(Section 1.5.1), the ICF is based on this model. The concept mapping study (Chapter 3) and 
the focus groups have identified symptoms which patients want to be able to manage 
themselves (medical/behavioural management), in order to do the specific things that they 
want or have to do (role management). The intervention content will be composed of those 
identified during the clinician validation process in Chapter 4 (see Section 4.4.2). This model 
of care will also support patients with emotional management by addressing, 
acknowledging and taking fatigue, sleep and pain symptoms seriously and including CBT and 
behavioural activation components. Furthermore, the model of care can be expanded in the 
future to include further options for symptom management including anxiety and 
depression. These were not included in this early stage of the model as patients did not 
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identify them as being priorities within the concept mapping study. Furthermore, the focus 
group study found that patients perceived low mood and worry to be a consequence of 
these other symptoms. Previous studies have demonstrated that psychological distress 
correlates highly with pain and fatigue (Segal et al., 2008; Segal et al., 2013). Therefore, by 
addressing fatigue, sleep and pain within this stepped intervention model, symptoms of 
anxiety and worry may also improve despite not being directly targeted. 
Outcome measures for all symptoms and quality of life, as well as participatory and 
functional outcomes should be carried out at baseline, at completion of the intervention as 
well as at follow up, to determine if any changes were sustained. Candidate outcome 
measures include those which have been specifically designed for the PSS population. These 
include those measures mentioned in Chapter 1 (Section 1.4) and these are included within 
the UKPSSR core set of outcome measures. These include individual symptom measures and 
composite disease and symptom scores. Specific examples of candidate measures to 
capture the symptoms of fatigue, pain and discomfort include: the Profile of Fatigue and 
Discomfort (PROFAD) (Bowman et al., 2004) and the ESSPRI (Seror et al., 2011). Patients 
discussed the impact of their symptoms on their mood during the focus groups, therefore it 
would be appropriate to capture the symptoms of anxiety and depression with the HADs. 
Quality of life measures include the SF-36 (Ware and Sherbourne, 1992) and EQ-5D (Brooks 
et al., 2003), both of which can also be used to calculate the cost effectiveness of an 
intervention. The SF-36 has the added advantage of being able to measure aspects of 
function and participation including the ability to both perform daily activities and take on 
life roles. The Evaluation of Daily Activities Questionnaire is another measure which can be 
used to measure daily activity ability (Hammond et al., 2014), as this has been shown to be a 
reliable and valid tool for use with PSS patients (Hammond et al., 2015).  
Further candidate outcome measures include those identified through the clinician 
validation process in Chapter 4 (see Section 4.4.2). Examples of these include activity diaries, 
sleep diaries, food diaries, activity monitor, Activity Balancing Scale (Dur et al., 2014), the 
Canadian Occupational Performance Measure (Law et al., 2005b), the Work and Social 
Adjustment Scale (Mundt et al., 2002), Acceptance and Action Scale II (Bond et al., 2011), 
the Revised Illness Perception Questionnaire (Moss-Morris et al., 2002) and the Brief COPE 
(Carver, 1997).  
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Another measure which might be considered in a future intervention study to improve 
function and participation is the Institutes for Health funded Patient-Reported Outcomes 
Measurement Information System (PROMIS®). The PROMIS-29 Profile assesses anxiety, 
depression, fatigue, pain interference, pain intensity, physical function, sleep disturbance, 
and ability to participate in social roles and activities. However, it has shown to have large 
ceiling affects in similar conditions (fibromyalgia, SLE, RA and osteoarthritis) which may limit 
its responsiveness (Katz et al., 2016).  
Appropriate outcome measurement may also help determine patients who may benefit 
from additional support. Patient activation (the amount of knowledge, skills and confidence 
a patient has at managing their own health and care) is a concept which can be measured 
with the Patient Activation Measure (Hibbard et al., 2005). Patients who are highly activated 
may manage well with a Level 1 or 2 intervention and those who demonstrate low levels of 
patient activation may benefit from a Level 3 intervention at the outset to avoid ‘failing’ at a 
lower intensity intervention. The necessity of failing at a lower level of intervention before 
being offered the appropriate level of care has been criticised in the UK’s stepped care 
model for anxiety and depression (Richards et al., 2012). Therefore, appropriate assessment 
at the outset may avoid this problem and ensure the patient is matched to the level of care 
appropriate for their individual requirements. However, patient activation has not yet been 
reported in the PSS literature and further research is required to determine whether the 
Patient Activation Measure would be an appropriate tool to help determine the appropriate 
level of intervention. 
Further investigation will be required to refine the precise intervention content and 
outcome measures within the stepped care model which has been formed as a result of 
extensive clinician and patient and family involvement. 
7.5.1 Summary 
This chapter has summarised the discussions which took place with focus group participants 
regarding future interventions to support symptom management, with the overall aim of 
maintaining or improving function and participation in PSS patients. Various modes of 
delivering interventions were considered and the discussions resulted in a model of care 
with increasing levels of intensity, which can be stepped up according to individual patient 
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need. This model will begin to fill the gap which was highlighted in my systematic review of 
non-pharmacological interventions (Chapter 2). 
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Chapter 8. Concluding remarks 
In this concluding chapter, I review the overall aims and objectives of the thesis, summarise 
my results, demonstrate how the programme of work presented within this thesis has 
brought an original contribution of knowledge to the fields of occupational therapy and the 
management of PSS and suggest areas for future research. 
At the beginning of this thesis I cited a person with PSS who said: ‘I wake up each day hoping 
a treatment is developed that will allow me to live an active and normal life again’ (Sjögren's 
Syndrome Foundation, 2016). During the process of conducting the studies reported within 
this thesis, I have identified factors preventing people with PSS from being able to live an 
active and normal life and have addressed them within a proposed model of care. The 
reported work has started a process, which combined with work from other fields, such as 
biological sciences, I hope will ultimately make this vision a reality.  
My doctoral thesis is built on findings from my previous research. My earlier work 
demonstrated that many people with PSS experience difficulties with function and 
participation and that there are few interventions available to support them, despite the 
obvious need (Hackett et al., 2012a; Hackett et al., 2012b). Although patients experience 
difficulties with daily function and participation, the reason for these difficulties was not 
known. The aim of this thesis was to develop a future model of care for PSS. 
The objectives were:   
1. To determine the effectiveness of any current non-pharmacological interventions for 
PSS. 
2. To collect data from different stakeholder groups to identify priority intervention 
target areas in PSS. 
3. To use existing clinical evidence to establish optimum intervention targets and 
mechanism of effect of intervention for selected intervention targets. 
4. To establish which of these priority areas could realistically be delivered within a UK 
NHS setting. 
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The aims and objectives were also published in the protocol for this PhD research in ‘BMJ 
Open’ (Hackett et al., 2014) (see Section A.4.1). 
To achieve the first objective, I conducted a systematic review of all the published evidence 
on non-pharmacological interventions. I was particularly interested in the effects of non-
pharmacological interventions on participatory or functional outcomes. There were only 8 
published studies which fitted the inclusion criteria. The interventions investigated included 
acupuncture for dry eyes, acupuncture for dry mouth, an intra-oral lubricating device, 
punctal plugs, silicon hydrogel contact lenses, and psychodynamic therapy. Overall, the 
quality of most of the included studies was poor and most studies were deemed to be at 
high risk of bias. Power calculations were not reported for any of the studies and they were 
likely to be underpowered to detect an effect size that is predicted to be modest. Overall I 
concluded that the results of the systematic review were inconclusive and there was not 
enough published evidence to either support or refute non-pharmacological interventions. 
An earlier version of this review was published in the journal ‘Rheumatology’ (Oxford) in 
2015 (Hackett et al., 2015) (see section A.4.1) and the systematic searches and review were 
subsequently updated for this thesis. 
As the systematic review did not give a clear indication of which direction to take when 
considering the development of an intervention model; it was important to next determine 
factors interfering with functional activities and participation. I therefore collected data 
from different stakeholder groups in order to identify priority factors which were deemed to 
interfere with function and participation. I used GCM methodology to carry out this study. 
The stakeholder groups included patients with PSS, adults who lived with someone who has 
PSS and health care professionals who treat PSS patients. The participants carried out 
brainstorming, sorting and prioritisation tasks which identified factors interfering with 
functional activity and participation, grouped these factors into themes and prioritised them 
for importance. Although the stakeholder groups will have their own unique perspectives on 
PSS, there was a high level of agreement regarding the priority themes and the individual 
factors within these themes. Interpretation of the concept maps which resulted from this 
study, demonstrated that it was a priority for people with PSS to be empowered by being 
taken seriously and given support to managing their symptoms themselves. Therefore, in 
theory, by supporting patients to manage their priority symptoms themselves (fatigue, sleep 
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disturbances and pain), their ability to perform daily activities and participate should 
improve. This hypothesis needs to be tested in future work.  
In order to determine optimum intervention components for these target symptoms, I 
consulted clinicians working in each of these specialist clinical areas to review statements 
within the concept maps and to determine which statements could be interventions and 
those which could be outcomes. This process meant that possible intervention components 
and outcomes were identified from the original ideas which had previously been generated 
from people with the lived experience of PSS and from clinicians working with PSS patients. 
The clinicians also provided specific examples of intervention components and outcome 
measures.  
To explore the lived experience of fatigue, sleep disturbances and pain in PSS further, I 
conducted focus groups with patients and spouses. Patients explained that these symptoms 
all interact with each other and if one symptom becomes worse, it seems to affect the 
others. The experience of symptoms varied between patients and also varied at different 
times for the same individuals. Patients currently employed a range of strategies to manage 
these symptoms themselves, but they were not always successful at employing them. They 
require individual support to manage these symptoms well and would welcome the 
provision of such interventions. Furthermore, it was apparent that it would be particularly 
helpful for patients to have accessible support and appropriate information around the time 
of receiving their PSS diagnosis. 
Patients were aware of constraints within the NHS and the focus groups demonstrated that 
different patients require different levels of support. A future model of care to support 
patients in the management of fatigue, sleep disturbances and pain symptoms has been 
proposed. Within this model, all patients will have access to appropriate information and 
support at diagnosis. Tailored interventions will then be made available to support with 
symptom management and patients would have choice over which symptom they choose to 
initially address. This support would be made available digitally with support from a clinician 
and/or via groups facilitated by a clinician with support from an expert patient. Some 
patients require a higher level of support and one-to-one face-to-face support would be 
made available to those individuals who are identified at assessment or those who require 
additional support following a digital or group intervention.  
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There are several limitations to this work. The work has resulted in a future model of care 
and has identified candidate intervention content and outcome measures. There is more 
work to be done in order to refine the specific intervention content, to pinpoint 
mechanisms of action and to narrow down identified outcomes to evaluate the resulting 
interventions within each step of the model. Further qualitative work should also be 
conducted with PSS patients who work full-time, as this population was not represented in 
the focus groups and their views need to be represented. Nevertheless, the work contained 
within this thesis has provided a platform for future research in this area by contributing 
new knowledge and developing a stakeholder informed model of non-pharmacological 
symptom management. 
This model of care developed in this thesis has focussed on the highest priorities of 
stakeholders as a result of the concept mapping study. However, other causal pathways 
which were identified within the maps (see Section 4.4.1.2) also warrant further attention, 
such as the development of healthcare systems to ensure the implementation of 
appropriate PSS self-management interventions. 
Self-management interventions are behavioural interventions which contain many 
interacting components (Jonkman et al., 2017). Therefore they are complex (Medical 
Research Council, 2000). In order to develop and evaluate such complex interventions the 
MRC has drawn up a Framework as guidance to follow (Craig et al., 2006) (also see Section 
1.5.5.1). The work contained within this thesis has been firmly rooted in the development 
phase of this Framework. I have used a combination of qualitative techniques in order to 
review of existing evidence and to explore and describe patient experience as 
recommended in the Framework. As a result, the findings within this thesis have formed a 
theoretical and empirical basis for the development of a stepped intervention model which 
targets unmet needs of PSS patients. Within this developmental stage, I have performed key 
tasks to identify intervention targets and develop an intervention model. In addition, I have 
begun to explore mechanisms whereby the proposed intervention model will lead to 
functional change through exploring the lived experience of important symptoms which are 
deemed to affect ability to perform daily activities and participation in PSS patients. Finally, 
by involving clinicians who work in the specialist areas of fatigue, sleep and pain, a longlist 
of outcome measures has been identified.  
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The programme of research reported within this thesis has established which priority areas 
could be realistically delivered within a UK NHS setting as I have sought and represented the 
views of multiple stakeholders from multiple NHS sites. Furthermore, patients and spouses 
have provided further insights into the appropriate delivery of future services.  
Future research should focus on developing the specific content of each level of 
intervention. This would include recommendations from the upcoming BSR/BHPR Guideline 
on PSS (Price et al., 2016) and use evidence from similar conditions which have similar 
symptoms, including fibromyalgia, inflammatory arthritis and SLE. Next, the feasibility and 
of delivering these interventions should be tested in feasibility studies. If the delivery of the 
specific intervention components were deemed to be feasible, the efficacy should then be 
evaluated in multi-site RCTs. Further research is also recommended to determine which 
patients would benefit most from higher and lower intensity interventions for fatigue, sleep 
disturbances and pain symptoms.  
Future research is needed to develop specific content for interventions at each level of the 
model, followed feasibility and piloting and multi-site randomised controlled trials to 
determine effectiveness. If these interventions are deemed to be effective, they should be 
implemented within an NHS setting, thereby offering patients practical ways of managing 
their symptoms and improving their quality of life. 
Following the work contained within this thesis, I have designed a future programme of 
work for which I have secured funding. This proposal is to develop the specific content of a 
Level 2 digital intervention, to co-design the interface with patients and web-developers and 
to conduct a feasibility study and process evaluation of the intervention. A summary of this 
proposal can be seen in Appendix 13.  
The unique model of intervention development used within this thesis can be replicated in 
other diseases and offers occupational therapists and other clinicians a practical approach 
to intervention development which incorporates both theory and stakeholder opinion.  
To conclude, the work within this thesis provides a comprehensive understanding of factors 
which influence daily function and participation in PSS patients. PSS has been an under 
researched disease, and as a consequence many needs of patients remain unmet within 
clinical settings. This work presents a stakeholder-informed model for delivering future non-
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pharmacological interventions to address stakeholder informed priorities. As such, a model 
has been developed which will ultimately support patients to manage symptoms of fatigue, 
sleep disturbances and pain, which are perceived by patients, their families and health 
professionals to impact on performance of daily activities and participation.  
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Appendix A.  
A.1 Ethical application and approval for concept mapping study 
A.1.1 Study protocol 
Background 
Primary Sjögren’s syndrome (PSS) is an autoimmune rheumatic condition affecting 
between 150,000-250,000 adults in the UK[1,2]. In addition to the classic symptoms of 
oral and ocular dryness, arthralgia and myalgia[3,4], people with PSS also experience 
significant fatigue[5,6], autonomic dysfunction[7,8], sleep disturbance, daytime 
somnolence[9], and a markedly reduced quality of life[10]. Furthermore, PSS is 
associated with significant direct and indirect healthcare costs[11-12]. 
We recently conducted a literature review on the impact of PSS on everyday activities 
and concluded that many PSS patients are restricted in their ability to engage in a wide 
range of everyday activities[13]. Consistently, using the Improved HAQ®, a validated 
instrument for assessing functional ability, we demonstrated that people with PSS 
have significant functional impairment that is comparable to those with chronic fatigue 
syndrome[14]. 
Despite their significant functional disability, current medical care for PSS patients has 
mainly focussed on pharmacological interventions for their classic symptoms, which 
are at best only partially effective[15]. There is currently no intervention aimed at 
improving their function or participation in everyday activities. This is in contrast to 
patients with other long-term conditions such as cancer, chronic fatigue syndrome and 
chronic pain who have access to psychosocial therapies which have been shown to 
improve symptoms and functional ability[16-19]. Therefore, there is a large unmet 
need for the development of effective interventions to improve function for people 
with PSS. 
In order to develop an effective intervention that is deliverable in the NHS, not only 
should we learn from existing evidence, it is also important for us to understand what 
the key issues are for the service users, their carers, healthcare professionals and those 
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who commission and manage NHS services for PSS patients to ensure deliverability of 
the intervention. The Medical Research Council (MRC) framework for complex 
intervention development[20] recommends an iterative stepped, structured, mixed-
methods approach. At the early stages, when little is known regarding the bio-
psychosocial determinates of illness and illness-associated functional capacity, a 
combination of qualitative techniques to explore and describe patient experience and 
a review of the existing evidence is recommended. Such findings will then form the 
theoretical and empirical basis for intervention development and disease model 
construction. The key tasks at this stage are to identify intervention targets, the 
mechanisms whereby the proposed intervention will lead to functional change, and a 
specification of how this change will be measured. 
Whilst the MRC guidelines[20] provide a useful framework for complex intervention 
development, they are less clear on what the modelling of the condition should look 
like. A variety of methods from economic modelling to computer simulation have been 
suggested, many of which are not applicable to complex psychosocial interventions. In 
this regard, concept mapping has been used to good effect for strategic complex 
planning in other diseases including dementia[21], intervention planning in cancer[22] 
as well as for designing interventions to prevent work disability in rheumatoid arthritis 
patients[23] and to understand their work requirements[24]. 
In this study, we aim to apply group concept mapping to identify priorities and 
intervention strategies that could improve daily function of people with PSS. Such 
findings will be used in combination with existing evidence as the basis for the 
development of an intervention package aimed at improving daily function for people 
with PSS. If effective, this approach also offers the potential for a portable framework 
that would introduce some consistency into a currently ad hoc process of complex 
intervention development. 
Aims and Objectives 
1. To identify what is of importance to different stakeholder groups regarding 
priority target areas for an intervention for PSS 
2. To establish which of these priorities might be desirable to implement as an 
intervention 
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Staff 
Katie Hackett, Arthritis Research UK AHP Training Fellow and PhD Student, Newcastle 
University 
Principle Investigator: Professor Wan-Fai Ng, Professor of Rheumatology/Honorary 
Consultant in Rheumatology, Newcastle University/Newcastle upon Tyne Hospitals 
NHS Foundation Trust 
Professor Julia Newton, Dean of Clinical Medicine/Honorary Consultant in Ageing and 
Medicine, Newcastle University/ Newcastle upon Tyne Hospitals NHS Foundation Trust 
Dr Tim Rapley, Lecturer, Newcastle University 
Dr Vincent Deary, Senior Lecturer, Northumbria University 
Dr Katherine Deane, Senior Lecturer in Research, University of East Anglia 
Research Governance and Sponsorship 
Research Sponsorship 
The Newcastle upon Tyne Hospitals NHS Foundation Trust is the sponsor of the project 
and will indemnify the project. 
Caldicott guardian approval 
Caldicott guardian approval will be obtained for the transfer of personal data (names 
and addresses of registry patients) between clinicians at Patient Identification Centres 
and the research team at Newcastle upon Tyne Hospitals NHS Foundation Trust. 
Recruitment 
Participant identification 
The following groups of participants will be invited to take part in the study: Patients 
who have PSS and are participants of the United Kingdom Primary Sjögren’s Syndrome 
Registry (UKPSSR). Secondly, adults who live with a another adult with PSS, who knows 
them very well, such as a partner or adult household member who has some insight 
into how their disease impacts on their life (AHMs). AHMs will be identified by the 
patient participants. Finally, healthcare professionals from the UKPSSR network and 
primary care network of North of Tyne (HCPs). 
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Approaching potential participants 
Patients who are part of the UKPSSR have already consented to being invited to 
participate in further PSS research studies via a written invitation. Local clinicians will 
provide a member of the research team via a secured nhs.net email account with a 
password protected spreadsheet containing the names and addresses of UKPSSR 
patients. The invitations packs will be posted out from Newcastle to participants. The 
invitation packs will contain an invitation to an adult household member. The patients 
will be given the option to pass on this invitation to their spouse or another adult who 
knows how their disease may impact on their life. Staff participants will be approached 
through email mailing lists, including clinicians who are part of the UKPSSR. These 
clinicians will be asked to forward the email to members of their teams. GPs will be 
invited via an email contact list held by North of England Commissioning Support 
Research and Development Officer, who will forward the email on our behalf. Potential 
staff participants may be sent reminder emails up to 3 times, with 1-3 weeks between 
each email. Postal reminders may be sent out twice to potential participants. 
Consenting procedures 
Participants will be given a consent form and study information sheet with their 
invitation pack or as attachments to their email invitation, in the case of staff 
participants. Participants will be provided with the contact details of a research team 
member and can contact him/her if they have any questions about the study before 
consenting to take part. All participants are free to withdraw at any time without 
giving a reason. 
Anonymisation procedure 
All data collected for this project will be “link anonymised”. Participants will be 
allocated a code which will be stored on a password protected nhs computer and will 
only be seen by Ms Hackett who has an honorary NHS contract.  
Data handling 
Paper documentation will be stored in a locked filing cabinet in a locked room at 
Newcastle upon Tyne NHS Foundation Trust. Only personnel who are members of the 
research team, with a contract at Newcastle upon Tyne NHS Foundation Trust will be 
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given access, on a “need to know” basis and will sign a confidentiality agreement. Data 
will be stored and treated according to the Data Protection Act 1998. 
Summary of project 
We will use concept mapping to explore the perspectives of PSS patients, their 
partners/carers, healthcare professionals and managers involved in their care on what 
will improve functional capacity of PSS patients. Concept mapping, developed by 
Trochim [25], is a mixed-methods participatory tool based on a combination of group 
processes (brainstorming, sorting, rating and group interpretation) and a sequence of 
multivariate statistical analysis (multidimensional scaling and hierarchical cluster 
analysis) that generate graphic representations ("Concept Maps") of all stakeholders 
opinions [30]. 
Methods 
Sample size 
We will recruit a minimum of 50 participants to each group, which is recommended for 
scientific validity[25]. However we will seek to recruit approximately 280 participants 
in total in order to conduct sub group analyses.  
Idea generation/Brainstorming 
I will seek open contribution of ideas from each stakeholder group in response to a 
focus prompt.  
Patients with PSS and adults who live with them/adult household members (AHMs) 
will participate in the concept mapping exercise via one of the following means: (a) 
face-to-face focus groups of 6-12 people, (b) a web-based interface or (c) paper-based 
questionnaire. Health care professionals (HCPs) will participate via the online web-
based interface or on paper-based questionnaires. Participants completing the web-
based concept mapping exercise will be given a unique username (not their name) and 
password. Baseline demographics will be collected for all participants. The patient 
group will be asked to complete some relevant validated patient reported outcome 
measures on mood, quality of life, function, fatigue, dryness, discomfort and pain. 
AHMs will be asked to complete some short validated questionnaires to measure the 
impact of their spouse/relative’s disease on them, as this may influence their opinion 
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in the concept mapping exercise, regarding what they feel as priority areas for health 
care intervention. All participants will be asked to complete the following sentence or 
focus prompt in these brainstorming sessions: 
“A person with primary Sjögren's syndrome would be able to do more of the things they 
want to do and the things they have to do if……………..” 
Participants will be asked to think of as many responses as they can during this 
process. In the face-to-face sessions, a facilitator will record the statements and the 
participants will see the statements as they evolve. A facilitator may use neutral 
prompts if ideas start to dry up. Participants also have the option of completing their 
responses on a piece of paper and handing it to a facilitator if they do not feel 
comfortable verbalising their responses. In the online format, participants will be able 
to see the anonymous responses of participants who have already completed the 
brainstorming process, which may help to prompt their own ideas. 
Ideas analysis 
All statements will be analysed and synchronised by the Study Advisory Group 
consisting of representatives of all stakeholder groups, myself and the research team. 
We will use a structured process recommended by Kane and Trochim[26] to remove 
duplicate statements and to ensure wording is clear. This will condense the statement 
set to one which is of manageable size (≤96 statements[25]) for the subsequent 
sorting and rating exercise but large enough to ensure saturation of the topic[25,27]. 
Sorting and rating 
All participants who have previously taken part in the brainstorming exercise will be 
invited to take part in the sorting and rating phase. Some participants may be recruited 
solely to the sorting and rating phase if saturation of the brainstorming topic is 
achieved prior to recruiting 300 participants or if there is significant participant 
attrition between the separate phases of the study. Participants will be asked to rate 
each statement in the distilled statement set for importance and feasibility on a 5 
point rating scale, and to sort the statements into themes or groups of similar 
statements or ideas. Participants may choose a different method to sort and rate to 
the one they chose for brainstorming if they wish, for example, complete the sorting 
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and rating exercise online if they attended a face-to-face meeting for brainstorming 
and vice versa. 
Concept mapping analysis and interpretation 
The data generated from the above exercises will be analysed and represented in 
objective form as visual maps using the Concept Systems Global© software package.  
The maps will highlight the priority areas for each stakeholder group in improving 
function of PSS patients. Similarities and disparities between the stakeholder groups 
can be identified and if appropriate, subgroup analysis can be carried out using the 
baseline demographic data collected at the start of the study. The “go zones” 
represent areas that are of most importance for more than one stakeholder group and 
so are of particular importance for planning interventions. 
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Rheumatology Research Office 
Level 1, Room 49 
Freeman Hospital 
Freeman Road  
Newcastle upon Tyne 
NE7 7DN  
Tel: 0191 2228125 
E-mail: Katie.Hackett@ncl.ac.uk 
 
Participant Information Sheet  
Research study: Developing service user informed interventions for primary 
Sjӧgren’s syndrome (PSS) [REC Ref: 13/NI/0190] 
Summary Information 
This front sheet gives you summary information about the research study that you are 
being invited to take part in. More details can be found in the following pages. 
 You are being invited to take part in a research study which we hope will 
provide us with information to help develop an intervention for PSS 
 We are involving three stakeholder groups in this study; adults with PSS; adults 
who live with someone with PSS and health care professionals involved in 
caring for people with PSS 
 There are three ways you can take part in the study;  
a) If you live within a 10 mile radius of Newcastle, you can 
choose to attend two separate face-to-face group meetings 
with other participants who have PSS 
b) By participating in two separate online questionnaire based 
exercises, or 
c) By completing questionnaires on two occasions by post 
 You will be asked to complete two exercises. On the first occasion, you will be 
asked to participate in a brainstorming exercise and to individually complete 
some questionnaires. On the second occasion, you will be asked to individually 
prioritise some statements and sort them into themes. 
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We are inviting you to take part in a research study. Before you decide, you need to 
understand why the research is being done and what it will involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you 
wish. Ask us if there is anything that is not clear to you or if you would like more 
information. We can be contacted on the telephone number at the end of this sheet.  
Take time to decide whether or not you wish to take part. 
What is the purpose of the study? 
The main treatment currently available to people with primary Sjӧgren’s syndrome (PSS) 
is relatively limited. Medical interventions can help with relieving some symptoms, but 
many people with PSS still have difficulties which can result in reducing their ability to 
participate fully in many everyday activities. 
In this study we will explore the specific difficulties that people with PSS have which 
impact on their ability to fully participate in the activities that they would like to do. To 
do this, we will collect information from adults with PSS, spouses or other adults who 
live with them and healthcare professionals who are experienced in managing PSS. The 
results of this study will help us to design a treatment program to help enable people 
with PSS to participate more fully in their preferred daily activities. 
Why have I been invited? 
You have been invited to participate in this study because you have a diagnosis of PSS.  
Are there any inclusion or exclusion criteria? 
We are seeking to recruit participants who have a confirmed diagnosis of primary 
Sjӧgren’s syndrome. These people should be aged 18 years or over.  
Do I have to take part? 
Participation in this study is entirely voluntary. If you agree to take part, we will ask you 
to sign a consent form. You are free to withdraw at any time without giving a reason.  
What will happen to me if I take part? 
There are 3 ways you can take part in this study. Please indicate your choice on the reply 
form and return it with the signed consent form. 
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Option A (Face-to-face group meetings) 
If you live within a 10 mile radius of Newcastle, you may participate in the face-to-face 
meetings. You will be asked to attend 2 meetings which will take place during the next 
9 months at the Freeman Hospital in Newcastle. The meetings involve informal 
discussions among a group of 8-15 people who have PSS. Each meeting will last 
approximately 60-90 minutes. There will be a break during both meetings and 
refreshments will be provided. The group meetings will be run by two researchers, Kate 
Hackett and Dr Tim Rapley.  
In the first meeting you will be asked to individually complete some questionnaires 
about yourself. Following this, the group will be asked to consider the following 
question:  
“People with primary Sjӧgren’s syndrome could do more of the things they want 
to do or have to do if…..”.  
The discussion will be tape-recorded and suggestions by the group will be written on flip 
charts. You will also have a note pad on which you can individually write your 
statements, rather than share with the group if you wish. There is no pressure on any 
individual to make any suggestions and any information you provide during the meeting 
will be kept anonymous. 
In the second meeting, the group will be asked to look at the suggestions that were 
generated by all three participant groups (people with primary Sjӧgren’s syndrome, 
adult household members and health care professionals) during the first meetings. 
There will be up to 80-100 statements or suggestions. You will be asked to rate each 
statement or suggestion using a scoring system for importance and for feasibility. You 
will also be asked to group the statements or suggestions into themes.  
Option B (Online participation) 
If you have access to a computer with internet access, you can complete the exercises 
described in option A online. You will be given the web address and be allocated a 
unique username and password for you to complete the exercises in your own time, like 
in the face-to-face option. You will need to do this on two separate occasions for the 
two parts of the study. You will be contacted when the second part of the study is ready 
for you to take part. 
When you log on to the website for the first time, you will be asked to complete some 
questions about yourself. Next, you will be asked to consider the following question: 
“People with primary Sjӧgren’s syndrome could do more of the things they want 
to do or have to do if…..”.   
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You will be asked to record as many responses to this statement as you can think of. 
There will be some responses available for you to see from people who have completed 
the exercise before you. It is not possible for you or the researchers to see who has 
recorded which answer, (i.e. your responses will be completely anonymous). If you think 
of more replies after you have completed the exercise, you can log back in again and 
add further statements, providing it is before the first part of the study has been 
completed. Overall we anticipate the first exercise taking 10-60 minutes to complete, 
depending on how many responses you provide. When we send out your username and 
password, we will enclose some additional questionnaires for you to complete and 
return in a prepaid envelope. We anticipate these taking up to 20 minutes to complete.  
You will then be contacted via telephone, letter or email at a later date to complete the 
second exercise. If you are logging on for the first time, (if you did not take part in the 
first part) you will first be asked to complete some questions about yourself. In the 
second exercise, you will be presented with a list of responses which have been 
produced by all participants in the first exercise. There will be around 80-100 
statements. You will be asked to rate each statement using a scoring system for 
importance and for feasibility. You will also be asked to group the statements into 
themes. Again, you will be able to log onto the interface on more than one occasion if 
this is easier for you. We anticipate this taking between 1 and 1.5 hours to complete. 
Option C (Questionnaire-based, by post) 
You will be sent some questionnaires about yourself which we will ask you to complete. 
You will also be asked to consider the following question:  
“People with primary Sjӧgren’s syndrome could do more of the things they want 
to do or have to do if…..”  
You will be asked to record as many responses to this statement as you can think of and 
to return the completed forms in the prepaid envelope within two to three weeks of 
receiving them. We anticipate this exercise will take 30-60 minutes to complete. 
For the second exercise, we will contact you again by post. We will enclose a set of 
replies from the first exercise. There should be about 80-100 statements. You will be 
asked to rate each statement using a scoring system for importance and for feasibility. 
You will also be asked to group the statements into themes. We anticipate this taking 1 
hour to 90 minutes to complete. However, you do not have to complete the exercise all 
in one go and you can do it over several sessions if this is easier for you. Again, you will 
be asked to return the completed forms in a prepaid envelope to us. 
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Expenses and payments 
There is no payment for your participation in this study. We will refund your travel 
expenses if you attend the face-to-face meetings.  
What are the possible benefits of taking part? 
There is no direct benefit for your participation, however the information we get from 
the study will help us to develop an intervention to improve the daily lives of people 
with primary Sjӧgren’s syndrome. 
Once I take part, can I change my mind? 
You can withdraw at any time and you do not have to explain the reason why you have 
decided to withdraw. Simply let us know of your decision using the contact details 
provided. 
What if I lose the ability to consent to taking part during the study? 
The research team would retain any non-identifiable data that you had already 
provided.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. Kate Hackett, can be 
contacted by telephone: 0191 2228125. If you remain unhappy and wish to complain 
formally, you can do this by contacting Kate’s academic supervisor, Dr Wan-Fai Ng, by 
telephone 0191 2223449. Alternatively, you can write to us at the address below. 
In the event that something does go wrong and you are harmed during the research and 
this is due to someone‘s negligence then you may have grounds for a legal action for 
compensation against Newcastle University but you may have to pay your legal costs. 
If the research team are concerned about your health after reviewing your responses in 
the questionnaire pack, we may contact your consultant or GP to ensure you are 
receiving appropriate support. 
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Will my taking part in this study be kept confidential? 
Yes. All information collected about you during the course of this study will be kept 
strictly confidential. Your personal details, such as your name and address, will be 
recorded and stored anonymously according to the Data Protection Act (1998). Your 
name will be substituted by a coded reference number so that your information cannot 
be traced back to you. Paper documents which contain your personal data will be stored 
in a locked cabinet in a locked room at Newcastle Hospitals NHS Foundation Trust. Paper 
documents will be shredded six months after the end of this study. Anonymised 
electronic data (i.e. without your personal information) will be stored securely on the 
password protected web based interface and on a password protected computer at 
Newcastle Hospitals NHS Foundation Trust for fifteen years. After this, all data will be 
deleted. Data will only be viewed by the research team. If the data collected in this study 
is used in a written report, such as a thesis or published paper, we will not use your 
name or personal details.  
What will happen to the results of the study? 
The results of this study can be used to develop an intervention to help people with PSS 
to do more of the activities they want to or have to do. We hope it will in turn improve 
the quality of life of many people with PSS as well as reducing the cost of healthcare.   
We aim to publish the results of this study in a report for Arthritis Research UK (the 
funder of this study) in scientific journals and the study will be used as part of a written 
PhD thesis.  
Who is organising and funding the research? 
This study is part of a research project funded by Arthritis Research UK. The main 
researcher is Arthritis Research UK Training Fellow, Kate Hackett. Kate will work under 
the supervision of Professor Wan-Fai Ng (Newcastle University) Professor Julia Newton 
(Newcastle University), Dr Tim Rapley (Newcastle University) and Dr Vincent Deary 
(Northumbria University).   
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favourable opinion by the Office for Research Ethics Committees, Northern Ireland. In 
addition, the research study has been reviewed by relevant research governance bodies 
at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. 
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Reminder letters 
Reminder letters may be sent to people who have not responded to the invitation to 
participate. 
Further information and contact details: 
Please do not hesitate to contact us if you need further information about this study: 
 Kate Hackett, Arthritis Research UK Training Fellow 
 Musculoskeletal Research Group, 4th Floor Catherine Cookson Building 
 Faculty of Medical Sciences 
 Newcastle University 
 Newcastle upon Tyne 
 NE2 4HH 
 Tel: 0191 2228125 
 E-mail: katie.hackett@ncl.ac.uk  
 
Advice as to whether you should participate:  
If you have any general queries about participating in research you can contact the 
hospital’s Patient Advisory and Liaison Service (PALS). General information is also 
available on the Involve website (www.invo.org.uk). INVOLVE is a national advisory 
Group, funded by the Department of Health, which supports active public involvement 
in NHS, public health and social care research. 
In the event that something does go wrong and you are harmed during the research and 
this is due to someone’s negligence then you may have grounds for a legal action for 
compensation against the Newcastle University but you may have to pay your legal 
costs. The normal National Health Service complaints mechanisms will still be available 
to you (if appropriate). 
Finally 
Many thanks for considering taking part. Please keep this information sheet. We will ask 
you to sign a consent form if you agree to take part and we will give you a copy of this 
to keep. 
Thank you for taking your time to read this information sheet. Please complete and 
return the enclosed reply slip in the envelope provided if you would like to 
participate in this study. 
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A.1.3 Consent form 
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A.1.4 Letter providing favourable ethical approval  
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A.2 Substantial amendment to previous ethical application 
A.2.1 Amendment to previous study protocol  
The following substantial amendment was added to the previous protocol (see Section 
A.1.1) and resubmitted to the ethical board, in order to gain appropriate approvals to 
conduct the focus groups. 
Developing the intervention 
We will identify where each priority factor from the GCM exercises fits within the 
World Health Organisation International Classification of Functioning Disability and 
Health (ICF) framework [1]. Key priority factors will be targeted for a proposed 
intervention to improve daily function and participation for PSS patients.  
First, potential intervention techniques or ‘active ingredients’ will be identified from 
existing literature and relevant evidence-based theories. These will be identified in 
relation to each priority factor identified in the concept mapping exercise. Second, the 
factor is specified as an observable and measurable ‘construct’ and a measure for 
identifying change in it will be selected. Third, each technique and barrier pair is 
presented as a testable hypothesis with function and participation as the ultimate 
outcome.  
An illustrative example of the application of this three-step method are shown below. 
Illustrative example: Potential factor: Chronic fatigue 
Evidence based intervention techniques to target chronic fatigue include, grading 
physical activity/exercise [2] and goal setting, biofeedback and body changes [3]. 
Chronic fatigue is commonly measured as the self-reported mental and physical 
tiredness, by using tools such as the Chalder Fatigue Scale [4] or the Profile of Fatigue 
[5]. The testable hypothesis may be articulated as “grading, goal setting, biofeedback 
and body changes can be used to reduce chronic fatigue in order to increase 
participation in meaningful occupations.”  
Focus Groups 
Once the potential intervention techniques have been identified from the literature, 
these will be presented to people with PSS, their carers and occupational therapists in 
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focus groups. The focus groups will provide opportunities to gather feedback regarding 
the specific intervention techniques, how the techniques will be best delivered and 
measures of effectiveness. Participants will be asked to generate ideas regarding how 
to deliver the techniques in an effective and acceptable way.  Patient and carer 
participants will be identified from a regional specialist medical service for PSS and will 
be those who have previously indicated an interest at being involved with further 
research. Potential therapist participants will be recruited from local hospitals and 
community based occupational therapists. 
Focus group participants will also be invited to comment on the proposed outcome 
measures, including the choice of instrument(s) and the processes of administering 
and completing these instrument(s). The results will be used to refine the intervention 
package. 
References 
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A.2.2 Participant information sheet 
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A.2.3 Consent form 
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A.2.4 Substantial amendment approval letter 
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A.3 Numbered statements within the concept maps 
The following table lists each of the numbered statements from within the concept 
maps. 
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 A person with Sjögren’s could do more of the things they want to do or have 
to do (they)………. 
1. Know who to contact when their symptoms flare up 
2. Have access to a range of good drug treatments 
3. Did not have mouth sores or ulcers 
4. Knew the range of available treatment options 
5. Could go out in the sun 
6. They have a good diet 
7. There were "one stop" Sjögren's clinics with all relevant health care professionals 
available 
8. Were less prone to getting infections 
9. Have access to physiotherapy 
10. Were less stressed or worried 
11. Have Sjögren's advice leaflets 
12. There were appropriate aids and adaptations in the community 
13. There was more good research to understand the underlying causes 
14. Have professional support during a flare up of symptoms 
15. Can see a consultant when needed 
16. There was education about Sjögren's for the general public 
17. There was education about Sjögren's for people who fund services 
18. Were less fatigued 
19. Could come to terms with their symptoms 
20. There was more good research to test and develop treatments 
21. Feel in control of their symptoms 
22. Look after their physical, emotional and spiritual wellbeing 
23. Felt a family member or supporter could be included in their care planning 
24. Have confidence to seek advice when needed 
25. Have support to manage their symptoms themselves 
26. Their vagina was less dry 
27. Their skin was less dry 
28. Have access to psychological support 
29. There was a cure 
30. Could continue to drive 
31. Skin problems were treated 
32. Their vision was not impaired 
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 A person with Sjögren’s could do more of the things they want to do or have 
to do (they)………. 
33. Friends and family include them in events 
34. Swallowing was easier 
35. Public spaces were more Sjögren's friendly e.g. heated/lit/airconditioned differently 
36. Didn't have sexual problems 
37. There was education on Sjögren's for patients 
38. Could access support to help set personal goals 
39. Have a disabled parking badge 
40. Have an individualised treatment plan 
41. Have supportive family and friends 
42. Have assistance with shopping, cleaning etc. 
43. Have a positive attitude 
44. There were diaries for recording symptoms and problems to bring to appointments 
with health care professionals 
45. There was better management of the side effects of drugs 
46. They have better mobility 
47. Exercise regularly 
48. Have access to appropriate aids and adaptations in their homes 
49. Could improve their concentration 
50. Have less pain 
51. There was education on Sjögren's for family members 
52. Their mood was better 
53. There was education on Sjögren's for healthcare professionals 
54. There is good communication between clinicians 
55. Could easily describe Sjögren's to others 
56. Health care professionals would raise sensitive topics (e.g. sex and vaginal dryness) 
during consultations 
57. Professionals could direct them to support groups and charities 
58. Take their medication as prescribed 
59. Have support with memory and concentration difficulties 
60. Have access to support and advice from other people with Sjögren's 
61. Their eyes were more comfortable 
62. Have access to a specialist nurse 
63. Could come to terms with their limitations 
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 A person with Sjögren’s could do more of the things they want to do or have 
to do (they)………. 
64. Employers were aware of things they could do in the workplace that are helpful for 
people with Sjögren's 
65. Learn to balance their activity and rest 
66. There was more funding for specialist rheumatology services 
67. Felt a family member or supporter would be welcome at their appointments 
68. Have healthy teeth and/or comfortable dentures 
69. Their throat was less dry 
70. Have access to occupational therapy 
71. Were able to sleep better 
72. Gastrointestinal (stomach and bowel) problems were managed 
73. Public transport was accessible 
74. Were less breathless 
75. There was information available on exercise and Sjögren's 
76. Fatigue was better managed/treated 
77. Have more feeling in their mouth and lips 
78. Have help with dental costs 
79. Diagnosis was quick 
80. Felt they were being taken seriously 
81. Have access to hydrotherapy 
82. Mouth and lips were less dry 
83. Family could understand the symptoms 
84. Their eyes were less dry 
85. Associated conditions are diagnosed and treated 
86. On a bad day people could tell by looking at them how they are feeling 
87. Those unable to work and/or needed support to function, were eligible for benefits 
88. Have access to complementary therapies or alternative remedies 
89. Develop good coping strategies 
90. Keep their body active 
91. Keep their mind active 
92. Were taught relaxation techniques 
93. Their healthcare is better coordinated 
94. Can explain to others what they can and cannot do 
Table A-1 The numbered statements within the concept maps 
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A.4 Publications during my PhD studies 
Full texts are provided of first author peer-reviewed publications. I provide references 
of other papers which I have co-authored or which were published in non-peer 
reviewed journals. 
A.4.1 First author peer-reviewed publications 
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Hackett, K.L., Gotts, Z., Ellis, J., Deary V., Rapley, T., Ng W-F., Newton, J.L., 
Deane, K.H.O. (2016) ‘An investigation into the prevalence of sleep 
disturbances in primary Sjogren’s syndrome: A systematic review of the 
literature’ Rheumatology (Oxford) (doi: 10.1093/rheumatology/kew443 First 
published online: December 24, 2016).
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Hackett, K.L., Lambson, R.L., Strassheim, V., Gotts, Z., Deary, V. and Newton, 
J.L. (2016) 'A concept mapping study evaluating the UK's first NHS generic 
fatigue clinic', Health Expectations, 19(5) 1138-1149. 
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Hackett, K.L., Deane, K.H., Strassheim, V., Deary, V., Rapley, T., Newton, J.L. 
and Ng, W.F. (2015) 'A systematic review of non-pharmacological interventions 
for primary Sjogren's syndrome', Rheumatology (Oxford), 54(11) 2025-2032.  
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Hackett, K.L., Newton, J.L., Deane, K.H.O., Rapley, T., Deary, V., Kolehmainen, 
N., Lendrem, D. and Ng, W.F. (2014) 'Developing a service user informed 
intervention to improve participation and ability to perform daily activities in 
primary Sjogren's syndrome: a mixed-methods study protocol', BMJ Open, 
4(8). 
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Hackett, K., Newton, J., Rapley, T., Deane, K., Deary, V. and Ng, W.F. (2014) 
'Systematic reviews of occupational therapy interventions: summarizing 
research evidence and highlighting the gaps', British Journal of Occupational 
Therapy, 77(9), pp. 479-482. 
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A.4.2 Other publications 
A.4.2.1Co-authored peer reviewed publications 
Price, E., Rauz, S., Sutcliffe, N., Hackett, K.L., Barone, F., Granata, G., Ng, W-F., Fisher, 
B.A., Bowman, S., on behalf of the BSR and NHPR Standards, Guideline and Audit 
Working Group (2017) ‘BSR and BHPR Guideline for the Management of Adults with 
Primary Sjögren’s Syndrome’ Rheumatology (Oxford) (In press). 
Syla, D., Sweenie, A., Lendrem, D., Newton, J.L., Hackett, K.L. (2017) ‘A scoping exercise 
to gauge the incidence of early post stroke fatigue for patients at Newcastle 
Community Stroke Services’ (letter) International Journal of Therapy and 
Rehabilitation (In press). 
Hart, R.I., Ng, W-F., Newton, J.L., Hackett, K.L., Lee, R.P., Thompson, B. (2016) ‘What 
impact does written information about fatigue have on patients with auto-immune 
rheumatic diseases? Findings from a qualitative study’ Musculoskeletal Care (epub 
ehead of print). 
Howard-Tripp, N., Tarn, J., Natasari, A., Gillespie, C., Mitchell, S., Bowman, S., Price, E., 
Pease, C.T., Emery, P., Andrews, J., Lanyon, P., Hunter, J., Gupta, M., Bombardieri, M., 
Sutcliffe, N., Pitzalis, C., McLaren, J., Cooper, A., Regan, M., Giles, I., Isenberg, D., 
Saravanan, V., Coady, D., Dasgupta, B., McHugh, N., Young-Min, S., Moots, R., Gendi, 
N., Akil, M., Hackett, K.L., Griffiths, B., Lendrem, D. and Ng, W-F. on behalf of the UK 
primary Sjögren’s Syndrome Registry. (2016) ‘Fatigue in primary Sjögren’s syndrome is 
associated with lower levels of pro-inflammatory cytokines’ RMD Open, 
DOI:10.1136/rmdopen-2016-000282 
Lendrem, D., Mitchell, S., McMeekin, P., Gompels, L., Hackett, K., Bowman, S. et.al. 
(2015) Do the EULAR Sjögren's syndrome outcome measures correlate with health 
status in primary Sjögren's syndrome? Rheumatology (Oxford), 54(4):655-9. 
A.4.2.2Non-peer reviewed publications 
Hackett K.L. (2016) ‘Being part of a group to develop new national guidelines for the 
clinical management of primary Sjögren’s syndrome: A reflective account’ (2016) 
Journal of Rheumatology Occupational Therapy 30(1), pp. 22-23. 
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Bannigan, K., Birken, M., Hackett, K.L. (2016) ‘Complex interventions; the latest 
thinking: Designing and evaluating complex interventions in health and social care: 
highlights from a recent conference’ Occupational Therapy News, February, pp. 22-23. 
Lambson, R.L., Newton, J.L., Strassheim, V., Gotts, Z., Deary, V. and Hackett, K.L. (2015) 
'The evolution of the Newcastle CRESTA Fatigue Clinic: a unique NHS multidisciplinary 
approach to fatigue', Journal of Rheumatology Occupational Therapy, 29(1), pp. 7-11. 
Hackett, K.L. (2013) 'Fighting Fatigue, Book Review', Journal of Rheumatology 
Occupational Therapy, 28(1), p5. 
A.4.2.3Peer reviewed publications under review and in press 
Strassheim V, Hackett K.L., Newton J.L. What is known about severe and very severe 
Chronic Fatigue Syndrome? A scoping review. Fatigue Biomedicine Health and 
Behavior. (Revised and under review). 
Strassheim V., Ballantine R., Hackett, K.L., Frith J., Newton J.L. Understanding severely 
affected chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): The gravity of 
the situation. Physiotherapy. (Under review). 
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A.5 National and International conference abstracts presented during my 
PhD studies 
Hackett K., Forder R, Lendrem D, Hargreaves B, Strassheim V., Gotts, Z., Deary V., Ng 
W-F, Newton J.L. (2016) Objective improvement in fatigue scores for primary Sjögren’s 
patients receiving a tailored multidisciplinary fatigue intervention in a generic fatigue 
clinic. American College of Rheumatology Annual Meeting, Washington D.C., USA. 
(Poster presentation) 
Lendrem D., Howard Tripp N., Mariette X., Johnsen SJA., Tarn J., Hackett K., Griffiths B., 
Mitchell S., Saraux A., Devauchelle, V., Norheim K., Isaacs JD., McMeekin P., Bowman 
S., Omdal R., Gottenberg J-E., Ng W-F. (2016) Rethinking Primary Sjögren’s Syndrome: 
Stratification by clinical phenotypes to improve understanding of disease 
pathogenesis, trial design, clinical management and prospective health gains? 
American College of Rheumatology Annual Meeting, Washington D.C., USA. (Oral 
presentation) 
Hackett K., Forder R, Lendrem D, Hargreaves B, Strassheim V., Gotts, Z., Deary V., Ng 
W-F, Newton J.L. (2016) Objective improvement in fatigue scores for primary Sjögren’s 
patients receiving a tailored multidisciplinary fatigue intervention in a generic fatigue 
clinic CFS/ME Research Collaborative Conference, Newcastle upon Tyne, UK. (Poster 
presentation) 
Strassheim V., Lambson R., Hackett KL., Newton JL. (2016) What is known about severe 
and very severe chronic fatigue syndrome? A scoping review. CFS/ME Research 
Collaborative Conference, Newcastle upon Tyne, UK. (Poster presentation) 
Syla D., Sweenie A., Lendrem D., Newton JL., Hackett KL. (2016) A scoping exercise to 
gauge the incidence of early post stroke fatigue for patients at Newcastle Community 
Stroke Services. CFS/ME Research Collaborative Conference, Newcastle upon Tyne, 
UK. (Poster presentation) 
Hackett K., Deary V., Deane K., Kolehmainen N., Newton J., Ng W-F., Rapley, T. (2016) 
“It isn’t pain pure and simple”: Experiences of pain and discomfort in primary Sjögren’s 
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syndrome: A qualitative focus group study. Biomarkers and Targeted Therapeutics in 
Sjögren's, Oklahoma City, USA. (Poster presentation) 
Hackett K., Hargreaves B., Lendrem D., Strassheim V., Gotts Z., Deary V., Ng W-F., 
Newton JL. (2016) Objective improvement in fatigue scores for primary Sjögren’s 
patients receiving a tailored multidisciplinary fatigue clinic intervention: Provisional 
findings from the first cohort of patients Biomarkers and Targeted Therapeutics in 
Sjögren's, Oklahoma City, USA. (Poster presentation) 
Howard Tripp N, Lendrem DW, Tarn J, McMeekin P, Gillespie C, Al-Ali S, Hackett K, 
Hargreaves B, Mitchell S, Bowman SJ, Price E, Pease CT, Emery P, Lanyon P, Hunter J, 
Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, 
Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, 
Gendi N, Akil M, Griffiths B, Isaacs J, Ng WF, on behalf of the UK Primary Sjögren’s 
Syndrome Registry. (2016) Symptom-Based Clinical Phenotyping in Primary Sjögren's 
Syndrome. Biomarkers and Targeted Therapeutics in Sjögren's, Oklahoma City, USA. 
(Oral and poster presentation) 
Howard Tripp N, Tarn J, Natasari A, Gillespie C, Mitchell S, Bowman SJ, Price E, Pease 
CT, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, 
Pitzalis C, McLaren J, Annie Cooper, Regan M, Giles I, Isenberg D, Saravanan V, Coady 
D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Hackett K, Griffiths 
B, Lendrem D and Ng W-F. (2016) Fatigue in Primary Sjögren’s Syndrome is Associated 
with Lower Levels of Pro-Inflammatory Cytokines. Biomarkers and Targeted 
Therapeutics in Sjögren's, Oklahoma City, USA. (Poster presentation) 
Howard Tripp N, Lendrem DW, Tarn J, Hackett K, Ng WF. (2016) Clinical Phenotyping in 
608 Patients from The United Kingdom Primary Sjögren's Syndrome Registry. EULAR 
Congress, London, UK. (Poster presentation) 
Hackett KL., Rapley, T., Deane, K., Deary, V., Kolehmainen, N., Newton J., W-F Ng. 
Identifying key participation barriers for people with primary Sjögren's syndrome to 
inform a future intervention package using a group concept mapping approach. (2015) 
United Kingdom Society of Behavioural Medicine Annual Meeting, Gateshead, UK. 
(Oral presentation) 
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Strassheim, V., Lambson, R., Hackett, KL., Newton, JL. The use of pilates style exercise 
in the treatment of individuals with chronic fatigue. (2015) CFS/ME Research 
Collaborative Conference, Newcastle upon Tyne, UK. (Poster presentation) 
Hackett, K., Lendrem, D., Rapley, T., Deane, K., Deary, V., Bowman, S., on behalf of the 
United Kingdom Primary Sjögren’s Syndrome Registry, Newton, J. and W-F Ng. (2015) 
‘Doing Every-Day Life’ With Primary Sjögren’s Syndrome: Factors Predicting Difficulties 
Performing Daily Activities and Taking on Life Roles. American College of 
Rheumatology Annual Meeting, San Francisco, USA. (Poster presentation) 
Hart R., Hackett K., Newton J., Ng W-F., Thompson B. (2015) The F word: Why is talking 
about fatigue so hard? American College of Rheumatology Annual Meeting, San 
Francisco, USA. (Poster presentation) 
Hackett K., Newton J., Deane K., Rapley T., Deary V., Kolehmainen N., Ng W-F. (2015) 
Identifying participation barriers and key intervention targets in an autoimmune 
disease College of Occupational Therapists 39th Annual Conference & Exhibition, 
Brighton, UK. (Oral presentation) Prize awarded for best MSc/PhD student oral 
presentation (UK Occupational Therapy Research Foundation (UKOTRF) Early 
Researcher Award) 
Hackett K., Rapley T., Kolehmainen N., Deary V., Deane K., Bowman S., Newton, J. Ng 
W-F. (2015) Identifying potential non-pharmacological intervention targets to improve 
participation in primary sjogren’s syndrome patients and their ability to perform daily 
activities: a group concept mapping study EULAR Congress, Rome, Italy. (Oral 
presentation) 
Hackett K., Lendrem D., Frith J., Rapley T., Deary V., Deane, K., Bowman S., Newton, 
J.L., Ng W-F. (2015) Cognitive symptoms are common in primary Sjögren’s syndrome 
and are associated with anxiety The 13th International Symposium on Sjögren’s 
Syndrome, Bergen, Norway. (Oral presentation) 
Hackett K., Lendrem D., Frith J., Rapley T., Deary V., Deane, K., Bowman S., Newton, 
J.L., W-F Ng. (2015) Identifying stakeholder informed priority targets for a non-
pharmacological intervention package to improve functional capacity: A multi-centre 
mixed methods study The 13th International Symposium on Sjögren’s Syndrome, 
Bergen, Norway. (Poster presentation) 
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Hackett K., Lendrem D., Frith J., Rapley T., Deary V., Deane, K., Bowman S., Newton, 
J.L., W-F Ng. (2015) Cognitive impairment in primary Sjögren’s syndrome British 
Society of Rheumatology, Rheumatology, Manchester, UK. (Poster presentation) 
Hackett K.L., Lambson R., Gotts Z.M., Strassheim V., Deary, V. Newton JL. (2015) 
Identifying and tackling unmet service-user needs in a novel generic fatigue clinic: A 
group concept mapping study British Association of CFS/ME Conference, Milton 
Keynes, UK. (Poster presentation) Poster prize awarded 
Hackett K., Deane K., Deary V., Rapley T., Newton JL., Ng W-F. (2015) Non-
pharmacological interventions for primary Sjögren's syndrome: a systematic review of 
the evidence EULAR Congress, Paris, France. (Poster presentation) 
Robinson LJ, Hackett K, S Bowman, B Griffiths, Ng W-F., P Gallagher, on behalf of UK 
Primary Sjögren's Syndrome Registry. (2014) Understanding the gap between 
subjective symptoms and objective illness markers in primary Sjögren’s syndrome 
EULAR Congress, Paris, France. (Poster presentation) 
Hackett KL., Deane KHO., Deary V., Newton JL., Rapley T., Ng W-F. (2014) A systematic 
review of non-pharmacological interventions for primary Sjögren’s syndrome British 
Society of Rheumatology, Rheumatology, Manchester, UK. (Poster presentation)  
 
A.6 Prizes and funding awarded during my PhD studies 
 Bright Ideas in Health Award, CRESTA Fatigue Team (Team award) (2015) 
 United Kingdom Occupational Therapy Research Foundation, Early Researcher 
Award, (2015) 
 BACME (British Association for CFS/ME) Conference, Poster Prize, (2015) 
 Newcastle upon Tyne NHS Foundation Trust, Therapy Services, National 
Recognition Award, (2015) 
 United Kingdom Occupational Therapy Research Foundation, Research Career 
Development Award, (2014-7) 
 College of Occupational Therapists, Innovation Award, (2014) 
 Arthritis Research UK, Postgraduate Training Fellowship (2013-7) 
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A.7 Invited oral presentations delivered during my PhD Studies 
February 2017: Guest Lecture, Masters in Health Psychology, Northumbria University, 
Developing Complex Interventions Newcastle upon Tyne, UK. 
October 2016: British Sjögren’s Syndrome Association AGM and Patient Meeting: The 
Academy, The Great Western Hospital, Swindon, UK. 
October 2016: British Sjögren’s Syndrome Association Medical Meeting: The Great 
Western Railway Museum, Swindon, UK. 
September 2016: North East Sjögren’s Syndrome Association Meeting: The Freeman 
Hospital, Newcastle upon Tyne, UK. 
June 2016: North East Fatigue Group Education Day: Learning from each other – 
clinical and research. Laing Art Gallery, Newcastle upon Tyne, UK.  
March 2016: Newcastle upon Tyne NHS Foundation Trust Master Class for nurses, 
midwives and allied health professionals. Applying for funding: Knowing 
the funder, Newcastle University, Newcastle upon Tyne, UK.  
February 2016: Guest Lecture, Masters in Health Psychology, Northumbria University, 
Developing Complex Interventions Newcastle upon Tyne, UK. 
September 2015: Academic Rheumatology Dept., University of the West of England, 
Bristol, UK. 
April 2015: Making a difference through clinical research: Nurses Midwives and Allied 
Health Professionals Regional Meeting, Great North Museum, 
Newcastle upon Tyne, UK  
January 2015: Guest Lecture, Masters in Health Psychology, Northumbria University, 
Developing Complex Interventions Newcastle upon Tyne, UK. 
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A.8 Summary of future research proposal 
This proposal has been awarded funding through an Arthritis Research UK postdoctoral 
Foundation Fellowship (Grant 21435). 
Introduction 
Primary Sjögren’s syndrome (PSS) patients experience fatigue, pain, sleep disturbances 
dryness and difficulty performing daily tasks including social/work activities. My PhD 
research identified; to facilitate independence, PSS patients should be supported to 
self-manage their symptoms and be informed about their disease. Patients therefore 
require access to reliable information and evidence-based symptom management 
programmes. However access to such support is limited for most PSS patients.  
This Fellowship follows the MRC guidance for complex intervention research. A self-
management intervention will be developed in collaboration with patients and 
informed by behaviour change techniques. The intervention will be delivered online 
with the aim of improving patients’ skills, knowledge and confidence in self-managing 
their disease (patient activation) and quality of life (QOL). A feasibility study of the 
intervention with an integrated process evaluation will be conducted. These results 
will inform the design and conduct of a future multi-centre trial. 
Methods  
Work Package 1a: Specifying the intervention content 
I will be supported by collaborators/sponsors to develop a PSS self-management, 
interactive intervention to be delivered via a digital platform (website and linked 
smartphone application) to deliver information on PSS as well as specific symptom 
management modules for pain, fatigue, sleep and dryness. The modules will be 
developed using the MRC Framework which will lead to the development of a specific 
model/theory that will guide the intervention development. I will utilise patient focus 
group data (from my PhD), evidence-based intervention components, and BSR/BHPR 
PSS Guideline recommendations. I have expertise in fatigue interventions and will be 
supported by sponsors/collaborators with expertise in designing behaviour change, 
pain, sleep, dryness, education and online interventions.  
WP1b: Co-designing the digital tools and user-testing 
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Regular meetings will occur with patient stakeholders, the research team and web-
developers to refine the design, functional elements and usability of the digital self-
management tool. Stakeholders will be invited to user-test the tool between meetings 
and refinements made based on their feedback. 
WP2: Feasibility study with process evaluation 
A feasibility study will determine both proof of concept/feasibility of the intervention 
for PSS patients and the protocol for a future multi-centre RCT. Patients will be 
randomised to receive either usual care plus access to the digital tool or usual care and 
a booklet. Primary outcomes will include QOL/function. Recruitment, randomisation, 
follow-up and website engagement rates will be established to inform sample size 
calculations for the future definitive trial. Further outcomes will include patient 
activation, health education impact, and symptom scores.  
Qualitative interviews with participants will explore experiences of the intervention 
(e.g. barriers/facilitators to engagement) and trial process. The interviews will inform 
further enhancements to the digital tool and design of a future multi-centre trial.  
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